<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Bioelectron Med</journal-id><journal-id journal-id-type="iso-abbrev">Bioelectron Med</journal-id><journal-id journal-id-type="pmc-domain-id">3779</journal-id><journal-id journal-id-type="pmc-domain">bioelecmed</journal-id><journal-title-group><journal-title>Bioelectronic Medicine</journal-title></journal-title-group><issn pub-type="epub">2332-8886</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11866872</article-id><article-id pub-id-type="pmcid-ver">PMC11866872.1</article-id><article-id pub-id-type="pmcaid">11866872</article-id><article-id pub-id-type="pmcaiid">11866872</article-id><article-id pub-id-type="pmid">40011942</article-id><article-id pub-id-type="doi">10.1186/s42234-025-00167-8</article-id><article-id pub-id-type="publisher-id">167</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Long COVID &#8211; a critical disruption of cholinergic neurotransmission?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Leitzke</surname><given-names initials="M">Marco</given-names></name><address><email>marco.leitzke@gmx.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Roach</surname><given-names initials="DT">Donald Troy</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hesse</surname><given-names initials="S">Swen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sch&#246;nknecht</surname><given-names initials="P">Peter</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Becker</surname><given-names initials="GA">Georg-Alexander</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rullmann</surname><given-names initials="M">Michael</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sattler</surname><given-names initials="B">Bernhardt</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sabri</surname><given-names initials="O">Osama</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03s7gtk40</institution-id><institution-id institution-id-type="GRID">grid.9647.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 7669 9786</institution-id><institution>Department of Nuclear Medicine, </institution><institution>University of Leipzig Medical Centre, </institution></institution-wrap>Leipzig, 04103 Germany </aff><aff id="Aff2"><label>2</label>Department of Anesthesiology, Intensive Care Medicine, Pain- and Palliative Therapy Helios Clinics, Colditzer Stra&#223;e 48, Leisnig, 04703 Germany </aff><aff id="Aff3"><label>3</label>School of Comillas University, Renegade Research, Madrid, 28015 Spain </aff><aff id="Aff4"><label>4</label>Department of Psychiatry and Neurology Altscherbitz, Schkeuditz, 04435 Germany </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03s7gtk40</institution-id><institution-id institution-id-type="GRID">grid.9647.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 7669 9786</institution-id><institution>Outpatient Department for Forensic-Psychiatric Research, </institution><institution>University of Leipzig, </institution></institution-wrap>Leipzig, 04103 Germany </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>11</volume><issue-id pub-id-type="pmc-issue-id">480073</issue-id><elocation-id>5</elocation-id><history><date date-type="received"><day>3</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>30</day><month>1</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>27</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-04 17:25:27.253"><day>04</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="42234_2025_Article_167.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Following the COVID-19 pandemic, there are many chronically ill Long COVID (LC) patients with different symptoms of varying degrees of severity. The pathological pathways of LC remain unclear until recently and make identification of path mechanisms and exploration of therapeutic options an urgent challenge. There is an apparent relationship between LC symptoms and impaired cholinergic neurotransmission.</p></sec><sec><title>Methods</title><p id="Par2">This paper reviews the current literature on the effects of blocked nicotinic acetylcholine receptors (nAChRs) on the main affected organ and cell systems and contrasts this with the unblocking effects of the alkaloid nicotine. In addition, mechanisms are presented that could explain the previously unexplained phenomenon of post-vaccination syndrome&#160;(PVS). The fact that not only SARS-CoV-2 but numerous other viruses can bind to nAChRs is discussed under the assumption that numerous other post-viral diseases and autoimmune diseases (ADs) may also be due to impaired cholinergic transmission. We also present a case report that demonstrates changes in cholinergic transmission, specifically, the availability of &#945;4&#946;2 nAChRs by using (-)-[<sup>18</sup>F]Flubatine whole-body positron emission tomography (PET) imaging of cholinergic dysfunction in a LC patient along with a significant neurological improvement before and after low-dose transcutaneous nicotine (LDTN) administration. Lastly, a descriptive analysis and evaluation were conducted on the results of a survey involving 231 users of LDTN.</p></sec><sec><title>Results</title><p id="Par3">A substantial body of research has emerged that offers a compelling explanation for the phenomenon of LC, suggesting that it can be plausibly explained because of impaired nAChR function in the human body. Following a ten-day course of transcutaneous nicotine administration, no enduring neuropathological manifestations were observed in the patient. This observation was accompanied by a significant increase in the number of free ligand binding sites (LBS) of nAChRs, as determined by (-)-[<sup>18</sup>F]Flubatine PET imaging. The analysis of the survey shows that the majority of patients (73.5%) report a significant improvement in the symptoms of their LC/MEF/CFS disease as a result of LDTN.</p></sec><sec><title>Conclusions</title><p id="Par4">In conclusion, based on current knowledge, LDTN appears to be a promising and safe procedure to relieve LC symptoms with no expected long-term harm.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s42234-025-00167-8.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Long COVID</kwd><kwd>Cholinergic neurotransmission</kwd><kwd>Nicotinic acetylcholine receptors</kwd><kwd>Low dose transdermal nicotine</kwd><kwd>Flubatine</kwd><kwd>Spike glycoprotein</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Feinstein Institute for Medical Research 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">The WHO declared the SARS-CoV-2 pandemic over on May 5, 2023 (Lenharo <xref ref-type="bibr" rid="CR120">2023</xref>). In the meantime, global healthcare systems are facing a complex of symptoms as a post-viral syndrome with a cumulative global incidence of around 400 million people (Al-Aly <xref ref-type="bibr" rid="CR8">2024</xref>). The appearance of the syndrome, referred to as long COVID (LC) (O'Mahoney&#160;<xref ref-type="bibr" rid="CR163">2023</xref>) or post-acute sequalae of COVID-19 (PASC) (Swank <xref ref-type="bibr" rid="CR212">2024</xref>) is reported to be between 10 and 30% of outpatient SARS-CoV-2 infections and 50&#8211;70% of hospitalized COVID-19 cases (Ceban <xref ref-type="bibr" rid="CR34">2022</xref>). The causes of this extremely diverse clinical picture (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) are still unclear. Until recently, most of the commonly observed pathological findings could only be managed symptomatically. An etiopathogenetic pathway has not been identified, and thus a curative therapeutic approach has not yet been established. Interestingly, there is a high degree of symptomatic concordance with the well-characterized symptom complex of Myalgic Encephalomyelitis /chronic fatigue syndrome (ME/CFS) (Komaroff <xref ref-type="bibr" rid="CR107">2023</xref>), which is also thought to have a post-viral/post-infection genesis (Pricoco <xref ref-type="bibr" rid="CR178">2024</xref>). In addition, there are increasing reports that, in rare cases, a very similar clinical picture also develops after vaccination against SARS-CoV-2 infection (Elsaid <xref ref-type="bibr" rid="CR59">2023</xref>; Altmann et al. <xref ref-type="bibr" rid="CR7">2023</xref>), which is referred to as post-vaccination syndrome (PVS) (Krumholz <xref ref-type="bibr" rid="CR110">2023</xref>). Finally, reactivation of various persistent viral diseases (Altmann et al.&#160;<xref ref-type="bibr" rid="CR7">2023</xref>) (EBV (Altmann et al. <xref ref-type="bibr" rid="CR7">2023</xref>), CMV (Altmann et al. <xref ref-type="bibr" rid="CR7">2023</xref>), HIV (Peluso <xref ref-type="bibr" rid="CR170">2023</xref>) as well as IAV (Kim <xref ref-type="bibr" rid="CR106">2023</xref>), IBV (Kim <xref ref-type="bibr" rid="CR106">2023</xref>), VZV (Kim <xref ref-type="bibr" rid="CR106">2023</xref>), HHV-1 (Kim <xref ref-type="bibr" rid="CR106">2023</xref>), HHV-2 (Kim <xref ref-type="bibr" rid="CR106">2023</xref>), HHV-6 (Kim <xref ref-type="bibr" rid="CR106">2023</xref>), HHV-7 (Kim <xref ref-type="bibr" rid="CR106">2023</xref>), HHV-8 (Kim <xref ref-type="bibr" rid="CR106">2023</xref>), HBV (Kim <xref ref-type="bibr" rid="CR106">2023</xref>), and Parvovirus B19 (Kim <xref ref-type="bibr" rid="CR106">2023</xref>) has been described in association with long COVID.
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Symptoms and frequency of occurrence (% of LC cases) (with permission of Cabrera Martimbianco et al. (<xref ref-type="bibr" rid="CR31">2021</xref>))</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="MO1" orientation="portrait" xlink:href="42234_2025_167_Tab1_HTML.jpg"/></table-wrap></p><p id="Par6">The current body of evidence opens new pathways for unraveling the mystery of LC. In this context, the &#8220;nicotine hypothesis&#8221; presented by Changeux et al. (<xref ref-type="bibr" rid="CR35">2020</xref>) is of groundbreaking importance (Changeux <xref ref-type="bibr" rid="CR35">2020</xref>). The authors point to a proline-arginine-arginine-alanine (PRRA) amino acid sequence (AAS) in the head region of the spike glycoprotein (SGP) of SARS-CoV-2, located at the interface between the S1 and S2 domains, just upstream of the S1/S2 cleavage site (Walls et al. <xref ref-type="bibr" rid="CR223">2020</xref>). This AAS in the Y674-R685 region of SARS-CoV-2 is similar to that of cholinergic toxins (e.g., from snakes of the genera Ophiophagus [cobra] and Bungarus, the G-ectodomains of three rabies lyssavirus strains [formerly rabies virus RABV] (Changeux <xref ref-type="bibr" rid="CR35">2020</xref>) or the muscarinic toxin-like protein and cobratoxin [naja siamensis] (Farsalinos <xref ref-type="bibr" rid="CR62">2020</xref>), whose main action is to block nicotinic acetylcholine receptors (nAChRs). The remarkably high AAS concordance led the authors to propose that SARS-CoV-2 functions as an nAChR antagonist, likely due to its potential binding affinity for these receptors (Changeux <xref ref-type="bibr" rid="CR35">2020</xref>). This assumption was later confirmed in further in silico and in vitro studies (Farsalinos <xref ref-type="bibr" rid="CR62">2020</xref>); Carlson <xref ref-type="bibr" rid="CR32">2023</xref>). Since, unexceptional every cell, even on the subcellular level (e.g. mitochondria), is subject to cholinergic neurotransmission in terms of its metabolic and functional regulation (Proceedings of the 2nd International Symposium on Non-Neuronal Acetylcholine <xref ref-type="bibr" rid="CR179">2007</xref>), a new pathogenetic understanding for these post-viral symptom complexes is possible. The alkaloid nicotine, with its extraordinarily high affinity for nAChRs, could enable competitive displacement of the virus particles to initiate immunological processing by preformed antibodies. This resulted in numerous instances of self-medication using nicotine patches (low-dose transcutaneous nicotine &#8211; LDTN) by LC/ME/CFS patients, with impressive improvements in many of the cases and insights into the LC/ME/CFS root causes to provide clearer subtyping (see Supplement 1). This review integrates current knowledge to connect pathological findings in LC with impaired cellular cholinergic neurotransmission and proposes conclusions for a therapeutic approach (Leitzke <xref ref-type="bibr" rid="CR118">2023</xref>).</p><p id="Par7">Furthermore, in an initial case study, we demonstrate alterations in vivo in nAChR imaging using simultaneous whole-body PET/CT and PET/MRI, along with significant clinical improvement following LDTN. This supports the underlying pathophysiological hypothesis and validates the proposed approach.</p><sec id="Sec2"><title>Acetylcholine receptors</title><p id="Par8">Acetylcholine receptors (AChRs) are classified into ionotropic nicotinic (nAChRs) (Gotti et al. <xref ref-type="bibr" rid="CR80">2006</xref>) and metabotropic muscarinic (mAChRs) (Jones <xref ref-type="bibr" rid="CR96">1992</xref>) receptors. These two groups are distinguishable by different binding behavior to nicotine and muscarine and the mode of signal transmission (Jones <xref ref-type="bibr" rid="CR96">1992</xref>; Graef et al. <xref ref-type="bibr" rid="CR82">2011</xref>). MAChRs usually act slowly by coupling to G-proteins that activate phospholipase C (PLC) or inhibit adenylate cyclase (Scarr <xref ref-type="bibr" rid="CR193">2012</xref>). In addition, non-canonical signaling pathways involving phospholipase A2, phospholipase D, tyrosine kinase, and calcium channels are modulated by mAChRs (Scarr <xref ref-type="bibr" rid="CR193">2012</xref>). Whether mAChRs act in an excitatory or inhibitory manner depends on the type of cell they target (Scarr <xref ref-type="bibr" rid="CR193">2012</xref>). Neuronal, non-neuronal and muscle-type nAChRs consist of a pentameric composition of nine &#945; (&#945;2-&#945;10), three &#946; (&#946;2-&#946;4) and &#947;, &#1013; or &#948; subunits (Osipov et al. <xref ref-type="bibr" rid="CR160">2023</xref>), which assemble in a homomeric (&#945;7) or heteromeric combination to fast-acting, excitatory membrane-bound channels allowing rapid cellular influx of cations upon activation (Gotti et al. <xref ref-type="bibr" rid="CR80">2006</xref>). Thus, activation of nAChRs in the brain leads to increased release of several important neurotransmitters, including dopamine, serotonin, glutamate, and gamma-aminobutyric acid (GABA) (Taly et al. <xref ref-type="bibr" rid="CR215">2009</xref>). The allosteric configuration of nAChRs is crucial for their function. Together with the orthosteric binding sites (OBS) for acetylcholine (ACh), there are allosteric binding sites (ABS) at the interface between &#945;- and non-&#945;-subunits. ABS can bind to a variety of transmitters or proteins that modulate the molecular quaternary structure of the receptor to increase (positive allosteric modulators [PAMs]) or decrease (negative allosteric modulators [NAMs]) the overall conductance of the channel by altering the steric energy required for a further conformational change (Kenakin <xref ref-type="bibr" rid="CR104">2024</xref>). The excitability of each cell is therefore subject to a variety of external influences, at the center of which is the coupling of ACh to its OBS (Spurny <xref ref-type="bibr" rid="CR210">2015</xref>).</p></sec><sec id="Sec3"><title>Neuropathology in long COVID</title><p id="Par9">Patients with LC suffer from cognitive dysfunction (Ceban <xref ref-type="bibr" rid="CR34">2022</xref>), poor concentration (L&#243;pez-Hern&#225;ndez <xref ref-type="bibr" rid="CR126">2023</xref>), memory loss (L&#243;pez-Hern&#225;ndez <xref ref-type="bibr" rid="CR126">2023</xref>), fatigue (L&#243;pez-Hern&#225;ndez <xref ref-type="bibr" rid="CR126">2023</xref>), depression (Ceban <xref ref-type="bibr" rid="CR34">2022</xref>), and other neurological disorders (Stefanou <xref ref-type="bibr" rid="CR211">2022</xref>). The so-called "brain fog" is characterized by an inability to think clearly (Kavanagh <xref ref-type="bibr" rid="CR100">2022</xref>). In discussing the associated damage patterns, Leng et al. (<xref ref-type="bibr" rid="CR121">2023</xref>) suggest direct viral neuroinvasion (Leng <xref ref-type="bibr" rid="CR121">2023</xref>). Other authors consider inflammatory mechanisms (Kavanagh <xref ref-type="bibr" rid="CR100">2022</xref>; Davis et al. <xref ref-type="bibr" rid="CR48">2023</xref>) perpetuated by cytokines (Kavanagh <xref ref-type="bibr" rid="CR100">2022</xref>; Davis et al. <xref ref-type="bibr" rid="CR48">2023</xref>; Monje and Iwasaki <xref ref-type="bibr" rid="CR144">2022</xref>), chemokines, and migrating immune cells (Davis et al. <xref ref-type="bibr" rid="CR48">2023</xref>) to be likely. Neuronal apoptosis (Iadecola et al. <xref ref-type="bibr" rid="CR91">2020</xref>) or hypoxia (Rutkai <xref ref-type="bibr" rid="CR185">2022</xref>) as well as circulatory central nervous system (CNS) dysfunction (Aj <xref ref-type="bibr" rid="CR5">2023</xref>) and neurotransmitter imbalances (Monje and Iwasaki <xref ref-type="bibr" rid="CR144">2022</xref>), microglial activation (Leng <xref ref-type="bibr" rid="CR121">2023</xref>) or impairment of certain receptor groups (Reiken et al. <xref ref-type="bibr" rid="CR184">2022</xref>) have also been associated with LC-associated neuropathy. All neurological symptoms of LC share low specificity (L&#243;pez-Hern&#225;ndez <xref ref-type="bibr" rid="CR126">2023</xref>) and highly fluctuating occurrence (O'Brien&#160;<xref ref-type="bibr" rid="CR162">2023</xref>), which suggests that these disorders may have a functional origin. We recently highlighted the neuromodulatory function of nAChRs (Leitzke <xref ref-type="bibr" rid="CR118">2023</xref>). Pre- and postsynaptic and axonal nAChRs regulate the amount and rate of transmitter release at all central and peripheral synapses (Gotti et al. <xref ref-type="bibr" rid="CR80">2006</xref>; Picciotto et al. <xref ref-type="bibr" rid="CR175">2012</xref>) and ensure a coordinated and adaptive interaction of all neuronal signals and adaptation of signaling to the situational requirements of the entire organism (Leitzke <xref ref-type="bibr" rid="CR118">2023</xref>; Picciotto et al. <xref ref-type="bibr" rid="CR175">2012</xref>). It also controls the excitability and responsiveness of axons and central and autonomic nuclei to stimulation in general (Picciotto et al. <xref ref-type="bibr" rid="CR175">2012</xref>). The brain-specific neuronal NO synthase (nNOS) is involved in modulation of long-term synaptic transmission and thus learning, memory, and neurogenesis (Zhou and Zhu <xref ref-type="bibr" rid="CR239">2009</xref>). Its obligate Ca<sup>++</sup>dependence (Cyr et al. <xref ref-type="bibr" rid="CR44">2020</xref>) suggests a close functional relationship with nAChRs as Ca<sup>++</sup>channels. Graef et al. (<xref ref-type="bibr" rid="CR82">2011</xref>) found in their review that nAChRs are involved in the regulation of cognition, positioning them as key regulators of attention and working memory (Graef et al. <xref ref-type="bibr" rid="CR82">2011</xref>) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a).&#160;Viral blockade of neuronal AChRs with marked impairment of cholinergic neuromodulation offers a very plausible etiopathogenetic explanation for LC-associated neuropathology (Leitzke <xref ref-type="bibr" rid="CR118">2023</xref>).</p></sec><sec id="Sec4"><title>Mitochondriopathy in long COVID</title><p id="Par10">Numerous authors have suggested that mitochondriopathy is the central pathologic element of LC. However, neither conclusive data nor etiopathogenetic models are available (Sakellaropoulos et al. <xref ref-type="bibr" rid="CR188">2022</xref>). Nevertheless, there are LC/ME/CFS-specific clinical findings such as post-exertional malaise (PEM), fatigue and loss of strength that suggest a general cellular energy deficiency (Sakellaropoulos et al. <xref ref-type="bibr" rid="CR188">2022</xref>). Mitochondria are the central energy suppliers of the cell, providing adenosine triphosphate (ATP) via oxidative phosphorylation (OXPHOS) (Mali <xref ref-type="bibr" rid="CR133">2019</xref>). Metabolically, mitochondria are responsible for &#946;-oxidation of fatty acids (Friedman <xref ref-type="bibr" rid="CR67">2014</xref>), steroid synthesis, Fe-S center formation, and heme synthesis (Friedman <xref ref-type="bibr" rid="CR67">2014</xref>). They are also the central structure for cytosolic Ca<sup>++&#160;</sup>buffering, thermogenesis, and the initiation of apoptosis (Friedman <xref ref-type="bibr" rid="CR67">2014</xref>). In addition, the electron transport chain (ETC) is the site of origin for reactive oxygen species (ROS) (Friedman <xref ref-type="bibr" rid="CR67">2014</xref>). The impairment of these core processes of cellular metabolism is characterized by decreased ATP synthesis, inefficient Ca<sup>++&#160;</sup>buffering and increased ROS production. In addition, pro-apoptotic factors are released (Mali <xref ref-type="bibr" rid="CR133">2019</xref>). Several nAChR subtypes, including &#945;7, &#945;3&#946;2, &#945;4&#946;2, &#945;7&#946;2, and &#945;9, have been identified on the outer mitochondrial membrane (OMM) in isolated mitochondria (Lykhmus et al. <xref ref-type="bibr" rid="CR129">2014</xref>). The distribution of the different subtypes is tissue specific (Friedman <xref ref-type="bibr" rid="CR67">2014</xref>; Skok&#160;<xref ref-type="bibr" rid="CR206">2022</xref>). They are responsible for the activation of intramitochondrial kinases such as Ca-calmodulin-activated kinase II (CaKMII), Src kinases, and phosphatidylinositol 3-kinase (PI3K) (Skok <xref ref-type="bibr" rid="CR206">2022</xref>). An important function of kinases is the post-transcriptional modification (PTM) of functional proteins. This, regarding mitochondria, means that activated kinases jointly orchestrate mitochondrial signaling and metabolic pathways thus providing reliable protection against pro-apoptotic factors such as Ca<sup>++</sup>and ROS accumulation, and ensuring a continuous cellular supply of ATP (Skok <xref ref-type="bibr" rid="CR206">2022</xref>) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>b). In their review, Chang et al. (<xref ref-type="bibr" rid="CR37">2021</xref>) linked the endothelial dysfunction observed in COVID-19 to increased oxidative stress caused by mitochondrial ROS overexpression (Chang <xref ref-type="bibr" rid="CR36">2021</xref>).</p><p id="Par11">The associations described suggest that viral blockade of mitochondrial nAChRs is most likely an important component of LC.</p></sec><sec id="Sec5"><title>Autoantibodies in long COVID</title><p id="Par12">Natural autoantibodies (nAAs) are encoded by non-mutated V(D)J gene sequences (Schettino <xref ref-type="bibr" rid="CR195">1997</xref>) and are synthesized in CD5<sup>+</sup>cells (Casali <xref ref-type="bibr" rid="CR33">1987</xref>) of the neonatal B cell reservoir (Ma <xref ref-type="bibr" rid="CR130">2022</xref>). They are part of the physiological immune system, albeit in small quantities. These mostly IgM-nAAs (Ma <xref ref-type="bibr" rid="CR130">2022</xref>) are an important component of immunological homeostasis (Wildbaum et al. <xref ref-type="bibr" rid="CR229">2003</xref>) and the first line of defense (Zhou et al. <xref ref-type="bibr" rid="CR240">2007</xref>). However, they have no autoaggressive potential (Ma <xref ref-type="bibr" rid="CR130">2022</xref>). Pathological, auto-aggressive, somatically mutated IgG-type autoantibodies (pAAs) (Ma <xref ref-type="bibr" rid="CR130">2022</xref>) can develop under the influence of toxins, chemicals, viral infections and excessive T-cell stimulation (Elkon and Casali <xref ref-type="bibr" rid="CR58">2008</xref>). These high-affinity monoreactive IgG-pAA are objective markers of pathoimmunologic processes and are associated with disturbed cellular homeostasis, altered antigen receptor signaling pathways and cell effector functions (Elkon and Casali <xref ref-type="bibr" rid="CR58">2008</xref>). The virus-induced switch from nAA to pAA (Elkon and Casali <xref ref-type="bibr" rid="CR58">2008</xref>) is attributed to molecular mimicry (Zhao <xref ref-type="bibr" rid="CR237">1998</xref>), with nAA acting as a template for the synthesis of pAA (Fleming <xref ref-type="bibr" rid="CR64">2006</xref>). Several authors report the observation of such a switch with increased pAA synthesis in the context of acute SARS-CoV-2 infection (Chang <xref ref-type="bibr" rid="CR37">2021</xref>; Damoiseaux <xref ref-type="bibr" rid="CR45">2022</xref>). In addition, there is evidence that pAAs cause a variety of LC symptoms (Ortona and Malorni <xref ref-type="bibr" rid="CR159">2022</xref>) via increased platelet clotting (Zuo <xref ref-type="bibr" rid="CR241">2020</xref>) and vascular or tissue inflammation (Cochrane <xref ref-type="bibr" rid="CR40">1973</xref>). Immune cells, including dendritic cells, T and B lymphocytes, monocytes and macrophages, express a considerable number of different AChRs (Fujii <xref ref-type="bibr" rid="CR69">2017</xref>). These include nAChRs with the subunits &#945;2, &#945;5, &#945;6 (Fujii <xref ref-type="bibr" rid="CR69">2017</xref>; Kawashima et al. <xref ref-type="bibr" rid="CR101">2007</xref>), &#945;7, &#945;9, and &#945;10 (Fujii <xref ref-type="bibr" rid="CR69">2017</xref>; Plazas&#160;<xref ref-type="bibr" rid="CR174">2005</xref>) as well as &#945;4, &#223;2, and &#223;4 (Plazas <xref ref-type="bibr" rid="CR174">2005</xref>) and all known mAChRs (M1-M5) (Fujii <xref ref-type="bibr" rid="CR69">2017</xref>; Kawashima et al.&#160;<xref ref-type="bibr" rid="CR101">2007</xref>). Other components of the cholinergic system such as choline acetyltransferase (ChAT) and ACh (Fujii <xref ref-type="bibr" rid="CR69">2017</xref>) are also expressed by T and B lymphocytes. They regulate the production of proinflammatory cytokines such as tumor necrosis factor &#945; (TNF&#945;) and interleukin 2 (IL2) (Fujii <xref ref-type="bibr" rid="CR69">2017</xref>) through &#945;7nAChRs via the so-called cholinergic anti-inflammatory pathway&#8212;CAP (Tracey <xref ref-type="bibr" rid="CR217">2007</xref>). This suggests a partial autocrine/paracrine regulation of the immunologic activation of both innate and humoral immune responses (Fujii <xref ref-type="bibr" rid="CR69">2017</xref>) and is particularly relevant because TNF&#945;, IL6 and interferon-&#947; (IFN&#947;), which are overexpressed in spleen cells of &#945;7 KO mice (Fujii <xref ref-type="bibr" rid="CR71">2007</xref>), play a major role in the nAA-IgM to pAA-IgG switch (Fujii <xref ref-type="bibr" rid="CR69">2017</xref>) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>c). Rodent B lymphocytes mainly express homomeric &#945;7 and heteromeric &#945;4&#946;2 receptors (Skok et al. <xref ref-type="bibr" rid="CR204">2005</xref>). Epibatidin binding sites, representing heteromeric receptors (Sihver et al. <xref ref-type="bibr" rid="CR203">1999</xref>), and bungarotoxin binding sites, specific for homomeric receptors (McLane <xref ref-type="bibr" rid="CR132">1991</xref>), were found in large numbers (12,200&#8201;&#177;&#8201;3200 per cell and 3130&#8201;&#177;&#8201;750 per cell, respectively) (Skok et al. <xref ref-type="bibr" rid="CR204">2005</xref>). AChRs are key regulators of antibody synthesis (Skok <xref ref-type="bibr" rid="CR207">2003</xref>). M1/M5 KO mice had significantly lower levels of antigen-specific IgG1 and serum cytokines compared to WT mice (Fujii <xref ref-type="bibr" rid="CR72">2007</xref>). In contrast, &#945;7-KO mice had significantly increased levels of ovalbumin (OVA)-specific IgG1 two weeks after OVA immunization compared to WT C57BL/6&#160;J mice (Fujii <xref ref-type="bibr" rid="CR71">2007</xref>). B-cell proliferation after stimulation with anti-CD40 or anti-B-cell receptor antibodies was also significantly greater in &#945;7-KO mice or in &#945;7nAChRs inhibited with methyllycaconitine (MLA) than in WT mice (Koval <xref ref-type="bibr" rid="CR109">2011</xref>; Skok et al. <xref ref-type="bibr" rid="CR205">2007</xref>). In conclusion, mAChRs upregulate both B lymphocyte numbers and antibody production, whereas nAChRs have an inhibitory effect on B cell function and proliferation (Fujii&#160;<xref ref-type="bibr" rid="CR71">2007</xref>; Fujii et al. <xref ref-type="bibr" rid="CR70">2003</xref>). In this context, it is noteworthy that the administration of nicotine resulted in a 30% reduction in the CD40-induced proliferation of &#946;2 KO cells (Skok et al. <xref ref-type="bibr" rid="CR204">2005</xref>). In a retrospective analysis, Peng et al. (<xref ref-type="bibr" rid="CR171">2023</xref>) compared data from previous PCR-confirmed COVID-19 infections (<italic toggle="yes">n</italic>&#8201;=&#8201;1,028,721) with COVID-19-negative controls (<italic toggle="yes">n</italic>=&#8201;3,168,467) with regard to the risk of autoimmune diseases (AD) (Peng <xref ref-type="bibr" rid="CR171">2023</xref>). There was a significantly higher risk of developing AD (pernicious anemia, spondyloarthritis, rheumatoid arthritis, other autoimmune arthritis, pemphigoid, Graves' disease, antiphospholipid antibody syndrome, immune-mediated thrombocytopenia, multiple sclerosis, and vasculitis) in COVID-19-positive individuals (Peng <xref ref-type="bibr" rid="CR171">2023</xref>) (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Impact of COVID-19 on the risk of newly diagnosed autoimmune disease (COVID-19 versus non-COVID-19). Hazard ratio (HR) and 95% confidence interval (95% CI) estimated by Cox regression. HR &gt; 1 (or &lt;1) means that patients with COVID-19 had a higher (lower) risk of newly diagnosed autoimmune disease than the control cohort without COVID-19. Error bars indicate the 95% CI of the respective HR (with permission of Peng et al. (<xref ref-type="bibr" rid="CR171">2023</xref>))</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="MO3" orientation="portrait" xlink:href="42234_2025_167_Tab2_HTML.jpg"/></table-wrap></p><p id="Par13">The described correlations explain the high incidence of IgG-type pAA associated with COVID-19 due to SARS-CoV-2 induced T-cell stimulation leading to a shift from nAA-IgM to pAA-IgG. Blockade of membrane-bound nAChRs of B cells by SGP may perpetuate this effect through release of proinflammatory cytokines with further nAA-IgM/pAA-IgG shift. The persistent disruption of nAChR-driven inhibition of inappropriate B cell proliferation and antibody overproduction would be a plausible cause of auto-aggressive immune dysregulation with subsequent ADs in LC.</p></sec><sec id="Sec6"><title>Mast cell activation syndrome (MCAS) in long COVID</title><p id="Par14">As a central component of the innate immune system, mast cells (MCs) are the first line of defense against external and internal threats. This includes allergic responses (Vitte et al. <xref ref-type="bibr" rid="CR220">2022</xref>) as well as defense against microbial threats, maintenance of tissue homeostasis, and modulation of the adaptive immune system (Xu <xref ref-type="bibr" rid="CR232">2020</xref>). MCs are particularly abundant on surfaces in contact with the external environment (Galli et al. <xref ref-type="bibr" rid="CR75">2011</xref>) such as the mucous membranes of the digestive and respiratory tracts, the skin, and the meninges of the brain (Dudeck <xref ref-type="bibr" rid="CR57">2019</xref>). The close anatomical relationship between neuronal structures and MCs illustrates their mutual control (Godinho-Silva <xref ref-type="bibr" rid="CR78">2019</xref>). For example, the MC membrane contains numerous receptors for classical neurotransmitters such as ACh, NO, gamma-aminobutyric acid (GABA), dopamine (DA), and glutamate (Xu <xref ref-type="bibr" rid="CR232">2020</xref>).</p><p id="Par15">In addition, there are neuropeptide receptors for substance P (SP), vasoactive intestinal peptide (VIP), corticotropin-releasing factor (CRF), calcitonin gene-related peptide (CGRP), neurotrophins (NTs) and neurotensin (NT), adenosine triphosphate (ATP), tachykinin, opioid peptides, and others (Xu <xref ref-type="bibr" rid="CR232">2020</xref>). Among the MC AChRs (Mishra <xref ref-type="bibr" rid="CR140">2010</xref>), the &#945;7nAChRs are the most important (Xu <xref ref-type="bibr" rid="CR232">2020</xref>), explaining their central role in limiting the release of proinflammatory cytokines via the CAP (Tracey <xref ref-type="bibr" rid="CR217">2007</xref>). Stimulation of these receptors reduces MC degranulation (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>d). Thus, administration of &#945;7nAChR agonists (e.g., GTS-21) was followed by inhibition of IgE-induced MC degranulation in mouse bone marrow-derived MCs (Kageyama-Yahara et al. <xref ref-type="bibr" rid="CR97">2008</xref>). TNF&#945; release from MCs reduced after lipopolysaccharide (LPS) challenge (Guzm&#225;n-Mej&#237;a et al. <xref ref-type="bibr" rid="CR86">2018</xref>) and a reduction in interleukin-6 (IL-6) release and NO efflux from mononuclear cells in chronic obstructive pulmonary disease (COPD) have also been demonstrated with &#945;7nAChR agonists (Douaoui <xref ref-type="bibr" rid="CR55">2020</xref>). Endogenous NO synthesis is catalyzed by three enzymes (neuronal NO synthase &#8212; nNOS, inducible NO synthase &#8212; iNOS, and endothelial NO synthase &#8212; eNOS). All these NO forms, as well as exogenous NO donors (e.g., sodium nitroprusside [SNP]) (Xu <xref ref-type="bibr" rid="CR232">2020</xref>) result in mastocyte degranulation inhibition. Other NO donors (spermine-NO and SIN-1) showed an inhibitory effect on IgE-induced MC degranulation in peritoneal and mesenteric MCs, but also a reduction in the expression of mRNA for IL4, IL6 and TNF&#945; in rat MCs (Coleman <xref ref-type="bibr" rid="CR41">2002</xref>; Davis <xref ref-type="bibr" rid="CR47">2004</xref>). Furthermore, this effect could be reversed with NOS inhibitors such as NG-nitro-L-arginine methyl ester (L-NAME) (Masini et al. <xref ref-type="bibr" rid="CR134">1991</xref>). At the molecular level, the effect of NO can be attributed to inhibition of the cysteine protease calpain. Calpain is associated with cellular integrin activation, has an adhesion-promoting effect on MCs, and is inhibited by NO via nitrosylation of a thiol group at its active site (Forsythe <xref ref-type="bibr" rid="CR61">2003</xref>). Furthermore, there is a pronounced bidirectional dependence between the effect of NO and nAChRs (Xu <xref ref-type="bibr" rid="CR232">2020</xref>) (described in detail in the "Endothelial Dysfunction" section). In mast cell activation syndrome (MCAS), nonspecific triggers (food, odors, stress, exercise, drugs, or temperature changes) (Arun <xref ref-type="bibr" rid="CR12">2022</xref>) lead to inappropriate mast cell degranulation with the release of histamine, heparin, cytokines, prostaglandins, leukotrienes, and proteases. This affects a large number of LC patients (Weinstock et al. <xref ref-type="bibr" rid="CR226">2021</xref>; Afrin et al. <xref ref-type="bibr" rid="CR4">2020</xref>). Therefore, some authors suggest that MCs play a central role in LC pathology&#160;(Weinstock et al. <xref ref-type="bibr" rid="CR226">2021</xref>; Afrin et al. <xref ref-type="bibr" rid="CR4">2020</xref>). Weinstock et al. (<xref ref-type="bibr" rid="CR226">2021</xref>) investigated the prevalence of MCAS in LC patients and compared 136 LC patients with 80 true MCAS patients and 136 healthy volunteers (Weinstock et al. <xref ref-type="bibr" rid="CR226">2021</xref>). They found almost identical Mast Cell Mediated Release Syndrome (MCMRS) scores in LC patients compared to patients with primary, untreated MCAS (Weinstock et al. <xref ref-type="bibr" rid="CR226">2021</xref>). The interpretation of MCAS in LC based on blockade of one of the key inhibitory regulators of MC degranulation (i.e. nAChRs) by SGP seems to be a very likely scenario.</p></sec><sec id="Sec7"><title>Dyspnea and hypothermic, pale, and painful extremities</title><p id="Par16">Patients with LC often complain of recurrent dyspnea (L&#243;pez-Hern&#225;ndez <xref ref-type="bibr" rid="CR126">2023</xref>) and painful, acrocyanotic extremities (Iftekhar and Sivan <xref ref-type="bibr" rid="CR92">2023</xref>). However, these complaints usually have no spirometric or imaging pathologic correlate (Frizzelli <xref ref-type="bibr" rid="CR68">2022</xref>) and the subjective dyspnea does not appear to have a pulmonary cause. The extremely high erythrocyte concentration of the membrane-spanning enzyme acetylcholinesterase (AChE) illustrates the central functional importance of ACh for these cells (Saldanha <xref ref-type="bibr" rid="CR190">2017</xref>). Membrane-bound erythrocyte nAChRs regulate the deformability and oxygen-binding capacity of red blood cells (RBCs) (Almeida et al. <xref ref-type="bibr" rid="CR6">2008</xref>).</p><p id="Par17">Their activation increases erythrocyte Ca<sup>++</sup>concentration and deformability in an NO-dependent manner (De Almeida and Saldanha <xref ref-type="bibr" rid="CR49">2010</xref>), while decreasing oxygen P50, erythrocyte plasma pH, Na<sup>+</sup> and K<sup>+</sup>concentrations (Mesquita et al. <xref ref-type="bibr" rid="CR138">2001</xref>) and erythrocyte aggregation propensity (Mesquita et al. <xref ref-type="bibr" rid="CR138">2001</xref>). Thus, ACh is at the center of physiological requirements for pulmonary and tissue gas exchange, both in terms of blood viscosity and erythrocyte oxygen-carrying capacity. Perturbations in erythrocyte cholinergic signaling result in NO efflux from the cell (Mesquita <xref ref-type="bibr" rid="CR136">2000</xref>) and, due to the increase in intraerythrocytic pH (De Almeida and Saldanha <xref ref-type="bibr" rid="CR49">2010</xref>) and oxygen P50, a rightward shift of the hemoglobin oxygen dissociation curve (ODC) (Saldanha <xref ref-type="bibr" rid="CR189">2018</xref>) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>e). The increased RBC stiffness associated with cholinergic under-representation is caused by a decrease in membrane lipid fluidity (Almeida et al. <xref ref-type="bibr" rid="CR6">2008</xref>). This leads to an increase in vascular shear stress (De Almeida and Saldanha <xref ref-type="bibr" rid="CR49">2010</xref>) and impassability of erythrocytes in microvessels, which are smaller in diameter than erythrocytes (Almeida et al. <xref ref-type="bibr" rid="CR6">2008</xref>). For pulmonary gas exchange, this means that arterial oxygen content is reduced both by a lower oxygen binding capacity of hemoglobin and by impaired pulmonary capillary passage of erythrocytes due to cell stiffness (Saldanha <xref ref-type="bibr" rid="CR189">2018</xref>).</p><p id="Par18">The increased respiratory drive and breathlessness, which inversely correlate with arterial oxygen partial pressure (paO<sub>2</sub>) (Pfl&#252;ger <xref ref-type="bibr" rid="CR173">1868</xref>), are likely caused by the P50 increase and the rightward shift of the ODC due to reduced cholinergic innervation of erythrocytes (De Almeida and Saldanha <xref ref-type="bibr" rid="CR49">2010</xref>). The problem of tissue hypoxia is aggravated by the increased tendency of erythrocytes to aggregate (Mesquita et al. <xref ref-type="bibr" rid="CR138">2001</xref>), also due to cholinergic under-representation. Thus, the increased serum lactate levels in LC described by several authors (Ghali <xref ref-type="bibr" rid="CR76">2019</xref>; Lane&#160;<xref ref-type="bibr" rid="CR112">1998</xref>) might be due to the increased anaerobic metabolism caused by oxygen deprivation. In addition, Doyle and Walker (<xref ref-type="bibr" rid="CR56">1990</xref>) showed that pulmonary arterial pressure increases during perfusion of the pulmonary circulation with less elastic erythrocytes (Doyle <xref ref-type="bibr" rid="CR56">1990</xref>), which is another known cause of dyspnea (Blasi <xref ref-type="bibr" rid="CR25">2012</xref>).</p><p id="Par19">In summary, both the intermittent dyspnea reported by patients and the occurrence of hypothermic, pale, and painful extremities could be explained by the viral impairment of the acetylcholine-dependent mechanisms on erythrocytes described above.</p></sec><sec id="Sec8"><title>Clotting dysfunction in long COVID</title><p id="Par20">Serologic hyper-coagulopathies associated with a thrombocytopenic constellation have been observed in severe COVID-19 (Leitzke&#160;and Sch&#246;nknecht <xref ref-type="bibr" rid="CR119">2021</xref>; Tang et al. <xref ref-type="bibr" rid="CR216">2020</xref>), with thrombocytopenia partially attributed to SARS-CoV-2-associated thrombopoietin (TPO)-neutralizing pAAs (Nunez-Castilla <xref ref-type="bibr" rid="CR154">2021</xref>). In contrast, the prothrombotic phenomena associated with LC are mainly related to platelet-derived cellular mechanisms and are referred to as "microclotting" (Kell <xref ref-type="bibr" rid="CR102">2023</xref>). P-selectin (PS), a glycoprotein from the C-type lectin family, is rapidly released upon cellular activation from the &#945;-granules of platelets and the Weibel-Palade bodies of endothelial cells (Hawiger <xref ref-type="bibr" rid="CR87">1995</xref>;&#160;Merten <xref ref-type="bibr" rid="CR137">2000</xref>). At the cell surface, PS mediates platelet and neutrophil rolling on activated endothelial cells (Frenette <xref ref-type="bibr" rid="CR66">2000</xref>) and controls neutrophil-monocyte-platelet interactions (Larsen <xref ref-type="bibr" rid="CR114">1989</xref>). After GP IIb/IIIa binds to soluble fibrinogen to bridge adjacent platelets or platelets and endothelial cells, PS stabilizes the initiated aggregation (Hawiger <xref ref-type="bibr" rid="CR87">1995</xref>). Thus, PS is not only the major determinant of the size and stability of platelet aggregates (Merten <xref ref-type="bibr" rid="CR137">2000</xref>) but also has a platelet-activating effect (Jankauskaite et al. <xref ref-type="bibr" rid="CR95">2022</xref>) and leads to a procoagulant shift in the prothrombotic-fibrinolytic balance by stimulating monocyte tissue factor (TF) (Frantzeskaki et al. <xref ref-type="bibr" rid="CR65">2017</xref>). Pretorius et al. (<xref ref-type="bibr" rid="CR177">2022</xref>) found a moderate degree of platelet activation (mean severity of 7.1 out of 10) due to significantly elevated PS (CD62P) levels in platelet-poor plasma (PPP) in 30 of 80 LC patients studied (Pretorius <xref ref-type="bibr" rid="CR177">2022</xref>). &#945;7nAChRs expressed on the platelet membrane control platelet activation (Bennett <xref ref-type="bibr" rid="CR16">2018</xref>) by inhibiting p38 mitogen-activated protein kinase (MAPK), which is critical for platelet activation and aggregation, thrombus formation, and consolidation (Li et al. <xref ref-type="bibr" rid="CR124">2001</xref>) and is one of the earliest intracellular platelet-activating responses to a variety of stimuli, including mitogens, cytokines, stress, and ROS (Shi <xref ref-type="bibr" rid="CR201">2017</xref>; Son&#160;<xref ref-type="bibr" rid="CR209">2013</xref>). ACh is a potent inhibitor of p38 MAPK. It prevents phosphorylation and thus activation of p38 MAPK (Zhao <xref ref-type="bibr" rid="CR236">2015</xref>) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>f). Bennett et al. (<xref ref-type="bibr" rid="CR16">2018</xref>) showed that agonistic stimulation of platelet nAChRs leads to an increase in intracellular nitric oxide (NO) levels, resulting in inhibition of both P-selectin release and GPIIb/IIIa activation (Bennett <xref ref-type="bibr" rid="CR16">2018</xref>). In addition to AChRs, central components of the cholinergic system such as ACh, ChAT, AChE have been detected in platelets (Wessler and Kirkpatrick <xref ref-type="bibr" rid="CR227">2008</xref>) suggesting an autocrine involvement in platelet activation (Schedel et al. <xref ref-type="bibr" rid="CR194">2011</xref>) and, via &#945;7nAChRs in the megakaryocytic cell line, also an autocrine inhibition of thrombopoiesis (Schedel et al. <xref ref-type="bibr" rid="CR194">2011</xref>). Bennett et al. (<xref ref-type="bibr" rid="CR16">2018</xref>) showed in their ex vivo study that an nAChR antagonist (pancuronium) had prothrombotic effects, while an AChE inhibitor (donepezil) inhibited platelet activation. These observations suggest that platelet-released ACh acts as an endogenous inhibitor of platelet activation (Bennett <xref ref-type="bibr" rid="CR16">2018</xref>). In their review, Jankauskaite et al. (<xref ref-type="bibr" rid="CR95">2022</xref>) again found that thrombocytic nAChRs orchestrate the inhibition of PS expression (Jankauskaite et al. <xref ref-type="bibr" rid="CR95">2022</xref>). It is noteworthy that P-selectin overexpression cannot be reversed by administration of GP IIb/IIIa inhibitors, acetylsalicylic acid, or oral anticoagulants that are not vitamin K antagonists (NOACs) (Merten <xref ref-type="bibr" rid="CR137">2000</xref>). These correlations make a causal involvement of blocked nAChRs in LC-associated perfusion disorders in the sense of microclotting very likely.</p></sec><sec id="Sec9"><title>Endothelial dysfunction in long COVID</title><p id="Par21">Oikonomou et al. (<xref ref-type="bibr" rid="CR157">2022</xref>) studied 73 COVID-19 patients using flow-mediated dilation (FMD), a validated test to assess systemic endothelial dysfunction (Oikonomou <xref ref-type="bibr" rid="CR157">2022</xref>). FMD studies in Sprang-Dawley rats with phenylephrine-constricted carotid arteries showed a significant improvement in FMD and endothelial NO concentrations with ACh administration as visualized by diaminofluorescein-FM diacetate (DAF-FM) (Wilson&#160;<xref ref-type="bibr" rid="CR230">2016</xref>). In the studies by Oikonomou et al. <xref ref-type="bibr" rid="CR157">2022</xref> endothelial function was significantly impaired during acute COVID-19 infection (1.65 &#177;&#160;2.31% vs. 6.51&#160;&#177; 2.91%). The measured values were inversely correlated with interleukin-6 (IL-6) and troponin levels (as markers of disease severity), and this impairment did not fully recover despite an overall improvement over 1 and 6&#160;months of follow-up compared to controls (acute: 1.75&#8201;&#177;&#8201;2.19% vs. 1&#160;month: 4.23&#8201;&#177;&#8201;2.02%, vs. 6&#160;months: 5.24&#8201;&#177;&#8201;1.62%;<italic toggle="yes">p</italic>=&#8201;0.001) (Oikonomou <xref ref-type="bibr" rid="CR157">2022</xref>). Also using FMD, Ambrosino et al. (<xref ref-type="bibr" rid="CR9">2021</xref>) showed in 133 convalescent COVID-19 patients with persistent, predominantly pulmonary, impairment that two months after a negative SARS-CoV-2 swab there was a significant impairment in systemic endothelial function compared to controls (3.2%&#8201;&#177;&#8201;2.6 vs. 6.4%&#8201;&#177;&#8201;4.1<italic toggle="yes">p</italic>&lt;&#8201;0.001) (Ambrosino <xref ref-type="bibr" rid="CR9">2021</xref>). As the most extensive organ in the body, the endothelium is a central regulator of hemostasis, vascular resistance, permeability, innate immunity, barrier function, oxidative stress, and functional integrity of perfused tissues (Xu <xref ref-type="bibr" rid="CR233">2021</xref>). Numerous endothelial vasoactive substances control the balance of vasoconstriction and vasodilation, proliferation and inhibition of proliferation, prothrombotic and antithrombotic, inflammatory and anti-inflammatory, fibrinolytic and antifibrinolytic, and oxidative and antioxidative processes (Xu&#160;<xref ref-type="bibr" rid="CR233">2021</xref>). NO, produced by Ca<sup>++</sup>-activated (Corretti <xref ref-type="bibr" rid="CR43">2002</xref>) endothelial NO synthase (eNOS), is the major vasodilator molecule that also promotes antithrombotic, fibrinolytic, anti-inflammatory, antiproliferative, and antioxidant endothelial effects (Cyr et al. <xref ref-type="bibr" rid="CR44">2020</xref>; Xu&#160;<xref ref-type="bibr" rid="CR233">2021</xref>). Its antithrombotic effect is achieved by inhibiting the adhesion of leukocytes and platelets (Cyr et al. <xref ref-type="bibr" rid="CR44">2020</xref>) to activated endothelial cells (ECs), thereby suppressing the formation of inflammation-related thrombi or atherosclerotic plaques (Xu <xref ref-type="bibr" rid="CR233">2021</xref>). The vasodilator and antithrombotic NO effects are counteracted by several vasoconstrictors. These include angiotensin II (AT2), endothelin I (ET1), and reactive oxygen species (ROS), which in turn directly reduce NO by inactivating and uncoupling eNOS (Cyr et al. <xref ref-type="bibr" rid="CR44">2020</xref>). After endothelial synthesis, NO is released from ECs into vascular smooth muscle, where it causes relaxation (Furchgott and Vanhoutte&#160;<xref ref-type="bibr" rid="CR73">1989</xref>). Intravascularly, erythrocytes serve as NO reservoirs (Furchgott and Vanhoutte <xref ref-type="bibr" rid="CR73">1989</xref>). The band 3 protein (B3P) serves as a pathway for bidirectional passage of NO from and into erythrocytes (Huang <xref ref-type="bibr" rid="CR89">2001</xref>) where NO storage occurs as S-nitrosohemoglobin (SNOHb) (Huang&#160;<xref ref-type="bibr" rid="CR89">2001</xref>). When needed, erythrocytes release NO from SNOHb binding by transferring NO to the thiol group of B3P, thereby expelling it into the vascular lumen (Pawloski&#160;<xref ref-type="bibr" rid="CR169">2005</xref>). These mechanisms are characterized by high efficiency and capacity and are essential for the functional integrity of endothelial function. As a result, the definition of ED as a reduced bioavailability of NO and thus a shift in the balance between vasoconstrictor and vasodilator as well as prothrombotic and antithrombotic effects in favor of vasoconstrictor and prothrombotic effects (Cyr et al. <xref ref-type="bibr" rid="CR44">2020</xref>) is well established. In primary cell cultures, nAChRs with &#945;3, &#945;5, &#946;2, and &#946;4 subunits have been detected on the membranes of human aortic ECs (Macklin et al. <xref ref-type="bibr" rid="CR131">1998</xref>) and &#945;2, &#945;3, &#945;4, &#945;5, &#945;7, and &#946;2 and &#946;4 substituted nAChRs on rat microvascular ECs (Moccia <xref ref-type="bibr" rid="CR141">2004</xref>). In ECs, stimulation of membrane-bound nAChRs increases intracellular NO levels (Kirkpatrick et al.&#160;<xref ref-type="bibr" rid="CR105">2003</xref>), which in turn is responsible for vascular relaxation (Furchgott and Zawadzki <xref ref-type="bibr" rid="CR74">1980</xref>). This effect of nAChRs results from the Ca<sup>++</sup>dependence of eNOS activity (Corretti&#160;<xref ref-type="bibr" rid="CR43">2002</xref>) and the primary function of nAChRs as Ca<sup>++</sup>channels (Kalamida <xref ref-type="bibr" rid="CR98">2007</xref>). Accordingly, viral blockade of endothelial nAChRs leads to a reduction in NO and a shift in the balance of vasomotor and coagulation toward vasoconstriction and thrombogenesis (Cyr et al. <xref ref-type="bibr" rid="CR44">2020</xref>; Saldanha&#160;<xref ref-type="bibr" rid="CR189">2018</xref>; Furchgott and Zawadzki&#160;<xref ref-type="bibr" rid="CR74">1980</xref>) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>g). This is followed by reduced blood flow and tissue hypoxia, as well as vascular shear stress, which in turn contributes to damage to the glycocalyx (GC) (Bai and Wang <xref ref-type="bibr" rid="CR13">2014</xref>) (the gel-like inner vascular layer of proteoglycans and glycosaminoglycans (Furchgott and Zawadzki <xref ref-type="bibr" rid="CR74">1980</xref>) which subsequently protectively modulates leukocyte-endothelial interactions, thrombus formation, and vascular permeability (Wu et al. <xref ref-type="bibr" rid="CR231">2024</xref>), with further enhancement of ED (Wu et al. <xref ref-type="bibr" rid="CR231">2024</xref>). Vollenberg et al. (<xref ref-type="bibr" rid="CR221">2021</xref>) demonstrated elevated syndecan-1 levels 88&#160;days after mild SARS-CoV-2 infection, which are specific for persistent GC damage (Vollenberg <xref ref-type="bibr" rid="CR221">2021</xref>). This increase was also observed 4 and 12&#160;months after COVID-19 infection (Lambadiari&#160;<xref ref-type="bibr" rid="CR113">2021</xref>; Ikonomidis&#160;<xref ref-type="bibr" rid="CR93">2022</xref>). The correlations described above indicate that the pathological endothelial processes observed in LC are possibly due to an initial blockade of endothelial nAChRs by the SARS-CoV-2 virus.</p></sec><sec id="Sec10"><title>Arthralgia/myalgia</title><p id="Par22">Despite various diagnostic approaches such as bioelectrical impedance analysis (BIA), computed tomography (CT) and ultrasound (US), no structural or pathogenetic correlate has been found for the muscle pain and weakness that occurs in up to 66.7% (L&#243;pez-Hern&#225;ndez <xref ref-type="bibr" rid="CR126">2023</xref>) of LC cases (Montes-Ibarra et al. <xref ref-type="bibr" rid="CR145">2022</xref>). It is therefore suggested that persistent inflammation with impaired muscle protein metabolism, loss of physical activity and inadequate nutritional intake are the likely causes of muscle dysfunction associated with LC (Montes-Ibarra et al. <xref ref-type="bibr" rid="CR145">2022</xref>). Guy-Coichard et al. (<xref ref-type="bibr" rid="CR85">2008</xref>) investigated the disease-related pain burden in 511 patients with neuromuscular diseases (NMD). They found that 67.3% of NMD patients reported a significant pain burden and that myasthenia gravis (MG) and metabolic myopathy had the highest pain intensity (severe, partially immobilizing pain) at 38% and 49%, respectively (Guy-Coichard&#160;<xref ref-type="bibr" rid="CR85">2008</xref>). The example of MG shows that the quantitative reduction of functional neuromuscular junctions (NMJ) is an independent risk factor for muscle pain, which could result from an overload of the remaining physiologically innervated muscle fibrils (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>h). Indeed, many authors have reported SARS-CoV-2-induced myasthenia gravis (Essajee et al. <xref ref-type="bibr" rid="CR60">2021</xref>; Karimi et al. <xref ref-type="bibr" rid="CR99">2021</xref>). Striated muscle nAChRs, essential for the function of the NMJ (Di <xref ref-type="bibr" rid="CR54">2013</xref>), and the pain-modulating role of neuronal nAChRs (Posselt&#160;<xref ref-type="bibr" rid="CR176">1829</xref>) offer a plausible explanation for both muscle weakness and pain caused by SGP-related nAChR blockade. The results of Peng et al. (<xref ref-type="bibr" rid="CR171">2023</xref>) show that an autoimmune genesis of joint and muscle pain in LC (Peng <xref ref-type="bibr" rid="CR171">2023</xref>) is also conceivable, which can also be attributed to nAChR blockade of B cells (see section "Autoantibodies in LC").<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>The consequences of spike glycoprotein (SGP)-related blockade of nicotinic acetylcholine receptors (nAChRs) are shown based on the individual organ systems affected, with receptor blockade and its consequences shown in the left semicircle and normal cholinergic receptor function after SGP displacement by nicotine shown in the right semicircle. <bold>a</bold>&#160;impaired cholinergic neuromodulation with reduced nitric oxide (NO) and impaired neuronal excitability; <bold>b</bold>&#160;impaired mitochondrial acetylcholine action with reduced adenosine triphosphate (ATP) synthesis capacity and reduced reactive oxygen species (ROS) and Ca<sup>++</sup>&#8201;clearance; <bold>c</bold>&#160;impaired b-lymphocytic cholinergic innervation with natural autoantibodies (nAA) to pathological autoantibodies (pAA) shift; <bold>d</bold>&#160;impaired mastocytic cholinergic innervation with reduced inducible NO synthetase (iNOS) and inadequate mast cell degranulation; <bold>e</bold>&#160;impaired acetylcholine action on erythrocytes with decreased erythrocyte elasticity and oxygen uptake with increased pH/P50<sub>O2</sub> and rightward shift of oxygen dissociation curve (ODC); <bold>f</bold>&#160;impaired thrombocyte cholinergic innervation with increased P-selectin expression and increased aggregability <bold>g</bold>&#160;impaired endothelial cholinergic innervation with reduced endothelial NO synthetase (eNOS) synthesis, vasoconstriction, leukocyte adhesion and thrombogenesis; <bold>h</bold>&#160;SGP-induced blockade of neuromuscular junctions leads to reduced strength and painful overloading of unblocked muscle fibrils</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="42234_2025_167_Fig1_HTML.jpg"/></fig></p></sec></sec><sec id="Sec11"><title>Postural orthostatic tachycardia syndrome (POTS)</title><p id="Par23">During selective perfusion of intracardiac ganglia with &#945;-conotoxin MII, a specific antagonist of the &#945;3/&#946;2 interface of nAChRs, Bibevski et al. (<xref ref-type="bibr" rid="CR22">2000</xref>) showed a reversible attenuation of the cardiac sinus cycle length (SCL) response to preganglionic vagal stimulation by approximately 70%. Local administration of &#945;-conotoxin AuIB, a specific antagonist of the &#945;3/&#946;4 interface, and &#945;-bungarotoxin, a specific &#945;7nAChR blocker, attenuated this vagal mechanism by approximately 20% and 30%, respectively (Bibevski&#160;<xref ref-type="bibr" rid="CR22">2000</xref>). The authors concluded that despite the extensive muscarinic cholinergic innervation of the heart (Osipov et al.&#160;<xref ref-type="bibr" rid="CR160">2023</xref>), &#945;3/&#946;2 nAChRs (&#945;3/&#946;4 and &#945;7nAChRs to a lesser extent) play an important role in vagal control of heart rate (Bibevski <xref ref-type="bibr" rid="CR22">2000</xref>). Since negative chronotropic control of the heart during orthostasis relies on rapid vagal signaling, it is more plausible that orthostatic rate control is governed by fast-acting ionotropic nicotinic AChRs rather than slower-acting metabotropic mAChRs.</p><p id="Par24">The hypothesized viral blockade of intracardiac ganglionic nAChRs provides a rational explanation for the previously unexplained phenomenon of postural orthostatic tachycardia syndrome (POTS), which is frequently observed in LC (Abbate <xref ref-type="bibr" rid="CR1">2023</xref>).</p><sec id="Sec12"><title>Postvaccination syndrome</title><p id="Par25">The ongoing controversy over the existence of PVS is being replaced by an increasing number of reports describing an LC-like spectrum of symptoms following SARS-CoV-2 vaccination (Krumholz&#160;<xref ref-type="bibr" rid="CR110">2023</xref>; Abicic et al.&#160;<xref ref-type="bibr" rid="CR3">2022</xref>). As with LC, the pathophysiological background of this phenomenon remains unclear&#160;(Turner et al.&#160;<xref ref-type="bibr" rid="CR219">2023</xref>). Symptoms of PVS include exercise intolerance, excessive fatigue, numbness, brain fog, and neuropathic and neuromuscular symptoms (Krumholz&#160;<xref ref-type="bibr" rid="CR110">2023</xref>). For example, Abicic et al. (<xref ref-type="bibr" rid="CR3">2022</xref>) recently described oculomotor weakness with diplopia that improved after administration of prednisolone and an AChE inhibitor (Abicic et al. <xref ref-type="bibr" rid="CR3">2022</xref>). In 2021, He et al. presented their studies on the sequence analysis of epitopes of the SARS-CoV-2 SGP that are suitable as immunogenic components of potential vaccines. Among 66 peptides, the authors identified 16 suitable gene loci based on their steric position, cytokine release ability, non-toxicity and non-allergenicity using mutational and immunoinformatics analyses (He&#160;<xref ref-type="bibr" rid="CR88">2021</xref>). Taking into account the recognizability of both HLA-I and HLA-II molecules as well as B- and T-cell relevance, three epitopes (aa 371&#8211;387, aa 379&#8211;395 and aa 897&#8211;913) remained as suitable candidates (He&#160;<xref ref-type="bibr" rid="CR88">2021</xref>). Two of these sequences correspond exactly to the gene locus (aa 381&#8211;386) of SGP, where the PRRA sequence (Farsalinos&#160;<xref ref-type="bibr" rid="CR62">2020</xref>) described by Changuex et al. (<xref ref-type="bibr" rid="CR35">2020</xref>) is located, which in turn binds to the extracellular domain of nAChRs (aa 189&#8211;192), the "core of the toxin binding site" (Farsalinos&#160;<xref ref-type="bibr" rid="CR62">2020</xref>). This strongly suggests that vaccines developed using these immunogenic sequences may exhibit the nAChR-blocking effect described by Changeux et al. (<xref ref-type="bibr" rid="CR35">2020</xref>). The correlations described provide a very plausible rationale for the comparability of symptoms of PVS and offer the possibility of destigmatizing people with PVS (Turner et al. <xref ref-type="bibr" rid="CR219">2023</xref>) and offering a promising therapeutic approach instead.</p></sec><sec id="Sec13"><title>Reactivation of previous viruses</title><p id="Par26">Numerous studies have shown that a variety of previous or persistent viral diseases (Altmann et al.&#160;<xref ref-type="bibr" rid="CR7">2023</xref>) (Epstein-Barr virus [EBV] (Altmann et al. <xref ref-type="bibr" rid="CR7">2023</xref>), cytomegalovirus [CMV](Altmann et al.&#160;<xref ref-type="bibr" rid="CR7">2023</xref>), human immunodeficiency virus [HIV] (Peluso <xref ref-type="bibr" rid="CR170">2023</xref>) and influenza A virus [IAV] (Kim&#160;<xref ref-type="bibr" rid="CR106">2023</xref>), infectious bronchitis virus [IBV](Kim&#160;<xref ref-type="bibr" rid="CR106">2023</xref>), varicella zoster virus [VZV](Kim&#160;<xref ref-type="bibr" rid="CR106">2023</xref>), human herpesvirus [HHV-1(Kim&#160;<xref ref-type="bibr" rid="CR106">2023</xref>), HHV-2(Kim&#160;<xref ref-type="bibr" rid="CR106">2023</xref>), HHV-6 (Kim&#160;<xref ref-type="bibr" rid="CR106">2023</xref>), HHV-7 (Kim&#160;<xref ref-type="bibr" rid="CR106">2023</xref>), HHV-8 (Kim <xref ref-type="bibr" rid="CR106">2023</xref>)], HBV(Kim <xref ref-type="bibr" rid="CR106">2023</xref>) and parvovirus B19 (Kim&#160;<xref ref-type="bibr" rid="CR106">2023</xref>) may be reactivated in the context of COVID-19 infection or in association with LC. Coincidently, there is now a consensus that not only SARS-CoV-2 can bind to nAChRs. Neri and colleagues (<xref ref-type="bibr" rid="CR153">1990</xref>) demonstrated high sequence homology between the AAS of HIV-1 gp120 and several AChR-affine snake venom neurotoxins and the nAChR-affine RABV glycoprotein (Lentz et al. <xref ref-type="bibr" rid="CR122">1983</xref>; Neri et al. <xref ref-type="bibr" rid="CR153">1990</xref>) and demonstrated nAChR binding of HIV-1 (Neri et al. <xref ref-type="bibr" rid="CR153">1990</xref>). Bracci et al. (<xref ref-type="bibr" rid="CR26">1997</xref>) confirmed the high AAS sequence homology of aa160-170 of HIV-1 gp120 and aa189-199 of RABV glycoprotein with the AAS aa30-40 in snake venom and also showed that antibodies formed after RABV vaccination cross-reacted with HIV-1, further confirming the homologous immunity of these AChR high-affinity epitopes (Bracci <xref ref-type="bibr" rid="CR26">1997</xref>). In addition, Myles et al. (<xref ref-type="bibr" rid="CR150">2003</xref>) demonstrated that transcutaneous continuous nicotine application leads to HSV-1 reactivation as measured by viral load in the tear film of latently infected New Zealand White rabbits (Myles&#160;<xref ref-type="bibr" rid="CR150">2003</xref>). Wang et al. (<xref ref-type="bibr" rid="CR225">2024</xref>) recently demonstrated that increasing the presence of D&#945;6 (the insect-associated analog of human &#945;7nAChR) reduced the titer of Drosophila melanogaster (DMG) sigmoid virus (DMelSV) (Wang&#160;<xref ref-type="bibr" rid="CR225">2024</xref>). Interestingly, the authors were able to reverse this effect with low doses of the low-dose nAChR-antagonistic spinosad (an insecticide), while high doses of spinosad (a high-dose nAChR agonist) in turn led to a reduction in viral load. This bidirectional regulation of virus levels was not possible in D&#945;6 knockout flies (Wang <xref ref-type="bibr" rid="CR225">2024</xref>). According to the allosteric configuration of nAChRs with an increase in LBS after agonistic stimulation (Kenakin&#160;<xref ref-type="bibr" rid="CR104">2024</xref>; Spurny&#160;<xref ref-type="bibr" rid="CR210">2015</xref>), this effect can be interpreted as an increase or decrease in nAChR LBS after agonistic and antagonistic stimulation with a corresponding change in nAChR virus binding and thus the detectability of DMelSV. Similarly, Diao et al. (<xref ref-type="bibr" rid="CR53">2018</xref>) showed an increase in viral load of chronic bee paralysis virus (CBPV) in Italian bees after exposure to high doses of the irreversibly binding (i.e. blocking) nAChR agonist imidacloprid (Diao&#160;<xref ref-type="bibr" rid="CR53">2018</xref>). Di Pisco et al. (<xref ref-type="bibr" rid="CR54">2013</xref>) describe identical observations regarding the detectability of Deformed Wing Virus (DWV) after 30&#160;days of sublethal doses of thiamethoxan (irreversible nAChR antagonist) and imidacloprid (Di&#160;<xref ref-type="bibr" rid="CR54">2013</xref>). The higher binding affinity or concentration of SARS-CoV-2 SGP at nAChRs may outcompete other viral particles, potentially triggering latent viral reactivation.</p></sec><sec id="Sec14"><title>Nicotine</title><p id="Par27">Nicotine, identified in 1928 by Posselt and Reimann as an alkaloid component of the tobacco plant (Posselt&#160;<xref ref-type="bibr" rid="CR176">1829</xref>), makes up approximately 0.6&#8211;3% of the dry weight of tobacco plants and is the addictive component of tobacco products (Prochaska <xref ref-type="bibr" rid="CR180">2016</xref>). Serum nicotine levels, and thus the clinical effects of nicotine, are highly dependent on the route of administration (Benowitz&#160;<xref ref-type="bibr" rid="CR19">2009</xref>). The affinity of nicotine for nAChRs is significantly higher than that of ACh and depends on the subunit composition of the receptors, with the inhibition constant (K<sub>i</sub>) of nicotine for &#945;7nAChRs (Leitzke&#160;<xref ref-type="bibr" rid="CR118">2023</xref>; Gotti&#160;<xref ref-type="bibr" rid="CR79">1994</xref>) being approximately 30-fold lower (inversely proportional to the binding affinity [Ramsay&#160;<xref ref-type="bibr" rid="CR183">2017</xref>]) than that of the natural ligand (ACh). The high dissociation constant (pKa&#8201;=&#8201;8.0) explains the large differences in absorption capacity across membranes in different parts of the body. Inhalation of tobacco smoke (pH 5.5&#8212;6.02) (Benowitz <xref ref-type="bibr" rid="CR19">2009</xref>) results in rapid arterial nicotine uptake (Molyneux&#160;<xref ref-type="bibr" rid="CR143">2004</xref>) and reaches high concentrations in the ventral tegmental area (VTA) (Le Houezec&#160;<xref ref-type="bibr" rid="CR115">2003</xref>) within 10&#8211;20&#160;s. This leads to high dopamine release in the nucleus accumbens (Yildiz <xref ref-type="bibr" rid="CR234">2004</xref>), which explains the behavioral reinforcing effects of smoking (Benowitz <xref ref-type="bibr" rid="CR17">1990</xref>) and activation of the reward system (Arias-Carri&#243;n et al. <xref ref-type="bibr" rid="CR11">2010</xref>). The conformational changes (Buisson&#160;<xref ref-type="bibr" rid="CR29">2001</xref>) and upregulation of nAChRs (Buisson&#160;<xref ref-type="bibr" rid="CR29">2001</xref>; Govind&#160;<xref ref-type="bibr" rid="CR83">2012</xref>) further support the development of addiction and withdrawal symptoms during smoking cessation (Benowitz&#160;<xref ref-type="bibr" rid="CR17">1990</xref>). All available nicotine replacement therapies (NRTs) are based on venous absorption of nicotine (Wadgave&#160;<xref ref-type="bibr" rid="CR222">2016</xref>). This results in a significant delay in the rise in concentration and a delayed dopaminergic response in the CNS (Wang&#160;<xref ref-type="bibr" rid="CR224">2014</xref>). Due to nicotine-induced monoamine oxidase A and B, which degrade dopamine (Sandhu&#160;<xref ref-type="bibr" rid="CR191">2024</xref>), the delayed absorption is also followed by significantly lower CNS concentrations of the alkaloid (West&#160;<xref ref-type="bibr" rid="CR228">2000</xref>). CNS nicotine concentrations comparable to smoking have been observed with nicotine nasal spray alone (Guthrie&#160;<xref ref-type="bibr" rid="CR84">1999</xref>). In their review, Dautzenberg et al. (<xref ref-type="bibr" rid="CR46">2021</xref>) analyzed a total of 33 studies on the use of transdermal nicotine application in nonsmokers or ex-smokers (Dautzenberg et al. <xref ref-type="bibr" rid="CR46">2021</xref>). None of the studies found withdrawal symptoms or associated addictive behavior. In non-smokers, neither craving for inhaled nicotine nor use of another nicotine source after discontinuation of therapy was observed during a longer follow-up period of 12&#160;weeks after discontinuation of transdermal nicotine application (Pullan&#160;<xref ref-type="bibr" rid="CR181">1994</xref>). Therefore, it can be concluded that transdermal nicotine delivery can be considered safe with respect to the risk of addiction. Base nicotine is readily absorbed transdermally (Benowitz&#160;<xref ref-type="bibr" rid="CR19">2009</xref>). All available transdermal therapeutic systems (TTS) are based on the release of the active substance through a matrix and/or membrane, which makes the systemic absorption dependent on the release properties of the matrix/membrane and the absorption properties of the skin (i.e. permeability, blood flow). In the liver, nicotine is metabolized to six primary metabolites. Of these, the neuroactive alkaloid cotinine is the most important at 70&#8211;80% (Benowitz&#160;<xref ref-type="bibr" rid="CR19">2009</xref>). The first metabolic steps are catalyzed by CYP2A6 and a cytoplasmic aldehyde oxidase (Benowitz&#160;<xref ref-type="bibr" rid="CR19">2009</xref>). Nicotine clearance is subject to several influences. For example, the postprandial increase in hepatic perfusion (30%) also results in increased nicotine clearance (40%) (Benowitz&#160;<xref ref-type="bibr" rid="CR19">2009</xref>). Nicotine clearance decreases by an average of 23% after the age of 65&#160;years (Molander&#160;<xref ref-type="bibr" rid="CR142">2001</xref>), while the age group between 18 and 69&#160;years shows identical steady-state plasma levels and clearance rates after transcutaneous nicotine application at identical doses&#160;(Gourlay and Benowitz&#160;<xref ref-type="bibr" rid="CR81">1996</xref>). Using urine and blood concentrations of cotinine, Dempsey et al. (<xref ref-type="bibr" rid="CR52">2000</xref>) showed that metabolic rates are identical in adults, children, and even neonates (Dempsey&#160;<xref ref-type="bibr" rid="CR52">2000</xref>). In contrast, nicotine and cotinine clearance is significantly higher in women than in men (Benowitz et al.&#160;<xref ref-type="bibr" rid="CR21">2006</xref>). This difference is increased by oral contraception (28% and 30%, respectively) (Benowitz et al. <xref ref-type="bibr" rid="CR21">2006</xref>) and pregnancy (60% and 140%, respectively) (Dempsey&#160;<xref ref-type="bibr" rid="CR51">2002</xref>) but not by the menstrual cycle (follicular vs. luteal phase) (Hukkanen et al.&#160;<xref ref-type="bibr" rid="CR90">2005</xref>). Some drugs, such as rifampicin, dexamethasone, and phenobarbital, induce CYP2A6 with considerable interindividual variability (Meunier&#160;<xref ref-type="bibr" rid="CR139">2000</xref>). Other drugs, such as methoxsalen (8-methoxypsoralen), tranylcypromine, tryptamine, and coumarin, inhibit CYP2A6 (Zhang et al.&#160;<xref ref-type="bibr" rid="CR235">2001</xref>). Raloxifene, on the other hand, is a potent inhibitor of aldehyde oxidase and therefore potentially interferes with hepatic cotinine formation at the level of nicotinic &#916;1&#8242;(5&#8242;)iminium ions (Obach&#160;<xref ref-type="bibr" rid="CR156">2004</xref>). However, in clinical practice, only methoxsalen (a phototherapy adjuvant for psoriasis) and tranylcypromine (a monoamine oxidase inhibitor) have been shown to significantly inhibit nicotine clearance in humans (Sellers&#160;<xref ref-type="bibr" rid="CR198">2000</xref>; Sellers&#160;<xref ref-type="bibr" rid="CR199">2003</xref>). Ethnicity plays a role only in that people of Black/African ancestry have a slightly lower metabolic rate than all other ethnic groups (total clearance 0.57 vs. 0.76&#160;ml&#160;min<sup>&#8722;1</sup>&#160;kg<sup>&#8722;1</sup>) (P&#233;rez-Stable&#160;<xref ref-type="bibr" rid="CR172">1998</xref>). The nicotine replacement therapies (NRTs) used produce approximately one to two thirds of the plasma nicotine levels measured in smokers, which range from 10 to 37&#160;ng&#160;ml<sup>&#8722;1</sup> (peak concentrations between 19 and 50&#160;ng&#160;ml<sup>&#8722;1</sup>) (Patterson&#160;<xref ref-type="bibr" rid="CR167">2003</xref>) and between 10 and 20&#160;ng&#160;ml<sup>&#8722;1</sup>in TTS (Schneider et al.&#160;<xref ref-type="bibr" rid="CR196">2001</xref>). Due to tissue distribution, plasma nicotine levels decrease within the next 20&#160;min after smoking with a half-life of 8&#160;min (Benowitz et al.&#160;<xref ref-type="bibr" rid="CR20">1988</xref>). In nicotine-na&#239;ve individuals, the most common immediate mild side effects of nicotine are occasional coughing/sneezing and scratchy throat (M&#252;ndel&#160;<xref ref-type="bibr" rid="CR148">2017</xref>) and the most common severe side effects are tachycardia, nausea, dizziness (M&#252;ndel <xref ref-type="bibr" rid="CR148">2017</xref>) and diarrhea (Debnath&#160;<xref ref-type="bibr" rid="CR50">2022</xref>). Occasional mood effects (anxiety [Ouagazzal et al.&#160;<xref ref-type="bibr" rid="CR161">1999</xref>]), sadness, confusion, anger, energy, and fatigue (Korhonen et al.&#160;<xref ref-type="bibr" rid="CR108">2006</xref>) have been attributed primarily to nAChRs with &#945;4, &#945;7, or &#946;2 subunits (Tucci et al.&#160;<xref ref-type="bibr" rid="CR218">2003</xref>). Sleep disturbances (Dependence Update Panel, Liaisons&#160;<xref ref-type="bibr" rid="CR2">2000</xref>), dizziness (M&#252;ndel&#160;<xref ref-type="bibr" rid="CR148">2017</xref>) as well as headaches (Prochaska&#160;<xref ref-type="bibr" rid="CR180">2016</xref>) and local skin reactions (Yildiz&#160;<xref ref-type="bibr" rid="CR234">2004</xref>) have also been observed. At low doses, nicotine has a general depressant effect, while at higher doses it has stimulant effects (Fagerstr&#246;m <xref ref-type="bibr" rid="CR63">2014</xref>). In animal studies, nicotine improved vigilance (Lloyd <xref ref-type="bibr" rid="CR125">2000</xref>), locomotor activity (Lloyd <xref ref-type="bibr" rid="CR125">2000</xref>), cognition in general (Lloyd&#160;<xref ref-type="bibr" rid="CR125">2000</xref>; Barr&#160;<xref ref-type="bibr" rid="CR14">2008</xref>), respiratory function (Lloyd&#160;<xref ref-type="bibr" rid="CR125">2000</xref>), cortical blood flow (Lloyd&#160;<xref ref-type="bibr" rid="CR125">2000</xref>), EEG activity (Lloyd <xref ref-type="bibr" rid="CR125">2000</xref>), and pain tolerance (Lloyd&#160;<xref ref-type="bibr" rid="CR125">2000</xref>) with improved gastrointestinal and cardiovascular regulation (Lloyd <xref ref-type="bibr" rid="CR125">2000</xref>). The originally postulated very low therapeutic range (LD50 0.5&#8211;1&#160;mg&#160;kg<sup>&#8722;1</sup>) has been found to be significantly higher in recent studies, especially with regard to the lethal dose (6.6&#8211;13&#160;mg&#160;kg<sup>&#8722;1</sup>) (Mayer&#160;<xref ref-type="bibr" rid="CR135">2014</xref>). For NRTs, there is no mention in the literature of life-threatening complications at commercially available doses (Moore <xref ref-type="bibr" rid="CR146">2009</xref>). NRTs are even considered safe in patients with stable coronary artery disease (Molyneux <xref ref-type="bibr" rid="CR143">2004</xref>), whereas caution is advised in the period (2&#160;weeks) after acute myocardial infarction&#160;<xref ref-type="bibr" rid="CR242">2008</xref>, in unstable acute coronary artery disease (Molyneux <xref ref-type="bibr" rid="CR143">2004</xref>); (<xref ref-type="bibr" rid="CR242">2008</xref>), during pregnancy (Molyneux <xref ref-type="bibr" rid="CR143">2004</xref>), during lactation (Molyneux&#160;<xref ref-type="bibr" rid="CR143">2004</xref>), and in persons younger than 18&#160;years&#160;(Molyneux&#160;<xref ref-type="bibr" rid="CR143">2004</xref>).</p><p id="Par28">Many cardiovascular pathologies are undoubtedly a consequence of smoking. These include alterations in hemostasis such as increased serum titers of activated platelets (Nair et al. <xref ref-type="bibr" rid="CR152">2001</xref>) with increased aggregation and thrombus formation, increased myocardial stress with coronary vasoconstriction (Keeley <xref ref-type="bibr" rid="CR103">1996</xref>) and unphysiological serum carbon monoxide concentrations with increased myocardial oxygen debt (Smith <xref ref-type="bibr" rid="CR208">2001</xref>). At the same time, proinflammatory and oxidative damage, together with endothelial dysfunction, lead to overall vascular pathology (Ambrose <xref ref-type="bibr" rid="CR10">2004</xref>).</p><p id="Par29">In comparative studies between smoking and TTS with respect to platelet activation and increased serum fibrinogen levels observed in smokers, Benowitz et al. (<xref ref-type="bibr" rid="CR18">1993</xref>) showed that these alterations in hemostasis are not detectable in TTS (Benowitz <xref ref-type="bibr" rid="CR18">1993</xref>), which has been confirmed in subsequent studies (Blann et al. <xref ref-type="bibr" rid="CR24">1997</xref>); Mundal&#160;<xref ref-type="bibr" rid="CR149">1995</xref>). The sympathomimetic autonomic imbalance associated with smoking, particularly with respect to autonomic cardiovascular control, is significantly less with transdermal administration of the monosubstance nicotine than with smoking (Lucini et al.&#160;<xref ref-type="bibr" rid="CR128">1998</xref>). Tobacco smoke contains 80 carcinogens (Li and Hecht <xref ref-type="bibr" rid="CR123">2022</xref>). For example, tobacco-associated nitrosamines (TSNA) or polycyclic hydrocarbons are known to be responsible for the development of many malignancies associated with long-term smoking (Church&#160;<xref ref-type="bibr" rid="CR39">2009</xref>; Bouvard&#160;<xref ref-type="bibr" rid="CR28">2009</xref>). And although a possible role for nicotine as a co-carcinogen remains controversial (Lee et al. <xref ref-type="bibr" rid="CR116">2011</xref>; Mousa<xref ref-type="bibr" rid="CR147">2006</xref>), there is now a large body of data showing that nicotine itself is not carcinogenic (Murray <xref ref-type="bibr" rid="CR155">2009</xref>; Murray&#160;<xref ref-type="bibr" rid="CR151">1996</xref>).</p><p id="Par30">Finally, the UK National Institute for Health and Care Excellence (NICE) concluded in 2013 that "studies with up to five years of follow-up suggest that 'pure' nicotine, as contained in nicotine replacement products (NRT), does not pose a significant health risk" (Lee and Fariss <xref ref-type="bibr" rid="CR117">2016</xref>; Mali&#160;<xref ref-type="bibr" rid="CR133">2019</xref>). Following our hypothesis (Leitzke&#160;<xref ref-type="bibr" rid="CR118">2023</xref>), many people with LC/ME/CFS have used LDTN to improve their symptoms and have shared their experiences in various forums. The results of a 60-question survey in one of these forums are appended to this paper (Supplement 1) and summarized in the discussion section. In addition, the effect of LDTN on the availability of free LBS of nAChRs was correlated with the course of LC symptoms in a patient under clinical conditions in an imaging experiment.</p></sec><sec id="Sec15"><title>Case report</title><p id="Par31">A teacher suffering from persistent symptoms for over three years following SARS-CoV-2 infection was referred to us from the Long COVID Outpatient Department at the University of Leipzig Medical Centre. The most prominent symptom was an inability to speak fluently, which the patient described as a delayed transmission of her perceived normal word-forming impulses to the motor speech-forming organs. The patient was asked to rate her symptoms on a chart (0&#8212;none, 1&#8212;mild, 2&#8212;marked, 3&#8212;severe, 4&#8212;very severe, and 5&#8212;unbearable). Her self-reported symptoms included post-exertional malaise (PEM) (2), fatigue (3), cognitive overstimulation and concentration problems (brain fog) (1), cold extremities (3), dizziness (3), numb fingers (1), and burning or irritated eyes (1).</p><p id="Par32">The hypothesis of viral blockade of nAChRs as a potential cause of her complaints, the therapeutic approach using LDTN and the evaluation of receptor occupancy with molecular hybrid PET imaging using a nAChR-specific tracer ([-]-[<sup>18</sup>F]Flubatine) were thoroughly explained to the patient. She consented to the procedure and the publication of her case details. Continuous LDTN therapy (7&#160;mg/24&#160;h) was administered for 7 consecutive days (days 2&#8211;8).</p><p id="Par33">We used the highly selective PET radiotracer (-)-[<sup>18</sup>F]Flubatine for imaging and in vivo quantification of &#945;4&#946;2* nAChRs availability (Sabri <xref ref-type="bibr" rid="CR186">2015</xref>; Patt&#160;<xref ref-type="bibr" rid="CR168">2013</xref>).</p><p id="Par34">Two PET scans within 26&#160;days (day1 and day 27) were performed on a PET/CT with long axial field of view (106&#160;cm, Biograph Vision Quadra, Siemens Healthineers, Erlangen, Germany) in ultra-high sensitivity mode following a bolus injection of 296.2&#160;MBq (pre LDTN) and 298.0&#160;MBq (post LDTN), respectively, MBq (-)-[<sup>18</sup>F]Flubatine consisting of three dynamic acquisitions 0 &#8211; 90&#160;min, 195 &#8211; 225&#160;min and 330 &#8211; 360&#160;min p.i. alongside arterial blood samples were taken over the six hours for the analysis of plasma to whole blood ratios, metabolites as well as plasma to protein binding (Sabri&#160;<xref ref-type="bibr" rid="CR186">2015</xref>; Patt&#160;<xref ref-type="bibr" rid="CR168">2013</xref>). To exclude the previously described immediate effect of nicotine on receptor density (Bhatt&#160;<xref ref-type="bibr" rid="CR23">2018</xref>), the second PET-CT/MRI scan was performed 7&#160;days after LDTN cessation (the half-life of nicotine: 1&#8211;2&#160;h (Sanner and Grimsrud&#160;<xref ref-type="bibr" rid="CR192">2015</xref>) and the absence of the alkaloid was confirmed by a negative cotinine test (Brody&#160;<xref ref-type="bibr" rid="CR27">2014</xref>).</p><p id="Par35">CT data were used for subject-specific multiple-organ objective segmentation (Sundar&#160;<xref ref-type="bibr" rid="CR214">2022</xref>), while brain segmentation was performed using FastSurfer (248). Dynamic PET data were motion corrected (Shiyam <xref ref-type="bibr" rid="CR202">2023</xref>) and kinetic modeling of the whole body including the brain was performed based on the metabolites-corrected arterial input function and by applying Logan (<xref ref-type="bibr" rid="CR127">1990</xref>) graphical analysis (t*&#8201;=&#8201;10&#160;min) to generate parametric images of total distribution volume (V<sub>T</sub>), which is defined by the ratio of the concentration of the radioligand in a region of tissue to that in plasma at equilibrium. The tissue itself may contain radioligand that is specifically bound to receptors, nonspecifically bound, or free in tissue water (Innis&#160;<xref ref-type="bibr" rid="CR94">2007</xref>). The total distribution volume is a linear function of the receptor binding site density available for the tracer and correlates well with the known distribution of &#945;4&#946;2* nAChRs in the brain (Sabri&#160;<xref ref-type="bibr" rid="CR186">2015</xref>). A detailed description of the kinetic model and its parameters, which was used to describe the PET-tracer dynamic, is given in (Becker&#160;<xref ref-type="bibr" rid="CR15">2013</xref>).</p></sec></sec><sec id="Sec16"><title>Results</title><p id="Par36">Metabolization of the tracer was minimal, with approximately 92% of the unchanged parent compound remaining at 90&#160;min and 91% at 330&#160;min post-injection (p.i.).</p><p id="Par37">Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref> shows coronal slices of parametric V<sub>T</sub> images of both, the pre and post treatment PET scan illustrating a slight increase in V<sub>T</sub> signal after treatment. This increase was approximately 7.6% within the brain, and &#8722;10.7 (upper lobe)&#160;&#8211;&#160;8.9% (lower lobe) in the lung, 7.4% in the muscles, 5.6% in the liver and 39.2% in the vertebrae (more details can be found in the Supplementary Table&#160;2).<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p><bold>A</bold>&#160;Coronal slices of whole-body (-)-[<sup>18</sup>F]Flubatine PET and <bold>B</bold> axial slices the brain fused with T1-MR images of the same patient before (top row) and after treatment (middle row) with nicotine patches. Parametric images of total distribution volume (obtained by Logan graphical analysis) depict the distribution of &#945;4&#946;2* nAChRs in the body. The higher V<sub>T</sub> signal observed post-treatment reflects increased receptor availability for the tracer. Bottom row illustrates the absolute V<sub>T</sub>&#160;differences between both scanning sessions with red indicating an increase and blue color a decrease after treatment</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="42234_2025_167_Fig2_HTML.jpg"/></fig></p><p id="Par38">By day 29, the patient's subjective complaints were reduced to dizziness (1) and irritated eyes (1). All the other complaints were no longer detectable.</p><sec id="Sec17"><title>Neurological findings</title><p id="Par39">The patient, a 44-year-old woman with a 3.5-year history of nonspecific subjective complaints, underwent specialized investigations. Upon admission, she underwent a comprehensive clinical evaluation, including psychiatric referral. Based on standardized procedures (physical exam, psychiatric exam, structured clinical interview [SCID] I and II) she was diagnosed with functional neurologic disorder (FND) (dysarthria) according to DSM V (F44.4 ICD-10).</p><p id="Par40">After the intervention, her condition was fully resolved. She was subsequently diagnosed with an adjustment disorder (DSM V / F43.1 ICD-10) not reaching the level of major depressive episode (Hamilton Depression Scale [HAMD] 4 points).</p><p id="Par41">At baseline she was rated with CGI-S score of 5 while her follow-up CGI-I score of 2 reflected significant clinical improvement. Concerning CGI, it was developed for use in NIMH-sponsored clinical trials to provide a brief, stand-alone assessment of the clinician's view of the patient's global functioning prior to and after initiating a study medication (Busner&#160;<xref ref-type="bibr" rid="CR30">2007</xref>). The Clinical Global Impression (CGI) scale was developed for use in NIMH-sponsored clinical trials and provides a brief, clinician-determined assessment of a patient&#8217;s global functioning before and after treatment (Busner <xref ref-type="bibr" rid="CR30">2007</xref>). It integrates all available information, including the patient&#8217;s history, psychosocial circumstances, symptoms, behavior, and functional impact of symptoms. Notably, the CGI-I score determined through clinical judgment at baseline and follow-up aligned with the patient&#8217;s self-reported improvements in subjective impairment (Busner&#160;<xref ref-type="bibr" rid="CR30">2007</xref>). The cognitive recovery (i.e. in speech) might be explained by central nAChR changes alone; however, the disease may also involve other organs or systems such as bone marrow or lymphocytes according to or as indicated by the figure and the review text.</p></sec></sec><sec id="Sec18"><title>Discussion</title><p id="Par42">In their study, Godellas, Cymes, and Grosman&#160;(<xref ref-type="bibr" rid="CR77">2022</xref>) challenged the nicotine hypothesis presented by Changuex et al. (<xref ref-type="bibr" rid="CR35">2020</xref>). Their study tested nicotine&#8217;s affinity for only a limited number of &#945;7nAChR AASs on HEK-293 cells, a limitation acknowledged by the authors themselves (Godellas et al. <xref ref-type="bibr" rid="CR77">2022</xref>). Other studies have clearly confirmed such an interaction between the SARS-CoV-2 SGP and the LBS of the different nAChRs (Farsalinos <xref ref-type="bibr" rid="CR62">2020</xref>; Lagoumintzis&#160;<xref ref-type="bibr" rid="CR111">2020</xref>). Furthermore, in a previous in silico study using the molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) approach, the &#945;7nAChR fraction had significantly lower binding energy to SARS-CoV-2 compared to &#945;4&#946;2nAChR and &#945;&#946;&#947;&#948;nAChR (muscle-type receptor from the electric organ of Tetronarce californica) (Oliveira <xref ref-type="bibr" rid="CR158">2021</xref>), which indicates a lower affinity and may be the reason for lower detectability in the results of Godellas, Cymes, and Grosman (Godellas et al. <xref ref-type="bibr" rid="CR77">2022</xref>). Although O&#180;Brien et al. (<xref ref-type="bibr" rid="CR164">2023</xref>) have demonstrated an augmentation of the effect of PAMs at the nAChRs in whole-cell and single-channel recordings following exposure to SGP (O&#8217;Brien et al. <xref ref-type="bibr" rid="CR164">2023</xref>) fragments (Chrestia et al.&#160;<xref ref-type="bibr" rid="CR38">2022</xref>), this phenomenon was only discernible at minimal SGP concentrations. At elevated SGP concentrations, the effect transitioned into an inhibitory mode of operation (O&#8217;Brien et al.&#160;<xref ref-type="bibr" rid="CR164">2023</xref>; Chrestia et al.&#160;<xref ref-type="bibr" rid="CR38">2022</xref>). It is imperative to underscore that, contingent upon their stoichiometry&#8212;defined as the distinct composition of different &#945;- and &#946;-subunits&#8212;nAChRs manifest disparate ED<sub>50</sub> and I<sub>max</sub> properties with regard to their affinity to agonists, as well as their Ca<sup>++</sup> conductance. Thus, nAChRs are classified into two distinct categories: high-sensitivity (HS) and low-sensitivity (LS) nAChRs. Furthermore, depending on the receptor occupancy at the corresponding orthosteric (e.g., ACh/nicotine) or allosteric (i.e., NAM/PAM) LBSs, they are characterized by both autologous (ACh) and heterologous (NAMs or PAMs) allosteric conformational changes. This enables nAChRs to adopt different functional states with respect to Ca<sup>++</sup>conductance (open/closed state) and affinity to the corresponding ligands (sensitized/desensitized state), depending on LBS saturation (Papke&#160;<xref ref-type="bibr" rid="CR166">2020</xref>). This highly complex balance of different functional states is likely to influence the LC/PASC pathology itself, but certainly also the efficacy of therapy with high-affinity ligands.</p><p id="Par43">The findings of the present case study demonstrate an overall augmentation of V<sub>T</sub> by 7.6% subsequent to the implementation of LDTN. This observation aligns with the discrepancies observed in specific regions of interest among patients diagnosed with mild Alzheimer's disease compared to those categorized as healthy individuals (1&#8211;10%) (Sabri&#160;<xref ref-type="bibr" rid="CR187">2018</xref>), indicating significant impairment in overall brain function.</p><p id="Par44">The studies by Swank et al. (<xref ref-type="bibr" rid="CR213">2023</xref>) demonstrate the persistence of SARS-CoV-2 associated antigens (S1, full-length SGP, nucleocapsid), indicating the presence of a reservoir in the organism of LC/PASC patients (Swank&#160;<xref ref-type="bibr" rid="CR213">2023</xref>). These findings support our hypothesis of the persistence of SARS-CoV-2 in binding to nAChRs.</p><p id="Par45">The fact that anthelmintic ivermectin (Shahbaznejad&#160;<xref ref-type="bibr" rid="CR200">2021</xref>) and the phosphodiesterase inhibitor pyridostigmine (Mestinon) (Davis et al.&#160;<xref ref-type="bibr" rid="CR48">2023</xref>) alleviate the symptoms in acute COVID-19 and LC patients, respectively is clear evidence that impaired cholinergic transmission is a central problem in LC. Since, ivermectin, as a PAM, increases the conductance of the nAChR cation channel by binding to the allosteric binding site (ABS) of nAChRs and thus enhances the effect of ACh on its receptors (Spurny&#160;<xref ref-type="bibr" rid="CR210">2015</xref>), mestinon generally increases the concentration of the transmitter at the nAChRs by inhibiting the cleavage of ACh (Pakala&#160;<xref ref-type="bibr" rid="CR165">2024</xref>), both drugs have a supportive effect on nAChR related cholinergic transmissibility. However, both substances only exert this supporting effect on nAChRs that do not exhibit blockade of the orthosteric binding site (OBS) of these receptors, since ivermectin as a PAM has no competitive effect at the OBS of nAChRs (Spurny&#160;<xref ref-type="bibr" rid="CR210">2015</xref>) and therefore cannot displace the blocking SGP from this position. Also, increasing the concentration of ACh to OBS (Gotti&#160;<xref ref-type="bibr" rid="CR79">1994</xref>), due to its high inhibition constant (K<sub>i</sub>) and low affinity, respectively, is not able to remove the viral blockade from the OBS. Thus, the application of the two substances leads to a general improvement of cholinergic transmission at receptors not affected by the blockade in the manner described, but without reversing the blockade of the affected nAChRs, which we believe is causative for LC. It is therefore unlikely that either substance alone will bring about a lasting improvement in the LC problem. Nevertheless, both approaches, in conjunction with vagal nerve stimulation (VNS) via non-invasive techniques (e.g., auricular vagus nerve stimulation (Zheng&#160;<xref ref-type="bibr" rid="CR238">2024</xref>), coherent breathing (Corrado&#160;<xref ref-type="bibr" rid="CR42">2022</xref>) or implantable devices (Rangon&#160;<xref ref-type="bibr" rid="CR182">2025</xref>), may potentially augment the unblocking effect of nicotine. In most cases, a delayed effect of alkaloid application is to be expected. For example, the average half-life of IgG antibodies (pAAs) in the circulation is 3&#160;months (Seijsing&#160;<xref ref-type="bibr" rid="CR197">2018</xref>).</p><p id="Par46">Additionally, T and B lymphocytes are particularly vulnerable to receptor blockade due to their extremely high number of nAChRs per cell (Skok et al.&#160;<xref ref-type="bibr" rid="CR204">2005</xref>). This means that an impaired immune response to released SGP is to be expected. In addition, the fact that every human cell could be affected by AChR blockade and that each of these cells has a myriad of AChRs (up to 15,000/cell (Skok et al.&#160;<xref ref-type="bibr" rid="CR204">2005</xref>)), which in turn exhibit different numbers of LBS (OBS or ABS) as part of allosteric conformational changes, correlates with the unimaginable individuality of the clinical picture of LC. At the same time, transcutaneous nicotine application is also subject to large variations in the number of affected nAChRs and their pharmacokinetic accessibility by nicotine. Consequently, it is almost impossible to predict the effectiveness of SGP elimination and thus the individual course of improvement.</p><p id="Par47">Moreover, the study by Changeux et al. (<xref ref-type="bibr" rid="CR35">2020</xref>) also showed a sequence homology between the PRRA motif of the SGP and the receptor binding domain of various muscarinic toxins (e.g., cobratoxin, muscarin toxin-like protein) (Changeux&#160;<xref ref-type="bibr" rid="CR35">2020</xref>). This leaves the question of a possible viral blockade of muscarinic acetylcholine receptors (mAChRs) unanswered. If these acetylcholine receptors are also blocked in the context of LC pathology, further investigations must show whether specific ligands with high affinity to mAChRs (i.e., scopolamine [hyoscine], which is also available for transcutaneous administration) are able to release mAChRs from potential viral binding in correspondence with nicotine in nAChRs. The continuous transcutaneous application of the alkaloid seems to be without alternative, because the presumed large affinity difference between ACh, SGP and the alkaloid in combination with the short half-life of nicotine (Yildiz&#160;<xref ref-type="bibr" rid="CR234">2004</xref>) makes a rapid re-attachment of SGP to the AChRs after short-term nicotine exposure very likely and possibly causes an SGP cyclic reattachment effect on the nAChRs with recurrence or postponement of symptoms. The reactivation of various previous or latent viral diseases in the context of SARS-CoV-2/LC and the observation that patients with SARS-CoV-2-independent diseases (e.g. ME/CFS, fibromyalgia) were also able to achieve significant improvements in their disease symptoms through transcutaneous nicotine application (see supplement 1) demonstrate the necessity of expanding the evaluation of prospective studies for transcutaneous nicotine application on the clinical picture of LC is of the utmost importance. The studies of Peng et al. (<xref ref-type="bibr" rid="CR171">2023</xref>) show a significantly increased risk of numerous ADs in association with LC (Peng&#160;<xref ref-type="bibr" rid="CR171">2023</xref>). As there is no known pathogenetic origin for any of the mentioned incidences (Table <xref rid="Tab2" ref-type="table">2</xref>), which have long been known independently of LC, we would like to discuss the possibility of a post-viral genesis of numerous ADs based on B-lymphocytic nAChR blockade. Further research into this possibility would be associated with the development of causal treatment options for a large number of previously symptomatically treated ADs and should be pursued. This is of extraordinary international importance in view of the high number of people affected, the expected costs in terms of the duration of current symptomatic treatment approaches, but also in view of the long-term professional and social non-participation of patients. In the case presented we saw a clear increase in nAChR LBS after LDTN therapy together with a profound clinical improvement. In particular, the speech formation was fully restored, allowing the teacher to resume her profession without any impairment.</p><p id="Par48">The study, which was limited by the single-case nature of the investigation, supports the hypothesis that the alkaloid nicotine is able to displace SGP from blocked nAChR binding sites and restore proper cholinergic neurotransmission. This might be the central issue in LC/ME/CFS/PVS. In addition, the results of the survey (Supplement 1), although retrospective and not randomized controlled, show clear support for the underlying hypothesis with improvement in 73.5% of cases and reported remissions in a third of cases.</p></sec><sec id="Sec19"><title>Conclusions</title><p id="Par49">A review of the literature indicates that a significant disruption of cholinergic neurotransmission might be a central issue for both LC/ME/CFS and PVS. The hypothesis of a viral blockade of nAChRs and the possibility of a competitive reversal of this blockade by LDTN has been corroborated by highly promising results in the broad application of this method to numerous patients. Randomized controlled trials are necessary to determine whether these preliminary results can be substantiated by evidence. However, LDTN application provides many patients with a method that offers a high probability of symptom relief with only minor side effects and represents an affordable therapeutic intervention for the majority of people affected worldwide. Furthermore, dose-finding studies are required to develop individually adapted therapy regimens with regard to dosage and duration of therapy.</p></sec><sec id="Sec20" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="42234_2025_167_MOESM1_ESM.xlsx" position="float" orientation="portrait"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="42234_2025_167_MOESM2_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 2.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="42234_2025_167_MOESM3_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 3.</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements
</title><p>The authors would like to thank Frank Jabin for the excellent illustration (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). In addition, the authors would like to thank Helios Kliniken GmbH for their support with the costs of producing an open access publication.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions
</title><p>Marco Leitzke was responsible for formulating the fundamental premise, composing the manuscript, conceptualizing the graphical elements, and contributing to the study design, data collection, and analysis. Donald Troy Roach generated the data collection (survey in the supplement) and edited the draft. Osama Sabri, Swen Hesse, Bernhardt Sattler and Michael Rullmann participated in designing the study as well as collecting, analyzing and interpreting the data. Georg-Alexander Becker contributed to the success of the study with modelling aspects. All authors participated in contributing to the text and the content of the manuscript. All authors approved the content of the manuscript and agreed to be held accountable for the work.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>No funding was granted.</p></notes><notes notes-type="data-availability"><title>Data availability
</title><p>All data utilized in the creation of the case report is available for review in the supplementary materials or may be requested in raw format from the authors.
</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par50">The patient in question consented to the examination and the individual treatment attempt after being informed in detail.</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par51">All authors have approved the content of the manuscript, agreed to its publication, and accepted responsibility for the work.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests
</title><p id="Par52">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><mixed-citation publication-type="other">Abbate G, De Iulio B, Thomas G, Priday A, Biondi-Zoccai G, Markley R, u.&amp;nbsp;a. Postural Orthostatic Tachycardia Syndrome After COVID-19: A Systematic Review of Therapeutic Interventions. J Cardiovasc Pharmacol. 2023;82(1):23&#8211;31.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FJC.0000000000001432</pub-id><pub-id pub-id-type="pmid">37094584</pub-id></mixed-citation></ref><ref id="CR2"><mixed-citation publication-type="other">A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA. 2000;283(24):3244&#8211;54.<pub-id pub-id-type="pmid">10866874</pub-id></mixed-citation></ref><ref id="CR3"><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abicic</surname><given-names>A</given-names></name><name name-style="western"><surname>Sitas</surname><given-names>B</given-names></name><name name-style="western"><surname>Adamec</surname><given-names>I</given-names></name><name name-style="western"><surname>Bilic</surname><given-names>E</given-names></name><name name-style="western"><surname>Habek</surname><given-names>M</given-names></name></person-group><article-title>New-Onset Ocular Myasthenia Gravis After Booster Dose of COVID-19 Vaccine</article-title><source>Cureus</source><year>2022</year><volume>14</volume><issue>7</issue><fpage>e27213</fpage><pub-id pub-id-type="pmid">36035038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.27213</pub-id><pub-id pub-id-type="pmcid">PMC9399320</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Abicic A, Sitas B, Adamec I, Bilic E, Habek M. New-Onset Ocular Myasthenia Gravis After Booster Dose of COVID-19 Vaccine. Cureus. 2022;14(7): e27213.<pub-id pub-id-type="pmid">36035038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.27213</pub-id><pub-id pub-id-type="pmcid">PMC9399320</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Afrin</surname><given-names>LB</given-names></name><name name-style="western"><surname>Weinstock</surname><given-names>LB</given-names></name><name name-style="western"><surname>Molderings</surname><given-names>GJ</given-names></name></person-group><article-title>Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome</article-title><source>Int J Infect Dis</source><year>2020</year><volume>100</volume><fpage>327</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.09.016</pub-id><pub-id pub-id-type="pmid">32920235</pub-id><pub-id pub-id-type="pmcid">PMC7529115</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327&#8211;32.<pub-id pub-id-type="pmid">32920235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijid.2020.09.016</pub-id><pub-id pub-id-type="pmcid">PMC7529115</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><mixed-citation publication-type="other">Aj&#269;evi&#263; M, Iscra K, Furlanis G, Michelutti M, Miladinovi&#263; A, Buoite Stella A, u.&amp;nbsp;a. Cerebral hypoperfusion in post-COVID-19 cognitively impaired subjects revealed by arterial spin labeling MRI. Sci Rep. 2023;13(1):5808.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-32275-3</pub-id><pub-id pub-id-type="pmcid">PMC10086005</pub-id><pub-id pub-id-type="pmid">37037833</pub-id></mixed-citation></ref><ref id="CR6"><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Almeida</surname><given-names>JP</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>FA</given-names></name><name name-style="western"><surname>Freitas</surname><given-names>T</given-names></name><name name-style="western"><surname>Saldanha</surname><given-names>C</given-names></name></person-group><article-title>Modulation of hemorheological parameters by the erythrocyte redox thiol status</article-title><source>Clin Hemorheol Microcirc</source><year>2008</year><volume>40</volume><issue>2</issue><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.3233/CH-2008-1120</pub-id><pub-id pub-id-type="pmid">19029635</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Almeida JP, Carvalho FA, Freitas T, Saldanha C. Modulation of hemorheological parameters by the erythrocyte redox thiol status. Clin Hemorheol Microcirc. 2008;40(2):99&#8211;111.<pub-id pub-id-type="pmid">19029635</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Altmann</surname><given-names>DM</given-names></name><name name-style="western"><surname>Whettlock</surname><given-names>EM</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Arachchillage</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Boyton</surname><given-names>RJ</given-names></name></person-group><article-title>The immunology of long COVID</article-title><source>Nat Rev Immunol</source><year>2023</year><volume>23</volume><issue>10</issue><fpage>618</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1038/s41577-023-00904-7</pub-id><pub-id pub-id-type="pmid">37433988</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nat Rev Immunol. 2023;23(10):618&#8211;34.<pub-id pub-id-type="pmid">37433988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-023-00904-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><mixed-citation publication-type="other">Al-Aly Z, Davis H, McCorkell L, Soares L, Wulf-Hanson S, Iwasaki A, u.&amp;nbsp;a. Long COVID science, research and policy. Nat Med. 2024;30(8):2148&#8211;64.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-03173-6</pub-id><pub-id pub-id-type="pmid">39122965</pub-id></mixed-citation></ref><ref id="CR9"><mixed-citation publication-type="other">Ambrosino P, Calcaterra I, Molino A, Moretta P, Lupoli R, Spedicato GA, u.&amp;nbsp;a. Persistent Endothelial Dysfunction in Post-Acute COVID-19 Syndrome: A Case-Control Study. Biomedicines. 2021;9(8):957.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines9080957</pub-id><pub-id pub-id-type="pmcid">PMC8391623</pub-id><pub-id pub-id-type="pmid">34440161</pub-id></mixed-citation></ref><ref id="CR10"><mixed-citation publication-type="other">Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease. J Am College Cardiol. 2004;43(10):1731&#8211;7.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2003.12.047</pub-id><pub-id pub-id-type="pmid">15145091</pub-id></mixed-citation></ref><ref id="CR11"><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arias-Carri&#243;n</surname><given-names>O</given-names></name><name name-style="western"><surname>Stamelou</surname><given-names>M</given-names></name><name name-style="western"><surname>Murillo-Rodr&#237;guez</surname><given-names>E</given-names></name><name name-style="western"><surname>Men&#233;ndez-Gonz&#225;lez</surname><given-names>M</given-names></name><name name-style="western"><surname>P&#246;ppel</surname><given-names>E</given-names></name></person-group><article-title>Dopaminergic reward system: a short integrative review</article-title><source>Int Arch Med</source><year>2010</year><volume>3</volume><issue>1</issue><fpage>24</fpage><pub-id pub-id-type="doi">10.1186/1755-7682-3-24</pub-id><pub-id pub-id-type="pmid">20925949</pub-id><pub-id pub-id-type="pmcid">PMC2958859</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Arias-Carri&#243;n O, Stamelou M, Murillo-Rodr&#237;guez E, Men&#233;ndez-Gonz&#225;lez M, P&#246;ppel E. Dopaminergic reward system: a short integrative review. Int Arch Med. 2010;3(1):24.<pub-id pub-id-type="pmid">20925949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1755-7682-3-24</pub-id><pub-id pub-id-type="pmcid">PMC2958859</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><mixed-citation publication-type="other">Arun S, Storan A, Myers B. Mast cell activation syndrome and the link with long COVID. Br J Hosp Med. 2022;83(7):1&#8211;10.<pub-id pub-id-type="doi" assigning-authority="pmc">10.12968/hmed.2022.0123</pub-id><pub-id pub-id-type="pmid">35938771</pub-id></mixed-citation></ref><ref id="CR13"><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name></person-group><article-title>Shear stress-induced redistribution of the glycocalyx on endothelial cells in vitro</article-title><source>Biomech Model Mechanobiol</source><year>2014</year><volume>13</volume><issue>2</issue><fpage>303</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1007/s10237-013-0502-3</pub-id><pub-id pub-id-type="pmid">23715899</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Bai K, Wang W. Shear stress-induced redistribution of the glycocalyx on endothelial cells in vitro. Biomech Model Mechanobiol. 2014;13(2):303&#8211;11.<pub-id pub-id-type="pmid">23715899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10237-013-0502-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><mixed-citation publication-type="other">Barr RS, Culhane MA, Jubelt LE, Mufti RS, Dyer MA, Weiss AP, u.&amp;nbsp;a. The Effects of Transdermal Nicotine on Cognition in Nonsmokers with Schizophrenia and Nonpsychiatric Controls. Neuropsychopharmacol. 2008;33(3):480&#8211;90.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.npp.1301423</pub-id><pub-id pub-id-type="pmid">17443126</pub-id></mixed-citation></ref><ref id="CR15"><mixed-citation publication-type="other">Becker GA, Ichise M, Barthel H, Luthardt J, Patt M, Seese A, u.&amp;nbsp;a. PET Quantification of <sup>18</sup>F-Florbetaben Binding to &#946;-Amyloid Deposits in Human Brains. J Nucl Med. 2013;54(5):723&#8211;31.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.112.107185</pub-id><pub-id pub-id-type="pmid">23471310</pub-id></mixed-citation></ref><ref id="CR16"><mixed-citation publication-type="other">Bennett JA, Ture SK, Schmidt RA, Mastrangelo MA, Cameron SJ, Terry LE, u. a. Acetylcholine inhibits platelet activation and regulates hemostasis [Internet]. 2018. Verf&#252;gbar unter: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://biorxiv.org/lookup/doi/10.1101/324319">http://biorxiv.org/lookup/doi/10.1101/324319</ext-link>
. Zitiert 15. April 2024.</mixed-citation></ref><ref id="CR17"><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name></person-group><article-title>Clinical pharmacology of inhaled drugs of abuse: implications in understanding nicotine dependence</article-title><source>NIDA Res Monogr</source><year>1990</year><volume>99</volume><fpage>12</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">2267009</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Benowitz NL. Clinical pharmacology of inhaled drugs of abuse: implications in understanding nicotine dependence. NIDA Res Monogr. 1990;99:12&#8211;29.<pub-id pub-id-type="pmid">2267009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><mixed-citation publication-type="other">Benowitz NL, Fitzgerald GA, Wilson M, Zhang Q. Nicotine effects on eicosanoid formation and hemostatic function: Comparison of transdermal nicotine and cigarette smoking. Journal of the American College of Cardiology. 1993;22(4):1159&#8211;67.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0735-1097(93)90431-y</pub-id><pub-id pub-id-type="pmid">7691912</pub-id></mixed-citation></ref><ref id="CR19"><mixed-citation publication-type="other">Benowitz NL, Hukkanen J, Jacob P. Nicotine Chemistry, Metabolism, Kinetics and Biomarkers. In: Henningfield JE, London ED, Pogun S, Herausgeber. Nicotine Psychopharmacology. Berlin, Heidelberg: Springer Berlin Heidelberg; 2009. S. 29&#8211;60. (Hofmann FB, Reihenherausgeber. Handbook of Experimental Pharmacology; Bd. 192). Verf&#252;gbar unter: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://link.springer.com/10.1007/978-3-540-69248-5_2">http://link.springer.com/10.1007/978-3-540-69248-5_2</ext-link>
. Zitiert 24. Februar 2024.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-540-69248-5_2</pub-id><pub-id pub-id-type="pmcid">PMC2953858</pub-id><pub-id pub-id-type="pmid">19184645</pub-id></mixed-citation></ref><ref id="CR20"><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name><name name-style="western"><surname>Porchet</surname><given-names>H</given-names></name><name name-style="western"><surname>Sheiner</surname><given-names>L</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>P</given-names></name></person-group><article-title>Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum</article-title><source>Clin Pharmacol Ther</source><year>1988</year><volume>44</volume><issue>1</issue><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1038/clpt.1988.107</pub-id><pub-id pub-id-type="pmid">3391001</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Benowitz NL, Porchet H, Sheiner L, Jacob P. Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum. Clin Pharmacol Ther. 1988;44(1):23&#8211;8.<pub-id pub-id-type="pmid">3391001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.1988.107</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benowitz</surname><given-names>N</given-names></name><name name-style="western"><surname>Lessovschlaggar</surname><given-names>C</given-names></name><name name-style="western"><surname>Swan</surname><given-names>G</given-names></name><name name-style="western"><surname>Jacobiii</surname><given-names>P</given-names></name></person-group><article-title>Female sex and oral contraceptive use accelerate nicotine metabolism</article-title><source>Clinical Pharmacology &amp; Therapeutics</source><year>2006</year><volume>79</volume><issue>5</issue><fpage>480</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1016/j.clpt.2006.01.008</pub-id><pub-id pub-id-type="pmid">16678549</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Benowitz N, Lessovschlaggar C, Swan G, Jacobiii P. Female sex and oral contraceptive use accelerate nicotine metabolism. Clinical Pharmacology &amp; Therapeutics. 2006;79(5):480&#8211;8.<pub-id pub-id-type="pmid">16678549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2006.01.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><mixed-citation publication-type="other">Bibevski S, Zhou Y, McIntosh JM, Zigmond RE, Dunlap ME. Functional Nicotinic Acetylcholine Receptors That Mediate Ganglionic Transmission in Cardiac Parasympathetic Neurons. J Neurosci. 2000;20(13):5076&#8211;82.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.20-13-05076.2000</pub-id><pub-id pub-id-type="pmcid">PMC6772271</pub-id><pub-id pub-id-type="pmid">10864965</pub-id></mixed-citation></ref><ref id="CR23"><mixed-citation publication-type="other">Bhatt S, Hillmer AT, Nabulsi N, Matuskey D, Lim K, Lin S, u.&amp;nbsp;a. Evaluation of (&#8208;)&#8208;[<sup>18</sup><sc>F]F</sc> lubatine&#8208;specific binding: Implications for reference region approaches. Synapse. 2018;72(3):e22016.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/syn.22016</pub-id><pub-id pub-id-type="pmcid">PMC6547815</pub-id><pub-id pub-id-type="pmid">29105121</pub-id></mixed-citation></ref><ref id="CR24"><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blann</surname><given-names>AD</given-names></name><name name-style="western"><surname>Steele</surname><given-names>C</given-names></name><name name-style="western"><surname>McCollum</surname><given-names>CN</given-names></name></person-group><article-title>The influence of smoking and of oral and transdermal nicotine on blood pressure, and haematology and coagulation indices</article-title><source>Thromb Haemost</source><year>1997</year><volume>78</volume><issue>3</issue><fpage>1093</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1055/s-0038-1657692</pub-id><pub-id pub-id-type="pmid">9308759</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Blann AD, Steele C, McCollum CN. The influence of smoking and of oral and transdermal nicotine on blood pressure, and haematology and coagulation indices. Thromb Haemost. 1997;78(3):1093&#8211;6.<pub-id pub-id-type="pmid">9308759</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blasi</surname><given-names>F</given-names></name></person-group><article-title>The challenge of breathlessness in the detection of pulmonary hypertension</article-title><source>European Respiratory Rev.</source><year>2012</year><volume>21</volume><issue>123</issue><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1183/09059180.00008511</pub-id><pub-id pub-id-type="pmcid">PMC9487478</pub-id><pub-id pub-id-type="pmid">22379166</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Blasi F. The challenge of breathlessness in the detection of pulmonary hypertension. European Respiratory Rev. 2012;21(123):1&#8211;3.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/09059180.00008511</pub-id><pub-id pub-id-type="pmcid">PMC9487478</pub-id><pub-id pub-id-type="pmid">22379166</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><mixed-citation publication-type="other">Bracci L, Ballas SK, Spreafico A, Neri P. Molecular Mimicry Between the Rabies Virus Glycoprotein and Human Immunodeficiency Virus-1 GP120: Cross-Reacting Antibodies Induced by Rabies Vaccination. Blood. 1997;90(9):3623&#8211;8.<pub-id pub-id-type="pmid">9345046</pub-id></mixed-citation></ref><ref id="CR27"><mixed-citation publication-type="other">Brody AL, Mukhin AG, Mamoun MS, Luu T, Neary M, Liang L, u.&amp;nbsp;a. Brain Nicotinic Acetylcholine Receptor Availability and Response to Smoking Cessation Treatment: A Randomized Trial. JAMA Psychiatry. 2014;71(7):797.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2014.138</pub-id><pub-id pub-id-type="pmcid">PMC4634637</pub-id><pub-id pub-id-type="pmid">24850280</pub-id></mixed-citation></ref><ref id="CR28"><mixed-citation publication-type="other">Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi FE, u.&amp;nbsp;a. A review of human carcinogens&#8212;Part B: biological agents. The Lancet Oncology. 2009;10(4):321&#8211;2.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1470-2045(09)70096-8</pub-id><pub-id pub-id-type="pmid">19350698</pub-id></mixed-citation></ref><ref id="CR29"><mixed-citation publication-type="other">Buisson B, Bertrand D. Chronic Exposure to Nicotine Upregulates the Human &#945;4&#946;2 Nicotinic Acetylcholine Receptor Function. J Neurosci. 2001;21(6):1819&#8211;29.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.21-06-01819.2001</pub-id><pub-id pub-id-type="pmcid">PMC6762627</pub-id><pub-id pub-id-type="pmid">11245666</pub-id></mixed-citation></ref><ref id="CR30"><mixed-citation publication-type="other">Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28&#8211;37.<pub-id pub-id-type="pmcid">PMC2880930</pub-id><pub-id pub-id-type="pmid">20526405</pub-id></mixed-citation></ref><ref id="CR31"><mixed-citation publication-type="other">Cabrera Martimbianco AL, Pacheco RL, Bagattini &#194;M, Riera R. Frequency, signs and symptoms, and criteria adopted for long COVID&#8208;19: A systematic review. Int J Clin Pract. 2021 ;75(10). Verf&#252;gbar unter: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://onlinelibrary.wiley.com/doi/10.1111/ijcp.14357">https://onlinelibrary.wiley.com/doi/10.1111/ijcp.14357</ext-link>. Zitiert 5. Juli 2024.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijcp.14357</pub-id><pub-id pub-id-type="pmcid">PMC8236920</pub-id><pub-id pub-id-type="pmid">33977626</pub-id></mixed-citation></ref><ref id="CR32"><mixed-citation publication-type="other">Carlson EC, Macsai M, Bertrand S, Bertrand D, Nau J. The SARS-CoV-2 Virus and the Cholinergic System: Spike Protein Interaction with Human Nicotinic Acetylcholine Receptors and the Nicotinic Agonist Varenicline. IJMS. 2023;24(6):5597.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24065597</pub-id><pub-id pub-id-type="pmcid">PMC10051900</pub-id><pub-id pub-id-type="pmid">36982671</pub-id></mixed-citation></ref><ref id="CR33"><mixed-citation publication-type="other">Casali P, Burastero S. E, Nakamura M, Inghirami G, Notkins AL. Human Lymphocytes Making Rheumatoid Factor and Antibody to ssDNA Belong to Leu-1 <sup>+</sup> B-Cell Subset. Science. 1987;236(4797):77&#8211;81.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.3105056</pub-id><pub-id pub-id-type="pmid">3105056</pub-id></mixed-citation></ref><ref id="CR34"><mixed-citation publication-type="other">Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, u.&amp;nbsp;a. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain, Behavior, and Immunity. 2022;101:93&#8211;135.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2021.12.020</pub-id><pub-id pub-id-type="pmcid">PMC8715665</pub-id><pub-id pub-id-type="pmid">34973396</pub-id></mixed-citation></ref><ref id="CR35"><mixed-citation publication-type="other">Changeux JP, Amoura Z, Rey FA, Miyara M. A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications. Comptes Rendus Biologies. 2020;343(1):33&#8211;9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.5802/crbiol.8</pub-id><pub-id pub-id-type="pmid">32720486</pub-id></mixed-citation></ref><ref id="CR36"><mixed-citation publication-type="other">Chang R, Mamun A, Dominic A, Le NT. SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress. Front Physiol. 2021;11:605908.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphys.2020.605908</pub-id><pub-id pub-id-type="pmcid">PMC7844210</pub-id><pub-id pub-id-type="pmid">33519510</pub-id></mixed-citation></ref><ref id="CR37"><mixed-citation publication-type="other">Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, u.&amp;nbsp;a. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021;12(1):5417.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-25509-3</pub-id><pub-id pub-id-type="pmcid">PMC8440763</pub-id><pub-id pub-id-type="pmid">34521836</pub-id></mixed-citation></ref><ref id="CR38"><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chrestia</surname><given-names>JF</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>AS</given-names></name><name name-style="western"><surname>Mulholland</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>T</given-names></name><name name-style="western"><surname>Berm&#250;dez</surname><given-names>I</given-names></name><name name-style="western"><surname>Bouzat</surname><given-names>C</given-names></name></person-group><article-title>A Functional Interaction Between Y674&#8211;R685 Region of the SARS-CoV-2 Spike Protein and the Human &#945;7 Nicotinic Receptor</article-title><source>Mol Neurobiol</source><year>2022</year><volume>59</volume><issue>10</issue><fpage>6076</fpage><lpage>6090</lpage><pub-id pub-id-type="doi">10.1007/s12035-022-02947-8</pub-id><pub-id pub-id-type="pmid">35859025</pub-id><pub-id pub-id-type="pmcid">PMC9299415</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Chrestia JF, Oliveira AS, Mulholland AJ, Gallagher T, Berm&#250;dez I, Bouzat C. A Functional Interaction Between Y674&#8211;R685 Region of the SARS-CoV-2 Spike Protein and the Human &#945;7 Nicotinic Receptor. Mol Neurobiol. 2022;59(10):6076&#8211;90.<pub-id pub-id-type="pmid">35859025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-022-02947-8</pub-id><pub-id pub-id-type="pmcid">PMC9299415</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><mixed-citation publication-type="other">Church TR, Anderson KE, Caporaso NE, Geisser MS, Le CT, Zhang Y, u.&amp;nbsp;a. A Prospectively Measured Serum Biomarker for a Tobacco-Specific Carcinogen and Lung Cancer in Smokers. Cancer Epidemiology, Biomarkers &amp; Prevention. 2009;18(1):260&#8211;6.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1055-9965.EPI-08-0718</pub-id><pub-id pub-id-type="pmcid">PMC3513324</pub-id><pub-id pub-id-type="pmid">19124507</pub-id></mixed-citation></ref><ref id="CR40"><mixed-citation publication-type="other">Cochrane CG, Koffler D. Immune Complex Disease in Experimental Animals and Man. In: Advances in Immunology. Elsevier; 1973. S. 185&#8211;264. Verf&#252;gbar unter: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S0065277608602989">https://linkinghub.elsevier.com/retrieve/pii/S0065277608602989</ext-link>. Zitiert 18. M&#228;rz 2024.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0065-2776(08)60298-9</pub-id><pub-id pub-id-type="pmid">4599389</pub-id></mixed-citation></ref><ref id="CR41"><mixed-citation publication-type="other">Coleman JW. Nitric oxide: a regulator of mast cell activation and mast cell-mediated inflammation. Clin Experimental Immunol. 2002;129(1):4&#8211;10.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2249.2002.01918.x</pub-id><pub-id pub-id-type="pmcid">PMC1906415</pub-id><pub-id pub-id-type="pmid">12100016</pub-id></mixed-citation></ref><ref id="CR42"><mixed-citation publication-type="other">Corrado J, Halpin S, Preston N, Whiteside D, Tarrant R, Davison J, u.&amp;nbsp;a. HEART rate variability biofeedback for long COVID symptoms (HEARTLOC): protocol for a feasibility study. BMJ Open. 2022;12(11):e066044.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2022-066044</pub-id><pub-id pub-id-type="pmcid">PMC9680157</pub-id><pub-id pub-id-type="pmid">36410797</pub-id></mixed-citation></ref><ref id="CR43"><mixed-citation publication-type="other">Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, u.&amp;nbsp;a. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. Journal of the American College of Cardiology. 2002;39(2):257&#8211;65.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0735-1097(01)01746-6</pub-id><pub-id pub-id-type="pmid">11788217</pub-id></mixed-citation></ref><ref id="CR44"><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cyr</surname><given-names>AR</given-names></name><name name-style="western"><surname>Huckaby</surname><given-names>LV</given-names></name><name name-style="western"><surname>Shiva</surname><given-names>SS</given-names></name><name name-style="western"><surname>Zuckerbraun</surname><given-names>BS</given-names></name></person-group><article-title>Nitric Oxide and Endothelial Dysfunction</article-title><source>Crit Care Clin</source><year>2020</year><volume>36</volume><issue>2</issue><fpage>307</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1016/j.ccc.2019.12.009</pub-id><pub-id pub-id-type="pmid">32172815</pub-id><pub-id pub-id-type="pmcid">PMC9015729</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Cyr AR, Huckaby LV, Shiva SS, Zuckerbraun BS. Nitric Oxide and Endothelial Dysfunction. Crit Care Clin. 2020;36(2):307&#8211;21.<pub-id pub-id-type="pmid">32172815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccc.2019.12.009</pub-id><pub-id pub-id-type="pmcid">PMC9015729</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><mixed-citation publication-type="other">Damoiseaux J, Dotan A, Fritzler MJ, Bogdanos DP, Meroni PL, Roggenbuck D, u.&amp;nbsp;a. Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies. Autoimmunity Reviews. 2022;21(3):103012.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.autrev.2021.103012</pub-id><pub-id pub-id-type="pmcid">PMC8656211</pub-id><pub-id pub-id-type="pmid">34896650</pub-id></mixed-citation></ref><ref id="CR46"><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dautzenberg</surname><given-names>B</given-names></name><name name-style="western"><surname>Levi</surname><given-names>A</given-names></name><name name-style="western"><surname>Adler</surname><given-names>M</given-names></name><name name-style="western"><surname>Gaillard</surname><given-names>R</given-names></name></person-group><article-title>Transdermal nicotine in non-smokers: A systematic review to design COVID-19 clinical trials</article-title><source>Respiratory Med Res</source><year>2021</year><volume>80</volume><fpage>100844</fpage><pub-id pub-id-type="doi">10.1016/j.resmer.2021.100844</pub-id><pub-id pub-id-type="pmcid">PMC8183099</pub-id><pub-id pub-id-type="pmid">34153704</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Dautzenberg B, Levi A, Adler M, Gaillard R. Transdermal nicotine in non-smokers: A systematic review to design COVID-19 clinical trials. Respiratory Medicine and Research. 2021;80: 100844.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.resmer.2021.100844</pub-id><pub-id pub-id-type="pmcid">PMC8183099</pub-id><pub-id pub-id-type="pmid">34153704</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><mixed-citation publication-type="other">Davis BJ, Flanagan BF, Gilfillan AM, Metcalfe DD, Coleman JW. Nitric Oxide Inhibits IgE-Dependent Cytokine Production and Fos and Jun Activation in Mast Cells. J Immunol. 2004;173(11):6914&#8211;20.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.173.11.6914</pub-id><pub-id pub-id-type="pmid">15557187</pub-id></mixed-citation></ref><ref id="CR48"><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>HE</given-names></name><name name-style="western"><surname>McCorkell</surname><given-names>L</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>JM</given-names></name><name name-style="western"><surname>Topol</surname><given-names>EJ</given-names></name></person-group><article-title>Long COVID: major findings, mechanisms and recommendations</article-title><source>Nat Rev Microbiol</source><year>2023</year><volume>21</volume><issue>3</issue><fpage>133</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00846-2</pub-id><pub-id pub-id-type="pmid">36639608</pub-id><pub-id pub-id-type="pmcid">PMC9839201</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#8211;46.<pub-id pub-id-type="pmid">36639608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41579-022-00846-2</pub-id><pub-id pub-id-type="pmcid">PMC9839201</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Almeida</surname><given-names>JPL</given-names></name><name name-style="western"><surname>Saldanha</surname><given-names>C</given-names></name></person-group><article-title>Nonneuronal Cholinergic System in Human Erythrocytes: Biological Role and Clinical Relevance</article-title><source>J Membrane Biol</source><year>2010</year><volume>234</volume><issue>3</issue><fpage>227</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1007/s00232-010-9250-9</pub-id><pub-id pub-id-type="pmid">20352203</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">De Almeida JPL, Saldanha C. Nonneuronal Cholinergic System in Human Erythrocytes: Biological Role and Clinical Relevance. J Membrane Biol. 2010;234(3):227&#8211;34.<pub-id pub-id-type="pmid">20352203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00232-010-9250-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><mixed-citation publication-type="other">Debnath M, Debnath D, Singh P, Wert Y, Nookala V. Effect of Electronic Cigarettes on the Gastrointestinal System. Cureus. 24. Juli 2022; Verf&#252;gbar unter: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cureus.com/articles/21580-effect-of-electronic-cigarettes-on-the-gastrointestinal-system">https://www.cureus.com/articles/21580-effect-of-electronic-cigarettes-on-the-gastrointestinal-system</ext-link>. Zitiert 3. M&#228;rz 2024.<pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.27210</pub-id><pub-id pub-id-type="pmcid">PMC9322142</pub-id><pub-id pub-id-type="pmid">35903484</pub-id></mixed-citation></ref><ref id="CR51"><mixed-citation publication-type="other">Dempsey D, Jacob P, Benowitz NL. Accelerated Metabolism of Nicotine and Cotinine in Pregnant Smokers. J Pharmacol Exp Ther. 2002;301(2):594&#8211;8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.301.2.594</pub-id><pub-id pub-id-type="pmid">11961061</pub-id></mixed-citation></ref><ref id="CR52"><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dempsey</surname><given-names>D</given-names></name></person-group><article-title>Nicotine metabolism and elimination kinetics in newborns</article-title><source>Clinical Pharmacology &amp; Therapeutics</source><year>2000</year><volume>67</volume><issue>5</issue><fpage>458</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1067/mcp.2000.106129</pub-id><pub-id pub-id-type="pmid">10824624</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Dempsey D. Nicotine metabolism and elimination kinetics in newborns. Clinical Pharmacology &amp; Therapeutics. 2000;67(5):458&#8211;65.<pub-id pub-id-type="pmid">10824624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2000.106129</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><mixed-citation publication-type="other">Diao Q, Li B, Zhao H, Wu Y, Guo R, Dai P, u.&amp;nbsp;a. Enhancement of chronic bee paralysis virus levels in honeybees acute exposed to imidacloprid: A Chinese case study. Science of The Total Environment. 2018;630:487&#8211;94.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.scitotenv.2018.02.258</pub-id><pub-id pub-id-type="pmid">29499530</pub-id></mixed-citation></ref><ref id="CR54"><mixed-citation publication-type="other">Di Prisco G, Cavaliere V, Annoscia D, Varricchio P, Caprio E, Nazzi F, u.&amp;nbsp;a. Neonicotinoid clothianidin adversely affects insect immunity and promotes replication of a viral pathogen in honey bees. Proc Natl Acad Sci USA. 2013;110(46):18466&#8211;71.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1314923110</pub-id><pub-id pub-id-type="pmcid">PMC3831983</pub-id><pub-id pub-id-type="pmid">24145453</pub-id></mixed-citation></ref><ref id="CR55"><mixed-citation publication-type="other">Douaoui S, Djidjik R, Boubakeur M, Ghernaout M, Touil-boukoffa C, Oumouna M, u.&amp;nbsp;a. GTS-21, an &#945;7nAChR agonist, suppressed the production of key inflammatory mediators by PBMCs that are elevated in COPD patients and associated with impaired lung function. Immunobiology. 2020;225(3):151950.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.imbio.2020.151950</pub-id><pub-id pub-id-type="pmcid">PMC7194070</pub-id><pub-id pub-id-type="pmid">32387130</pub-id></mixed-citation></ref><ref id="CR56"><mixed-citation publication-type="other">Doyle MP, Walker BR. Stiffened erythrocytes augment the pulmonary hemodynamic response to hypoxia. J Appl Physiol. 1990;69(4):1270&#8211;5.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/jappl.1990.69.4.1270</pub-id><pub-id pub-id-type="pmid">2124584</pub-id></mixed-citation></ref><ref id="CR57"><mixed-citation publication-type="other">Dudeck A, K&#246;berle M, Goldmann O, Meyer N, Dudeck J, Lemmens S, u.&amp;nbsp;a. Mast cells as protectors of health. J Allergy Clin Immunol. 2019;144(4):S4&#8211;18.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2018.10.054</pub-id><pub-id pub-id-type="pmid">30468774</pub-id></mixed-citation></ref><ref id="CR58"><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elkon</surname><given-names>K</given-names></name><name name-style="western"><surname>Casali</surname><given-names>P</given-names></name></person-group><article-title>Nature and functions of autoantibodies</article-title><source>Nat Rev Rheumatol</source><year>2008</year><volume>4</volume><issue>9</issue><fpage>491</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1038/ncprheum0895</pub-id><pub-id pub-id-type="pmcid">PMC2703183</pub-id><pub-id pub-id-type="pmid">18756274</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Elkon K, Casali P. Nature and functions of autoantibodies. Nat Rev Rheumatol. 2008;4(9):491&#8211;8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncprheum0895</pub-id><pub-id pub-id-type="pmcid">PMC2703183</pub-id><pub-id pub-id-type="pmid">18756274</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><mixed-citation publication-type="other">Elsaid M, Nune A, Hesham D, Fouad FM, Hassan H, Hamouda H, u.&amp;nbsp;a. Multisystem Inflammatory Syndrome (MIS) following SARS-CoV-2 vaccinations; a systematic review. Trop Dis Travel Med Vaccines. 2023;9(1):19.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40794-023-00204-x</pub-id><pub-id pub-id-type="pmcid">PMC10625711</pub-id><pub-id pub-id-type="pmid">37925466</pub-id></mixed-citation></ref><ref id="CR60"><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Essajee</surname><given-names>F</given-names></name><name name-style="western"><surname>Lishman</surname><given-names>J</given-names></name><name name-style="western"><surname>Solomons</surname><given-names>R</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>DR</given-names></name><name name-style="western"><surname>Goussard</surname><given-names>P</given-names></name><name name-style="western"><surname>Van Toorn</surname><given-names>R</given-names></name></person-group><article-title>Transient acetylcholine receptor-related myasthenia gravis, post multisystem inflammatory syndrome in children (MIS-C) temporally associated with COVID-19 infection</article-title><source>BMJ Case Rep</source><year>2021</year><volume>14</volume><issue>8</issue><fpage>e244102</fpage><pub-id pub-id-type="doi">10.1136/bcr-2021-244102</pub-id><pub-id pub-id-type="pmid">34380685</pub-id><pub-id pub-id-type="pmcid">PMC8359482</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Essajee F, Lishman J, Solomons R, Abraham DR, Goussard P, Van Toorn R. Transient acetylcholine receptor-related myasthenia gravis, post multisystem inflammatory syndrome in children (MIS-C) temporally associated with COVID-19 infection. BMJ Case Rep. 2021;14(8): e244102.<pub-id pub-id-type="pmid">34380685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bcr-2021-244102</pub-id><pub-id pub-id-type="pmcid">PMC8359482</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><mixed-citation publication-type="other">Forsythe P, Befus AD. Inhibition of Calpain Is a Component of Nitric Oxide-Induced Down-Regulation of Human Mast Cell Adhesion. J Immunol. 2003;170(1):287&#8211;93.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.170.1.287</pub-id><pub-id pub-id-type="pmid">12496411</pub-id></mixed-citation></ref><ref id="CR62"><mixed-citation publication-type="other">Farsalinos K, Eliopoulos E, Leonidas DD, Papadopoulos GE, Tzartos S, Poulas K. Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications. IJMS. 2020;21(16):5807.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21165807</pub-id><pub-id pub-id-type="pmcid">PMC7461543</pub-id><pub-id pub-id-type="pmid">32823591</pub-id></mixed-citation></ref><ref id="CR63"><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fagerstr&#246;m</surname><given-names>K</given-names></name></person-group><article-title>Nicotine: Pharmacology, Toxicity and Therapeutic use</article-title><source>J Smok Cessat</source><year>2014</year><volume>9</volume><issue>2</issue><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1017/jsc.2014.27</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Fagerstr&#246;m K. Nicotine: Pharmacology, Toxicity and Therapeutic use. J Smok Cessat. 2014;9(2):53&#8211;9.</mixed-citation></citation-alternatives></ref><ref id="CR64"><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleming</surname><given-names>SD</given-names></name></person-group><article-title>Natural antibodies, autoantibodies and complement activation in tissue injury</article-title><source>Autoimmunity</source><year>2006</year><volume>39</volume><issue>5</issue><fpage>379</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1080/08916930600739381</pub-id><pub-id pub-id-type="pmid">16923537</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Fleming SD. Natural antibodies, autoantibodies and complement activation in tissue injury. Autoimmunity. 2006;39(5):379&#8211;86.<pub-id pub-id-type="pmid">16923537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08916930600739381</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frantzeskaki</surname><given-names>F</given-names></name><name name-style="western"><surname>Armaganidis</surname><given-names>A</given-names></name><name name-style="western"><surname>Orfanos</surname><given-names>SE</given-names></name></person-group><article-title>Immunothrombosis in Acute Respiratory Distress Syndrome: Cross Talks between Inflammation and Coagulation</article-title><source>Respiration</source><year>2017</year><volume>93</volume><issue>3</issue><fpage>212</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1159/000453002</pub-id><pub-id pub-id-type="pmid">27997925</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Frantzeskaki F, Armaganidis A, Orfanos SE. Immunothrombosis in Acute Respiratory Distress Syndrome: Cross Talks between Inflammation and Coagulation. Respiration. 2017;93(3):212&#8211;25.<pub-id pub-id-type="pmid">27997925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000453002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><mixed-citation publication-type="other">Frenette PS, Denis CV, Weiss L, Jurk K, Subbarao S, Kehrel B, u.&amp;nbsp;a. P-Selectin Glycoprotein Ligand 1 (Psgl-1) Is Expressed on Platelets and Can Mediate Platelet&#8211;Endothelial Interactions in Vivo. J Experimental Med. 2000;191(8):1413&#8211;22.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.191.8.1413</pub-id><pub-id pub-id-type="pmcid">PMC2193129</pub-id><pub-id pub-id-type="pmid">10770806</pub-id></mixed-citation></ref><ref id="CR67"><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>JR</given-names></name><name name-style="western"><surname>Nunnari</surname><given-names>J</given-names></name></person-group><article-title>Mitochondrial form and function</article-title><source>Nature.</source><year>2014</year><volume>505</volume><issue>7483</issue><fpage>335</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1038/nature12985</pub-id><pub-id pub-id-type="pmid">24429632</pub-id><pub-id pub-id-type="pmcid">PMC4075653</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Friedman JR, Nunnari J. Mitochondrial form and function. Nature. 2014;505(7483):335&#8211;43.<pub-id pub-id-type="pmid">24429632</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature12985</pub-id><pub-id pub-id-type="pmcid">PMC4075653</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><mixed-citation publication-type="other">Frizzelli A, Di Spigno F, Moderato L, Halasz G, Aiello M, Tzani P, u.&amp;nbsp;a. An Impairment in Resting and Exertional Breathing Pattern May Occur in Long-COVID Patients with Normal Spirometry and Unexplained Dyspnoea. JCM. 2022;11(24):7388.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm11247388</pub-id><pub-id pub-id-type="pmcid">PMC9784722</pub-id><pub-id pub-id-type="pmid">36556003</pub-id></mixed-citation></ref><ref id="CR69"><mixed-citation publication-type="other">Fujii T, Mashimo M, Moriwaki Y, Misawa H, Ono S, Horiguchi K, u.&amp;nbsp;a. Expression and Function of the Cholinergic System in Immune Cells. Front Immunol. 2017;8:1085.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2017.01085</pub-id><pub-id pub-id-type="pmcid">PMC5592202</pub-id><pub-id pub-id-type="pmid">28932225</pub-id></mixed-citation></ref><ref id="CR70"><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujii</surname><given-names>T</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>Y</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>T</given-names></name><name name-style="western"><surname>Kawashima</surname><given-names>K</given-names></name></person-group><article-title>Upregulation of mRNA Encoding the M5 Muscarinic Acetylcholine Receptor in Human T- and B-Lymphocytes During Immunological Responses</article-title><source>Neurochem Res</source><year>2003</year><volume>28</volume><issue>3/4</issue><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1023/A:1022840416292</pub-id><pub-id pub-id-type="pmid">12675126</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Fujii T, Watanabe Y, Inoue T, Kawashima K. Upregulation of mRNA Encoding the M5 Muscarinic Acetylcholine Receptor in Human T- and B-Lymphocytes During Immunological Responses. Neurochem Res. 2003;28(3/4):423&#8211;9.<pub-id pub-id-type="pmid">12675126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1022840416292</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><mixed-citation publication-type="other">Fujii Y, Fujigaya H, Moriwaki Y, Misawa H, Kasahara T, Grando S, u.&amp;nbsp;a. Enhanced serum antigen-specific IgG1 and proinflammatory cytokine production in nicotinic acetylcholine receptor &#945;7 subunit gene knockout mice. Journal of Neuroimmunology. 2007;189(1&#8211;2):69&#8211;74.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jneuroim.2007.07.003</pub-id><pub-id pub-id-type="pmid">17675251</pub-id></mixed-citation></ref><ref id="CR72"><mixed-citation publication-type="other">Fujii YX, Tashiro A, Arimoto K, Fujigaya H, Moriwaki Y, Misawa H, u.&amp;nbsp;a. Diminished antigen-specific IgG1 and interleukin-6 production and acetylcholinesterase expression in combined M1 and M5 muscarinic acetylcholine receptor knockout mice. J Neuroimmunol. 2007;188(1&#8211;2):80&#8211;5.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jneuroim.2007.05.017</pub-id><pub-id pub-id-type="pmid">17586055</pub-id></mixed-citation></ref><ref id="CR73"><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furchgott</surname><given-names>RF</given-names></name><name name-style="western"><surname>Vanhoutte</surname><given-names>PM</given-names></name></person-group><article-title>Endothelium-derived relaxing and contracting factors</article-title><source>FASEB J</source><year>1989</year><volume>3</volume><issue>9</issue><fpage>2007</fpage><lpage>2018</lpage><pub-id pub-id-type="doi">10.1096/fasebj.3.9.2545495</pub-id><pub-id pub-id-type="pmid">2545495</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J. 1989;3(9):2007&#8211;18.<pub-id pub-id-type="pmid">2545495</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furchgott</surname><given-names>RF</given-names></name><name name-style="western"><surname>Zawadzki</surname><given-names>JV</given-names></name></person-group><article-title>The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine</article-title><source>Nature</source><year>1980</year><volume>288</volume><issue>5789</issue><fpage>373</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1038/288373a0</pub-id><pub-id pub-id-type="pmid">6253831</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288(5789):373&#8211;6.<pub-id pub-id-type="pmid">6253831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/288373a0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galli</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Borregaard</surname><given-names>N</given-names></name><name name-style="western"><surname>Wynn</surname><given-names>TA</given-names></name></person-group><article-title>Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils</article-title><source>Nat Immunol</source><year>2011</year><volume>12</volume><issue>11</issue><fpage>1035</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1038/ni.2109</pub-id><pub-id pub-id-type="pmid">22012443</pub-id><pub-id pub-id-type="pmcid">PMC3412172</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Galli SJ, Borregaard N, Wynn TA. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol. 2011;12(11):1035&#8211;44.<pub-id pub-id-type="pmid">22012443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni.2109</pub-id><pub-id pub-id-type="pmcid">PMC3412172</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><mixed-citation publication-type="other">Ghali A, Lacout C, Ghali M, Gury A, Beucher AB, Lozac&#8217;h P, u.&amp;nbsp;a. Elevated blood lactate in resting conditions correlate with post-exertional malaise severity in patients with Myalgic encephalomyelitis/Chronic fatigue syndrome. Sci Rep. 2019;9(1):18817.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-55473-4</pub-id><pub-id pub-id-type="pmcid">PMC6906377</pub-id><pub-id pub-id-type="pmid">31827223</pub-id></mixed-citation></ref><ref id="CR77"><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Godellas</surname><given-names>NE</given-names></name><name name-style="western"><surname>Cymes</surname><given-names>GD</given-names></name><name name-style="western"><surname>Grosman</surname><given-names>C</given-names></name></person-group><article-title>An experimental test of the nicotinic hypothesis of COVID-19</article-title><source>Proc Natl Acad Sci USA</source><year>2022</year><volume>119</volume><issue>44</issue><fpage>e2204242119</fpage><pub-id pub-id-type="doi">10.1073/pnas.2204242119</pub-id><pub-id pub-id-type="pmid">36279466</pub-id><pub-id pub-id-type="pmcid">PMC9636949</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Godellas NE, Cymes GD, Grosman C. An experimental test of the nicotinic hypothesis of COVID-19. Proc Natl Acad Sci USA. 2022;119(44): e2204242119.<pub-id pub-id-type="pmid">36279466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2204242119</pub-id><pub-id pub-id-type="pmcid">PMC9636949</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><mixed-citation publication-type="other">Godinho-Silva C, Cardoso F, Veiga-Fernandes H. Neuro&#8211;Immune Cell Units: A New Paradigm in Physiology. Annu Rev Immunol. 2019;37(1):19&#8211;46.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-immunol-042718-041812</pub-id><pub-id pub-id-type="pmid">30379595</pub-id></mixed-citation></ref><ref id="CR79"><mixed-citation publication-type="other">Gotti C, Hanke W, Maury K, Moretti M, Ballivet M, Clementi F, u.&amp;nbsp;a. Pharmacology and Biophysical Properties of &#945;7 and &#945;7 - &#945;8 &#945;-Bungarotoxin Receptor Subtypes Immunopurified from the Chick Optic Lobe. European Journal of Neuroscience. 1994;6(8):1281&#8211;91.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1460-9568.1994.tb00318.x</pub-id><pub-id pub-id-type="pmid">7981870</pub-id></mixed-citation></ref><ref id="CR80"><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gotti</surname><given-names>C</given-names></name><name name-style="western"><surname>Zoli</surname><given-names>M</given-names></name><name name-style="western"><surname>Clementi</surname><given-names>F</given-names></name></person-group><article-title>Brain nicotinic acetylcholine receptors: native subtypes and their relevance</article-title><source>Trends Pharmacol Sci</source><year>2006</year><volume>27</volume><issue>9</issue><fpage>482</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2006.07.004</pub-id><pub-id pub-id-type="pmid">16876883</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci. 2006;27(9):482&#8211;91.<pub-id pub-id-type="pmid">16876883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2006.07.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><mixed-citation publication-type="other">Gourlay SG, Benowitz NL. The Benefits of Stopping Smoking and the Role of Nicotine Replacement Therapy in Older Patients: Drugs &amp; Aging. 1996;9(1):8&#8211;23.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00002512-199609010-00002</pub-id><pub-id pub-id-type="pmid">8818582</pub-id></mixed-citation></ref><ref id="CR82"><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graef</surname><given-names>S</given-names></name><name name-style="western"><surname>Sch&#246;nknecht</surname><given-names>P</given-names></name><name name-style="western"><surname>Sabri</surname><given-names>O</given-names></name><name name-style="western"><surname>Hegerl</surname><given-names>U</given-names></name></person-group><article-title>Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: An overview of preclinical and clinical findings</article-title><source>Psychopharmacology</source><year>2011</year><volume>215</volume><issue>2</issue><fpage>205</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1007/s00213-010-2153-8</pub-id><pub-id pub-id-type="pmid">21212938</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Graef S, Sch&#246;nknecht P, Sabri O, Hegerl U. Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: An overview of preclinical and clinical findings. Psychopharmacology. 2011;215(2):205&#8211;29.<pub-id pub-id-type="pmid">21212938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-010-2153-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><mixed-citation publication-type="other">Govind AP, Walsh H, Green WN. Nicotine-Induced Upregulation of Native Neuronal Nicotinic Receptors Is Caused by Multiple Mechanisms. J Neurosci. 2012;32(6):2227&#8211;38.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.5438-11.2012</pub-id><pub-id pub-id-type="pmcid">PMC3286518</pub-id><pub-id pub-id-type="pmid">22323734</pub-id></mixed-citation></ref><ref id="CR84"><mixed-citation publication-type="other">Guthrie SK, Zubieta JK, Ohl L, Ni L, Koeppe RA, Minoshima S, u.&amp;nbsp;a. Arterial/venous plasma nicotine concentrations following nicotine nasal spray. Eur J Clin Pharmacol. 1999;55(9):639&#8211;43.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002280050686</pub-id><pub-id pub-id-type="pmid">10638392</pub-id></mixed-citation></ref><ref id="CR85"><mixed-citation publication-type="other">Guy-Coichard C, Nguyen DT, Delorme T, Boureau F. Pain in Hereditary Neuromuscular Disorders and Myasthenia Gravis: A National Survey of Frequency, Characteristics, and Impact.&#160;J Pain Symptom Manage. 2008;35(1):40&#8211;50.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpainsymman.2007.02.041</pub-id><pub-id pub-id-type="pmid">17981001</pub-id></mixed-citation></ref><ref id="CR86"><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guzm&#225;n-Mej&#237;a</surname><given-names>F</given-names></name><name name-style="western"><surname>L&#243;pez-Rubalcava</surname><given-names>C</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Espinosa</surname><given-names>C</given-names></name></person-group><article-title>Stimulation of nAchR&#945;7 Receptor Inhibits TNF Synthesis and Secretion in Response to LPS Treatment of Mast Cells by Targeting ERK1/2 and TACE Activation</article-title><source>J Neuroimmune Pharmacol</source><year>2018</year><volume>13</volume><issue>1</issue><fpage>39</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1007/s11481-017-9760-7</pub-id><pub-id pub-id-type="pmid">28822039</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Guzm&#225;n-Mej&#237;a F, L&#243;pez-Rubalcava C, Gonz&#225;lez-Espinosa C. Stimulation of nAchR&#945;7 Receptor Inhibits TNF Synthesis and Secretion in Response to LPS Treatment of Mast Cells by Targeting ERK1/2 and TACE Activation. J Neuroimmune Pharmacol. 2018;13(1):39&#8211;52.<pub-id pub-id-type="pmid">28822039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11481-017-9760-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hawiger</surname><given-names>J</given-names></name></person-group><article-title>Mechanisms involved in platelet vessel wall interaction</article-title><source>Thromb Haemost</source><year>1995</year><volume>74</volume><issue>07</issue><fpage>369</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">8578487</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Hawiger J. Mechanisms involved in platelet vessel wall interaction. Thromb Haemost. 1995;74(07):369&#8211;72.<pub-id pub-id-type="pmid">8578487</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><mixed-citation publication-type="other">He J, Huang F, Zhang J, Chen Q, Zheng Z, Zhou Q, u.&amp;nbsp;a. Vaccine design based on 16 epitopes of SARS&#8208;CoV&#8208;2 spike protein. J Med Virology. 2021;93(4):2115&#8211;31.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.26596</pub-id><pub-id pub-id-type="pmcid">PMC7675516</pub-id><pub-id pub-id-type="pmid">33091154</pub-id></mixed-citation></ref><ref id="CR89"><mixed-citation publication-type="other">Huang KT, Han TH, Hyduke DR, Vaughn MW, Van Herle H, Hein TW, u.&amp;nbsp;a. Modulation of nitric oxide bioavailability by erythrocytes. Proc Natl Acad Sci USA. 2001;98(20):11771&#8211;6.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.201276698</pub-id><pub-id pub-id-type="pmcid">PMC58805</pub-id><pub-id pub-id-type="pmid">11573011</pub-id></mixed-citation></ref><ref id="CR90"><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hukkanen</surname><given-names>J</given-names></name><name name-style="western"><surname>Gourlay</surname><given-names>SG</given-names></name><name name-style="western"><surname>Kenkare</surname><given-names>S</given-names></name><name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name></person-group><article-title>Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine*</article-title><source>Clin Pharmacol Ther</source><year>2005</year><volume>77</volume><issue>3</issue><fpage>159</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.clpt.2004.10.012</pub-id><pub-id pub-id-type="pmid">15735610</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Hukkanen J, Gourlay SG, Kenkare S, Benowitz NL. Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine*. Clin Pharmacol Ther. 2005;77(3):159&#8211;69.<pub-id pub-id-type="pmid">15735610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2004.10.012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iadecola</surname><given-names>C</given-names></name><name name-style="western"><surname>Anrather</surname><given-names>J</given-names></name><name name-style="western"><surname>Kamel</surname><given-names>H</given-names></name></person-group><article-title>Effects of COVID-19 on the Nervous System</article-title><source>Cell</source><year>2020</year><volume>183</volume><issue>1</issue><fpage>16</fpage><lpage>27.e1</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.08.028</pub-id><pub-id pub-id-type="pmid">32882182</pub-id><pub-id pub-id-type="pmcid">PMC7437501</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Iadecola C, Anrather J, Kamel H. Effects of COVID-19 on the Nervous System. Cell. 2020;183(1):16-27.e1.<pub-id pub-id-type="pmid">32882182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.08.028</pub-id><pub-id pub-id-type="pmcid">PMC7437501</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iftekhar</surname><given-names>N</given-names></name><name name-style="western"><surname>Sivan</surname><given-names>M</given-names></name></person-group><article-title>Venous insufficiency and acrocyanosis in long COVID: dysautonomia</article-title><source>The Lancet</source><year>2023</year><volume>402</volume><issue>10401</issue><fpage>e9</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)01461-7</pub-id><pub-id pub-id-type="pmid">37573078</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Iftekhar N, Sivan M. Venous insufficiency and acrocyanosis in long COVID: dysautonomia. The Lancet. 2023;402(10401): e9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(23)01461-7</pub-id><pub-id pub-id-type="pmid">37573078</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><mixed-citation publication-type="other">Ikonomidis I, Lambadiari V, Mitrakou A, Kountouri A, Katogiannis K, Thymis J, u.&amp;nbsp;a. Myocardial work and vascular dysfunction are partially improved at 12 months after <sc>COVID</sc> &#8208;19 infection. European J of Heart Fail. 2022;24(4):727&#8211;9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ejhf.2451</pub-id><pub-id pub-id-type="pmcid">PMC9087421</pub-id><pub-id pub-id-type="pmid">35138689</pub-id></mixed-citation></ref><ref id="CR94"><mixed-citation publication-type="other">Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, u.&amp;nbsp;a. Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533&#8211;9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.jcbfm.9600493</pub-id><pub-id pub-id-type="pmid">17519979</pub-id></mixed-citation></ref><ref id="CR95"><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jankauskaite</surname><given-names>L</given-names></name><name name-style="western"><surname>Malinauskas</surname><given-names>M</given-names></name><name name-style="western"><surname>Snipaitiene</surname><given-names>A</given-names></name></person-group><article-title>Effect of stimulated platelets in COVID-19 thrombosis: Role of alpha7 nicotinic acetylcholine receptor</article-title><source>Front Cardiovasc Med</source><year>2022</year><volume>9</volume><fpage>1037369</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2022.1037369</pub-id><pub-id pub-id-type="pmid">36312286</pub-id><pub-id pub-id-type="pmcid">PMC9614055</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Jankauskaite L, Malinauskas M, Snipaitiene A. Effect of stimulated platelets in COVID-19 thrombosis: Role of alpha7 nicotinic acetylcholine receptor. Front Cardiovasc Med. 2022;9:1037369.<pub-id pub-id-type="pmid">36312286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcvm.2022.1037369</pub-id><pub-id pub-id-type="pmcid">PMC9614055</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><mixed-citation publication-type="other">Jones SVP, Levey AI, Weiner DM, Ellis J, Novotny E, Yu SH, u.&amp;nbsp;a. Muscarinic Acetylcholine Receptors. In: Brann MR, Herausgeber. Molecular Biology of G-Protein-Coupled Receptors. Boston, MA: Birkh&#228;user Boston; 1992. S. 170&#8211;97. Verf&#252;gbar unter: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://link.springer.com/10.1007/978-1-4684-6772-7_8">http://link.springer.com/10.1007/978-1-4684-6772-7_8</ext-link>
. Zitiert 2. Februar 2021.</mixed-citation></ref><ref id="CR97"><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kageyama-Yahara</surname><given-names>N</given-names></name><name name-style="western"><surname>Suehiro</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Kadowaki</surname><given-names>M</given-names></name></person-group><article-title>IgE-induced degranulation of mucosal mast cells is negatively regulated via nicotinic acetylcholine receptors</article-title><source>Biochem Biophysical Res Commun</source><year>2008</year><volume>377</volume><issue>1</issue><fpage>321</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2008.10.004</pub-id><pub-id pub-id-type="pmid">18848921</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Kageyama-Yahara N, Suehiro Y, Yamamoto T, Kadowaki M. IgE-induced degranulation of mucosal mast cells is negatively regulated via nicotinic acetylcholine receptors. Biochemical and Biophysical Research Communications. 2008;377(1):321&#8211;5.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2008.10.004</pub-id><pub-id pub-id-type="pmid">18848921</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><mixed-citation publication-type="other">Kalamida D, Poulas K, Avramopoulou V, Fostieri E, Lagoumintzis G, Lazaridis K, u.&amp;nbsp;a. Muscle and neuronal nicotinic acetylcholine receptors: Structure, function and pathogenicity. FEBS J. 2007;274(15):3799&#8211;845.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1742-4658.2007.05935.x</pub-id><pub-id pub-id-type="pmid">17651090</pub-id></mixed-citation></ref><ref id="CR99"><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karimi</surname><given-names>N</given-names></name><name name-style="western"><surname>Okhovat</surname><given-names>AA</given-names></name><name name-style="western"><surname>Ziaadini</surname><given-names>B</given-names></name><name name-style="western"><surname>Haghi Ashtiani</surname><given-names>B</given-names></name><name name-style="western"><surname>Nafissi</surname><given-names>S</given-names></name><name name-style="western"><surname>Fatehi</surname><given-names>F</given-names></name></person-group><article-title>Myasthenia gravis associated with novel coronavirus 2019 infection: A report of three cases</article-title><source>Clin Neurol Neurosurg</source><year>2021</year><volume>208</volume><fpage>106834</fpage><pub-id pub-id-type="doi">10.1016/j.clineuro.2021.106834</pub-id><pub-id pub-id-type="pmid">34329810</pub-id><pub-id pub-id-type="pmcid">PMC8299214</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Karimi N, Okhovat AA, Ziaadini B, Haghi Ashtiani B, Nafissi S, Fatehi F. Myasthenia gravis associated with novel coronavirus 2019 infection: A report of three cases. Clin Neurol Neurosurg. 2021;208: 106834.<pub-id pub-id-type="pmid">34329810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clineuro.2021.106834</pub-id><pub-id pub-id-type="pmcid">PMC8299214</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><mixed-citation publication-type="other">Kavanagh E. Long Covid brain fog: a neuroinflammation phenomenon? Oxford Open Immunology. 2022;3(1):iqac007.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/oxfimm/iqac007</pub-id><pub-id pub-id-type="pmcid">PMC9914477</pub-id><pub-id pub-id-type="pmid">36846556</pub-id></mixed-citation></ref><ref id="CR101"><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawashima</surname><given-names>K</given-names></name><name name-style="western"><surname>Yoshikawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>YX</given-names></name><name name-style="western"><surname>Moriwaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Misawa</surname><given-names>H</given-names></name></person-group><article-title>Expression and function of genes encoding cholinergic components in murine immune cells</article-title><source>Life Sciences</source><year>2007</year><volume>80</volume><issue>24&#8211;25</issue><fpage>2314</fpage><lpage>2319</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2007.02.036</pub-id><pub-id pub-id-type="pmid">17383684</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Kawashima K, Yoshikawa K, Fujii YX, Moriwaki Y, Misawa H. Expression and function of genes encoding cholinergic components in murine immune cells. Life Sciences. 2007;80(24&#8211;25):2314&#8211;9.<pub-id pub-id-type="pmid">17383684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2007.02.036</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><mixed-citation publication-type="other">Kell DB, Pretorius E. Are fibrinaloid microclots a cause of autoimmunity in Long Covid and other post-infection diseases? Biochem J. 2023;480(15):1217&#8211;40.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BCJ20230241</pub-id><pub-id pub-id-type="pmid">37584410</pub-id></mixed-citation></ref><ref id="CR103"><mixed-citation publication-type="other">Keeley EC, Pirwitz MJ, Landau C, Lange RA, David Hillis L, Foerster EH, u.&amp;nbsp;a. Intranasal nicotine spray does not augment the adverse effects of cigarette smoking on myocardial oxygen demand or coronary arterial dimensions. Am J Med. 1996;101(4):357&#8211;63.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0002-9343(96)00237-9</pub-id><pub-id pub-id-type="pmid">8873505</pub-id></mixed-citation></ref><ref id="CR104"><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kenakin</surname><given-names>T</given-names></name></person-group><article-title>Allostery: The Good, the Bad, and the Ugly</article-title><source>J Pharmacol Exp Ther</source><year>2024</year><volume>388</volume><issue>1</issue><fpage>110</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1124/jpet.123.001838</pub-id><pub-id pub-id-type="pmid">37918859</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Kenakin T. Allostery: The Good, the Bad, and the Ugly. J Pharmacol Exp Ther. 2024;388(1):110&#8211;20.<pub-id pub-id-type="pmid">37918859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.123.001838</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirkpatrick</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Bittinger</surname><given-names>F</given-names></name><name name-style="western"><surname>Nozadze</surname><given-names>K</given-names></name><name name-style="western"><surname>Wessler</surname><given-names>I</given-names></name></person-group><article-title>Expression and function of the non-neuronal cholinergic system in endothelial cells</article-title><source>Life Sciences</source><year>2003</year><volume>72</volume><issue>18&#8211;19</issue><fpage>2111</fpage><lpage>2116</lpage><pub-id pub-id-type="doi">10.1016/S0024-3205(03)00069-9</pub-id><pub-id pub-id-type="pmid">12628465</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Kirkpatrick CJ, Bittinger F, Nozadze K, Wessler I. Expression and function of the non-neuronal cholinergic system in endothelial cells. Life Sciences. 2003;72(18&#8211;19):2111&#8211;6.<pub-id pub-id-type="pmid">12628465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0024-3205(03)00069-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><mixed-citation publication-type="other">Kim JYH, Ragusa M, Tortosa F, Torres A, Gresh L, M&#233;ndez-Rico JA, u.&amp;nbsp;a. Viral reactivations and co-infections in COVID-19 patients: a systematic review. BMC Infect Dis. 2023;23(1):259.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12879-023-08117-y</pub-id><pub-id pub-id-type="pmcid">PMC10131452</pub-id><pub-id pub-id-type="pmid">37101275</pub-id></mixed-citation></ref><ref id="CR107"><mixed-citation publication-type="other">Komaroff AL, Lipkin WI. ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature. Front Med. 2023;10:1187163.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2023.1187163</pub-id><pub-id pub-id-type="pmcid">PMC10278546</pub-id><pub-id pub-id-type="pmid">37342500</pub-id></mixed-citation></ref><ref id="CR108"><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korhonen</surname><given-names>T</given-names></name><name name-style="western"><surname>Kinnunen</surname><given-names>TH</given-names></name><name name-style="western"><surname>Garvey</surname><given-names>AJ</given-names></name></person-group><article-title>Impact of Nicotine Replacement Therapy on Post-Cessation Mood Profile by Pre-Cessation Depressive Symptoms</article-title><source>Tob Induced Dis</source><year>2006</year><volume>3</volume><issue>2</issue><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/1617-9625-3-2-17</pub-id><pub-id pub-id-type="pmcid">PMC2633369</pub-id><pub-id pub-id-type="pmid">19570294</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Korhonen T, Kinnunen TH, Garvey AJ. Impact of Nicotine Replacement Therapy on Post-Cessation Mood Profile by Pre-Cessation Depressive Symptoms. Tob Induced Dis. 2006;3(2):17.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1617-9625-3-2-17</pub-id><pub-id pub-id-type="pmcid">PMC2633369</pub-id><pub-id pub-id-type="pmid">19570294</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><mixed-citation publication-type="other">Koval L, Lykhmus O, Zhmak M, Khruschov A, Tsetlin V, Magrini E, u.&amp;nbsp;a. Differential involvement of &#945;4&#946;2, &#945;7 and &#945;9&#945;10 nicotinic acetylcholine receptors in B lymphocyte activation in vitro. Int J Biochem Cell Biol. 2011;43(4):516&#8211;24.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biocel.2010.12.003</pub-id><pub-id pub-id-type="pmid">21146628</pub-id></mixed-citation></ref><ref id="CR110"><mixed-citation publication-type="other">Krumholz HM, Wu Y, Sawano M, Shah R, Zhou T, Arun AS, u.&amp;nbsp;a. Post-Vaccination Syndrome: A Descriptive Analysis of Reported Symptoms and Patient Experiences After Covid-19 Immunization. Public and Global Health; 2023. Verf&#252;gbar unter: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://medrxiv.org/lookup/doi/10.1101/2023.11.09.23298266">http://medrxiv.org/lookup/doi/10.1101/2023.11.09.23298266</ext-link>
. Zitiert 9. Februar 2024.</mixed-citation></ref><ref id="CR111"><mixed-citation publication-type="other">Lagoumintzis G, Chasapis CT, Alexandris N, Tzartos S, Eliopoulos E, Farsalinos K, u.&amp;nbsp;a. COVID-19 and Cholinergic Anti-inflammatory Pathway: In silico Identification of an Interaction between &#945;7 Nicotinic Acetylcholine Receptor and the Cryptic Epitopes of SARS-CoV and SARS-CoV-2 Spike Glycoproteins. Immunology; 2020. Verf&#252;gbar unter: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://biorxiv.org/lookup/doi/10.1101/2020.08.20.259747">http://biorxiv.org/lookup/doi/10.1101/2020.08.20.259747</ext-link>
. Zitiert 25. April 2022.</mixed-citation></ref><ref id="CR112"><mixed-citation publication-type="other">Lane RJM, Barrett MC, Woodrow D, Moss J, Fletcher R, Archard LC. Muscle fibre characteristics and lactate responses to exercise in chronic fatigue syndrome. Journal of Neurology, Neurosurgery &amp; Psychiatry. 1998;64(3):362&#8211;7.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.64.3.362</pub-id><pub-id pub-id-type="pmcid">PMC2169994</pub-id><pub-id pub-id-type="pmid">9527150</pub-id></mixed-citation></ref><ref id="CR113"><mixed-citation publication-type="other">Lambadiari V, Mitrakou A, Kountouri A, Thymis J, Katogiannis K, Korakas E, u.&amp;nbsp;a. Association of <sc>COVID</sc> &#8208;19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection. European J of Heart Fail. 2021;23(11):1916&#8211;26.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ejhf.2326</pub-id><pub-id pub-id-type="pmcid">PMC8426810</pub-id><pub-id pub-id-type="pmid">34415085</pub-id></mixed-citation></ref><ref id="CR114"><mixed-citation publication-type="other">Larsen E, Celi A, Gilbert GE, Furie BC, Erban JK, Bonfanti R, u.&amp;nbsp;a. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell. 1989;59(2):305&#8211;12.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0092-8674(89)90292-4</pub-id><pub-id pub-id-type="pmid">2478294</pub-id></mixed-citation></ref><ref id="CR115"><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Houezec</surname><given-names>J</given-names></name></person-group><article-title>Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review</article-title><source>Int J Tuberc Lung Dis</source><year>2003</year><volume>7</volume><issue>9</issue><fpage>811</fpage><lpage>819</lpage><pub-id pub-id-type="pmid">12971663</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Le Houezec J. Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review. Int J Tuberc Lung Dis. 2003;7(9):811&#8211;9.<pub-id pub-id-type="pmid">12971663</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>CH</given-names></name><name name-style="western"><surname>Wu</surname><given-names>CH</given-names></name><name name-style="western"><surname>Ho</surname><given-names>YS</given-names></name></person-group><article-title>From Smoking to Cancers: Novel Targets to Neuronal Nicotinic Acetylcholine Receptors</article-title><source>J Oncol</source><year>2011</year><volume>2011</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1155/2011/365651</pub-id><pub-id pub-id-type="pmcid">PMC3136181</pub-id><pub-id pub-id-type="pmid">21772846</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Lee CH, Wu CH, Ho YS. From Smoking to Cancers: Novel Targets to Neuronal Nicotinic Acetylcholine Receptors. J Oncol. 2011;2011:1&#8211;10.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2011/693424</pub-id><pub-id pub-id-type="pmcid">PMC3136181</pub-id><pub-id pub-id-type="pmid">21772846</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><mixed-citation publication-type="other">Lee PN, Fariss MW. A systematic review of possible serious adverse health effects of nicotine replacement therapy.&#160;Arch&#160;Toxicol&#160;[Internet]. 2016;91(4):1565&#8211;94. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5364244/">https://pmc.ncbi.nlm.nih.gov/articles/PMC5364244/</ext-link>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00204-016-1856-y</pub-id><pub-id pub-id-type="pmcid">PMC5364244</pub-id><pub-id pub-id-type="pmid">27699443</pub-id></mixed-citation></ref><ref id="CR118"><mixed-citation publication-type="other">Leitzke M. Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration? Bioelectron Med. 2023;9(1):2.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s42234-023-00104-7</pub-id><pub-id pub-id-type="pmcid">PMC9845100</pub-id><pub-id pub-id-type="pmid">36650574</pub-id></mixed-citation></ref><ref id="CR119"><mixed-citation publication-type="other">Leitzke M, Sch&#246;nknecht P. The Viral Accelerated NF-&#954;B Pathway Probably Drives COVID-19-associated Coagulopathy via Excessive Transcription of Tissue Factor and Plasminogen Activator Inhibitor 1 &#8211; Case Report. Arch Clin Biomed Res. 2021 ;05(04). Verf&#252;gbar unter: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fortunejournals.com/articles/the-viral-accelerated-nfkappab-pathway-probably-drives-covid19associated-coagulopathy-via-excessive-transcription-of-tissue-factor.html">https://www.fortunejournals.com/articles/the-viral-accelerated-nfkappab-pathway-probably-drives-covid19associated-coagulopathy-via-excessive-transcription-of-tissue-factor.html</ext-link>. Zitiert 20. April 2022.</mixed-citation></ref><ref id="CR120"><mixed-citation publication-type="other">Lenharo M. WHO declares end to COVID-19's emergency phase. Nature. 2023. 10.1038/d41586-023-01559-z. Epub ahead of print. PMID: 37147368.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-023-01559-z</pub-id><pub-id pub-id-type="pmid">37147368</pub-id></mixed-citation></ref><ref id="CR121"><mixed-citation publication-type="other">Leng A, Shah M, Ahmad SA, Premraj L, Wildi K, Li Bassi G, u.&amp;nbsp;a. Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics. Cells. 2023;12(5):816.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells12050816</pub-id><pub-id pub-id-type="pmcid">PMC10001044</pub-id><pub-id pub-id-type="pmid">36899952</pub-id></mixed-citation></ref><ref id="CR122"><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lentz</surname><given-names>TL</given-names></name><name name-style="western"><surname>Burrage</surname><given-names>TG</given-names></name><name name-style="western"><surname>Smith</surname><given-names>AL</given-names></name><name name-style="western"><surname>Tignor</surname><given-names>GH</given-names></name></person-group><article-title>The acetylcholine receptor as a cellular receptor for rabies virus</article-title><source>Yale J Biol Med</source><year>1983</year><volume>56</volume><issue>4</issue><fpage>315</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">6367238</pub-id><pub-id pub-id-type="pmcid">PMC2589619</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Lentz TL, Burrage TG, Smith AL, Tignor GH. The acetylcholine receptor as a cellular receptor for rabies virus. Yale J Biol Med. 1983;56(4):315&#8211;22.<pub-id pub-id-type="pmid">6367238</pub-id><pub-id pub-id-type="pmcid">PMC2589619</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>SS</given-names></name></person-group><article-title>Carcinogenic components of tobacco and tobacco smoke: A 2022 update</article-title><source>Food and Chemical Toxicology</source><year>2022</year><volume>165</volume><fpage>113179</fpage><pub-id pub-id-type="doi">10.1016/j.fct.2022.113179</pub-id><pub-id pub-id-type="pmid">35643228</pub-id><pub-id pub-id-type="pmcid">PMC9616535</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Li Y, Hecht SS. Carcinogenic components of tobacco and tobacco smoke: A 2022 update. Food and Chemical Toxicology. 2022;165: 113179.<pub-id pub-id-type="pmid">35643228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.fct.2022.113179</pub-id><pub-id pub-id-type="pmcid">PMC9616535</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xi</surname><given-names>X</given-names></name><name name-style="western"><surname>Du</surname><given-names>X</given-names></name></person-group><article-title>A Mitogen-activated Protein Kinase-dependent Signaling Pathway in the Activation of Platelet Integrin &#945;IIb&#946;3</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><issue>45</issue><fpage>42226</fpage><lpage>42232</lpage><pub-id pub-id-type="doi">10.1074/jbc.M106129200</pub-id><pub-id pub-id-type="pmid">11522789</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Li Z, Xi X, Du X. A Mitogen-activated Protein Kinase-dependent Signaling Pathway in the Activation of Platelet Integrin &#945;IIb&#946;3. J Biol Chem. 2001;276(45):42226&#8211;32.<pub-id pub-id-type="pmid">11522789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M106129200</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR125"><mixed-citation publication-type="other">Lloyd GK, Williams M. Neuronal Nicotinic Acetylcholine Receptors as Novel Drug Targets. J Pharmacol Exp Ther. 2000;292(2):461.<pub-id pub-id-type="pmid">10640281</pub-id></mixed-citation></ref><ref id="CR126"><mixed-citation publication-type="other">L&#243;pez-Hern&#225;ndez Y, Mon&#225;rrez-Espino J, L&#243;pez DAG, Zheng J, Borrego JC, Torres-Calzada C, u.&amp;nbsp;a. The plasma metabolome of long COVID patients two years after infection. Sci Rep. 2023;13(1):12420.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-39049-x</pub-id><pub-id pub-id-type="pmcid">PMC10394026</pub-id><pub-id pub-id-type="pmid">37528111</pub-id></mixed-citation></ref><ref id="CR127"><mixed-citation publication-type="other">Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, u.&amp;nbsp;a. Graphical Analysis of Reversible Radioligand Binding from Time&#8212;Activity Measurements Applied to [ N - <sup>11</sup> C-Methyl]-(&#8722;)-Cocaine PET Studies in Human Subjects. J Cereb Blood Flow Metab. 1990;10(5):740&#8211;7.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jcbfm.1990.127</pub-id><pub-id pub-id-type="pmid">2384545</pub-id></mixed-citation></ref><ref id="CR128"><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucini</surname><given-names>D</given-names></name><name name-style="western"><surname>Bertocchi</surname><given-names>F</given-names></name><name name-style="western"><surname>Malliani</surname><given-names>A</given-names></name><name name-style="western"><surname>Pagani</surname><given-names>M</given-names></name></person-group><article-title>Autonomic Effects of Nicotine Patch Administration in Habitual Cigarette Smokers: A Double-Blind, Placebo-Controlled Study Using Spectral Analysis of RR Interval and Systolic Arterial Pressure Variabilities</article-title><source>J Cardiovasc Pharmacol</source><year>1998</year><volume>31</volume><issue>5</issue><fpage>714</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1097/00005344-199805000-00010</pub-id><pub-id pub-id-type="pmid">9593071</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Lucini D, Bertocchi F, Malliani A, Pagani M. Autonomic Effects of Nicotine Patch Administration in Habitual Cigarette Smokers: A Double-Blind, Placebo-Controlled Study Using Spectral Analysis of RR Interval and Systolic Arterial Pressure Variabilities: Journal of Cardiovascular Pharmacology. 1998;31(5):714&#8211;20.<pub-id pub-id-type="pmid">9593071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00005344-199805000-00010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lykhmus</surname><given-names>O</given-names></name><name name-style="western"><surname>Gergalova</surname><given-names>G</given-names></name><name name-style="western"><surname>Koval</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhmak</surname><given-names>M</given-names></name><name name-style="western"><surname>Komisarenko</surname><given-names>S</given-names></name><name name-style="western"><surname>Skok</surname><given-names>M</given-names></name></person-group><article-title>Mitochondria express several nicotinic acetylcholine receptor subtypes to control various pathways of apoptosis induction</article-title><source>Int J Biochem Cell Biol</source><year>2014</year><volume>53</volume><fpage>246</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2014.05.030</pub-id><pub-id pub-id-type="pmid">24880090</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Lykhmus O, Gergalova G, Koval L, Zhmak M, Komisarenko S, Skok M. Mitochondria express several nicotinic acetylcholine receptor subtypes to control various pathways of apoptosis induction. Int J Biochem Cell Biol. 2014;53:246&#8211;52.<pub-id pub-id-type="pmid">24880090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biocel.2014.05.030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><mixed-citation publication-type="other">Ma H, Murphy C, Loscher CE, O&#8217;Kennedy R. Autoantibodies - enemies, and/or potential allies? Front Immunol. 2022;13:953726.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.953726</pub-id><pub-id pub-id-type="pmcid">PMC9627499</pub-id><pub-id pub-id-type="pmid">36341384</pub-id></mixed-citation></ref><ref id="CR131"><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macklin</surname><given-names>KD</given-names></name><name name-style="western"><surname>Maus</surname><given-names>AD</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>EF</given-names></name><name name-style="western"><surname>Albuquerque</surname><given-names>EX</given-names></name><name name-style="western"><surname>Conti-Fine</surname><given-names>BM</given-names></name></person-group><article-title>Human vascular endothelial cells express functional nicotinic acetylcholine receptors</article-title><source>J Pharmacol Exp Ther</source><year>1998</year><volume>287</volume><issue>1</issue><fpage>435</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1016/S0022-3565(24)37807-3</pub-id><pub-id pub-id-type="pmid">9765366</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">Macklin KD, Maus AD, Pereira EF, Albuquerque EX, Conti-Fine BM. Human vascular endothelial cells express functional nicotinic acetylcholine receptors. J Pharmacol Exp Ther. 1998;287(1):435&#8211;9.<pub-id pub-id-type="pmid">9765366</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><mixed-citation publication-type="other">McLane KE, Wu X, Diethelm B, Conti-Tronconi BM. Structural determinants of .alpha.-bungarotoxin binding to the sequence segment 181&#8211;200 of the muscle nicotinic acetylcholine receptor .alpha. subunit: effects of cysteine/cystine modification and species-specific amino acid substitutions. Biochemistry. 1991;30(20):4925&#8211;34.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/bi00234a013</pub-id><pub-id pub-id-type="pmid">2036361</pub-id></mixed-citation></ref><ref id="CR133"><mixed-citation publication-type="other">Mali&#324;ska D, Wi&#281;ckowski MR, Michalska B, Drabik K, Prill M, Patalas-Krawczyk P, u.&amp;nbsp;a. Mitochondria as a possible target for nicotine action. J Bioenerg Biomembr. 2019;51(4):259&#8211;76.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10863-019-09800-z</pub-id><pub-id pub-id-type="pmcid">PMC6679833</pub-id><pub-id pub-id-type="pmid">31197632</pub-id></mixed-citation></ref><ref id="CR134"><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masini</surname><given-names>E</given-names></name><name name-style="western"><surname>Salvemini</surname><given-names>D</given-names></name><name name-style="western"><surname>Pistelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Mannaioni</surname><given-names>PF</given-names></name><name name-style="western"><surname>Vane</surname><given-names>JR</given-names></name></person-group><article-title>Rat mast cells synthesize a nitric oxide like-factor which modulates the release of histamine</article-title><source>Agents and Actions</source><year>1991</year><volume>33</volume><issue>1&#8211;2</issue><fpage>61</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1007/BF01993127</pub-id><pub-id pub-id-type="pmid">1716838</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Masini E, Salvemini D, Pistelli A, Mannaioni PF, Vane JR. Rat mast cells synthesize a nitric oxide like-factor which modulates the release of histamine. Agents and Actions . 1991;33(1&#8211;2):61&#8211;3.<pub-id pub-id-type="pmid">1716838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF01993127</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayer</surname><given-names>B</given-names></name></person-group><article-title>How much nicotine kills a human? Tracing back the generally accepted lethal dose to dubious self-experiments in the nineteenth century</article-title><source>Arch Toxicol</source><year>2014</year><volume>88</volume><issue>1</issue><fpage>5</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/s00204-013-1127-0</pub-id><pub-id pub-id-type="pmid">24091634</pub-id><pub-id pub-id-type="pmcid">PMC3880486</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Mayer B. How much nicotine kills a human? Tracing back the generally accepted lethal dose to dubious self-experiments in the nineteenth century. Arch Toxicol. 2014;88(1):5&#8211;7.<pub-id pub-id-type="pmid">24091634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00204-013-1127-0</pub-id><pub-id pub-id-type="pmcid">PMC3880486</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR136"><mixed-citation publication-type="other">Mesquita R, Saldanha C, Silva JM e. Acetylcholine induces nitric oxide production by erythrocytes in vitro. Nitric Oxide. 2000;4:313&#8211;4.</mixed-citation></ref><ref id="CR137"><mixed-citation publication-type="other">Merten M, Thiagarajan P. P-Selectin Expression on Platelets Determines Size and Stability of Platelet Aggregates. Circulation. 2000;102(16):1931&#8211;6.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.cir.102.16.1931</pub-id><pub-id pub-id-type="pmid">11034941</pub-id></mixed-citation></ref><ref id="CR138"><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mesquita</surname><given-names>R</given-names></name><name name-style="western"><surname>Pires</surname><given-names>I</given-names></name><name name-style="western"><surname>Saldanha</surname><given-names>C</given-names></name><name name-style="western"><surname>Martins-Silva</surname><given-names>J</given-names></name></person-group><article-title>Effects of acetylcholine and spermineNONOate on erythrocyte hemorheologic and oxygen carrying properties</article-title><source>Clin Hemorheol Microcirc</source><year>2001</year><volume>25</volume><issue>3&#8211;4</issue><fpage>153</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">11847418</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Mesquita R, Pires I, Saldanha C, Martins-Silva J. Effects of acetylcholine and spermineNONOate on erythrocyte hemorheologic and oxygen carrying properties. Clin Hemorheol Microcirc. 2001;25(3&#8211;4):153&#8211;63.<pub-id pub-id-type="pmid">11847418</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><mixed-citation publication-type="other">Meunier V, Bourrie M, Julian B, Marti E, Guillou F, Berger Y, u.&amp;nbsp;a. Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up. Xenobiotica. 2000;30(6):589&#8211;607.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/004982500406426</pub-id><pub-id pub-id-type="pmid">10923861</pub-id></mixed-citation></ref><ref id="CR140"><mixed-citation publication-type="other">Mishra NC, Rir-sima-ah J, Boyd RT, Singh SP, Gundavarapu S, Langley RJ, u.&amp;nbsp;a. Nicotine Inhibits Fc&#949;RI-Induced Cysteinyl Leukotrienes and Cytokine Production without Affecting Mast Cell Degranulation Through &#945;7/&#945;9/&#945;10-Nicotinic Receptors. J Immunol. 2010;185(1):588&#8211;96.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.0902227</pub-id><pub-id pub-id-type="pmcid">PMC2954495</pub-id><pub-id pub-id-type="pmid">20505147</pub-id></mixed-citation></ref><ref id="CR141"><mixed-citation publication-type="other">Moccia F, Frost C, Berra-Romani R, Tanzi F, Adams DJ. Expression and function of neuronal nicotinic ACh receptors in rat microvascular endothelial cells. American Journal of Physiology-Heart and Circulatory Physiology. 2004;286(2):H486&#8211;91.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpheart.00620.2003</pub-id><pub-id pub-id-type="pmid">14512281</pub-id></mixed-citation></ref><ref id="CR142"><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molander</surname><given-names>L</given-names></name></person-group><article-title>Pharmacokinetics of nicotine in healthy elderly people</article-title><source>Clin Pharmacol Therapeutics</source><year>2001</year><volume>69</volume><issue>1</issue><fpage>57</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1067/mcp.2001.113181</pub-id><pub-id pub-id-type="pmid">11180039</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Molander L. Pharmacokinetics of nicotine in healthy elderly people. Clinical Pharmacology &amp; Therapeutics. 2001;69(1):57&#8211;65.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2001.113181</pub-id><pub-id pub-id-type="pmid">11180039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><mixed-citation publication-type="other">Molyneux A, Kr&#225;l&#237;kov&#225; E, Himmerov&#225; V. [ABC of smoking cessation. Nicotine replacement therapy]. Cas Lek Cesk. 2004;143(11):781&#8211;3.<pub-id pub-id-type="pmid">15628577</pub-id></mixed-citation></ref><ref id="CR144"><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monje</surname><given-names>M</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>A</given-names></name></person-group><article-title>The neurobiology of long COVID</article-title><source>Neuron</source><year>2022</year><volume>110</volume><issue>21</issue><fpage>3484</fpage><lpage>3496</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2022.10.006</pub-id><pub-id pub-id-type="pmid">36288726</pub-id><pub-id pub-id-type="pmcid">PMC9537254</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Monje M, Iwasaki A. The neurobiology of long COVID. Neuron. 2022;110(21):3484&#8211;96.<pub-id pub-id-type="pmid">36288726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2022.10.006</pub-id><pub-id pub-id-type="pmcid">PMC9537254</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montes-Ibarra</surname><given-names>M</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>CLP</given-names></name><name name-style="western"><surname>Orsso</surname><given-names>CE</given-names></name><name name-style="western"><surname>Landi</surname><given-names>F</given-names></name><name name-style="western"><surname>Marzetti</surname><given-names>E</given-names></name><name name-style="western"><surname>Prado</surname><given-names>CM</given-names></name></person-group><article-title>The Impact of Long COVID-19 on Muscle Health</article-title><source>Clin Geriatr Med</source><year>2022</year><volume>38</volume><issue>3</issue><fpage>545</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1016/j.cger.2022.03.004</pub-id><pub-id pub-id-type="pmid">35868672</pub-id><pub-id pub-id-type="pmcid">PMC8934728</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Montes-Ibarra M, Oliveira CLP, Orsso CE, Landi F, Marzetti E, Prado CM. The Impact of Long COVID-19 on Muscle Health. Clin Geriatr Med. 2022;38(3):545&#8211;57.<pub-id pub-id-type="pmid">35868672</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cger.2022.03.004</pub-id><pub-id pub-id-type="pmcid">PMC8934728</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><mixed-citation publication-type="other">Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ. 2009;338(apr02 3):b1024&#8211;b1024.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.b1024</pub-id><pub-id pub-id-type="pmcid">PMC2664870</pub-id><pub-id pub-id-type="pmid">19342408</pub-id></mixed-citation></ref><ref id="CR147"><mixed-citation publication-type="other">Mousa S, Mousa SA. Cellular and molecular mechanisms of nicotine&#8217;s pro&#8208;angiogenesis activity and its potential impact on cancer. J of Cellular Biochemistry. 2006;97(6):1370&#8211;8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcb.20741</pub-id><pub-id pub-id-type="pmid">16365874</pub-id></mixed-citation></ref><ref id="CR148"><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ndel</surname><given-names>T</given-names></name></person-group><article-title>Nicotine: Sporting Friend or Foe? A Review of Athlete Use, Performance Consequences and Other Considerations</article-title><source>Sports Med</source><year>2017</year><volume>47</volume><issue>12</issue><fpage>2497</fpage><lpage>2506</lpage><pub-id pub-id-type="doi">10.1007/s40279-017-0764-5</pub-id><pub-id pub-id-type="pmid">28791650</pub-id><pub-id pub-id-type="pmcid">PMC5684328</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">M&#252;ndel T. Nicotine: Sporting Friend or Foe? A Review of Athlete Use, Performance Consequences and Other Considerations. Sports Med. 2017;47(12):2497&#8211;506.<pub-id pub-id-type="pmid">28791650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40279-017-0764-5</pub-id><pub-id pub-id-type="pmcid">PMC5684328</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR149"><mixed-citation publication-type="other">Mundal HH, Gjesdal K, Hjemdahl P. Acute effects of low dose nicotine gum on platelet function in non-smoking hypertensive and normotensive men. Eur J Clin Pharmacol. 1995;47(5). Verf&#252;gbar unter: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://link.springer.com/10.1007/BF00196854">http://link.springer.com/10.1007/BF00196854</ext-link>
. Zitiert 27. Februar 2024.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00196854</pub-id><pub-id pub-id-type="pmid">7720762</pub-id></mixed-citation></ref><ref id="CR150"><mixed-citation publication-type="other">Myles ME, Alack C, Manino PM, Reish ER, Higaki S, Maruyama K, u.&amp;nbsp;a. Nicotine Applied by Transdermal Patch Induced HSV-1 Reactivation and Ocular Shedding in Latently Infected Rabbits. Journal of Ocular Pharmacology and Therapeutics. 2003;19(2):121&#8211;33.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/108076803321637654</pub-id><pub-id pub-id-type="pmid">12804057</pub-id></mixed-citation></ref><ref id="CR151"><mixed-citation publication-type="other">Murray RP, Bailey WC, Daniels K, Bjornson WM, Kurnow K, Connett JE, u.&amp;nbsp;a. Safety of Nicotine Polacrilex Gum Used by 3,094 Participants in the Lung Health Study. Chest. 1996;109(2):438&#8211;45.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1378/chest.109.2.438</pub-id><pub-id pub-id-type="pmid">8620719</pub-id></mixed-citation></ref><ref id="CR152"><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nair</surname><given-names>S</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>S</given-names></name><name name-style="western"><surname>Camoens</surname><given-names>HMT</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>K</given-names></name><name name-style="western"><surname>Mohanty</surname><given-names>D</given-names></name></person-group><article-title>Changes in platelet glycoprotein receptors after smoking &#8211; a flow cytometric study</article-title><source>Platelets</source><year>2001</year><volume>12</volume><issue>1</issue><fpage>20</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1080/09537100120046020</pub-id><pub-id pub-id-type="pmid">11281626</pub-id></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Nair S, Kulkarni S, Camoens HMT, Ghosh K, Mohanty D. Changes in platelet glycoprotein receptors after smoking &#8211; a flow cytometric study. Platelets. 2001;12(1):20&#8211;6.<pub-id pub-id-type="pmid">11281626</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09537100120046020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR153"><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neri</surname><given-names>P</given-names></name><name name-style="western"><surname>Bracci</surname><given-names>L</given-names></name><name name-style="western"><surname>Rustici</surname><given-names>M</given-names></name><name name-style="western"><surname>Santucci</surname><given-names>A</given-names></name></person-group><article-title>Sequence homology between HIV gp120, rabies virus glycoprotein, and snake venom neurotoxins: Is the nicotinic acetylcholine receptor an HIV receptor?</article-title><source>Adv Virol</source><year>1990</year><volume>114</volume><issue>3&#8211;4</issue><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF01310756</pub-id><pub-id pub-id-type="pmid">2241576</pub-id></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Neri P, Bracci L, Rustici M, Santucci A. Sequence homology between HIV gp120, rabies virus glycoprotein, and snake venom neurotoxins: Is the nicotinic acetylcholine receptor an HIV receptor? Adv Virol. 1990;114(3&#8211;4):265&#8211;9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF01310756</pub-id><pub-id pub-id-type="pmid">2241576</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR154"><mixed-citation publication-type="other">Nunez-Castilla J, Stebliankin V, Baral P, Balbin CA, Sobhan M, Cickovski T, u.&amp;nbsp;a. Potential autoimmunity resulting from molecular mimicry between SARS-CoV-2 Spike and human proteins. 2021. Verf&#252;gbar unter: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://biorxiv.org/lookup/doi/10.1101/2021.08.10.455737">http://biorxiv.org/lookup/doi/10.1101/2021.08.10.455737</ext-link>
. Zitiert 15. April 2024.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v14071415</pub-id><pub-id pub-id-type="pmcid">PMC9318917</pub-id><pub-id pub-id-type="pmid">35891400</pub-id></mixed-citation></ref><ref id="CR155"><mixed-citation publication-type="other">Murray RP, Connett JE, Zapawa LM. Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study. Nicotine &amp; Tobacco Research. 2009;11(9):1076&#8211;82.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ntr/ntp104</pub-id><pub-id pub-id-type="pmcid">PMC2725009</pub-id><pub-id pub-id-type="pmid">19571249</pub-id></mixed-citation></ref><ref id="CR156"><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Obach</surname><given-names>RS</given-names></name></person-group><article-title>POTENT INHIBITION OF HUMAN LIVER ALDEHYDE OXIDASE BY RALOXIFENE</article-title><source>Drug Metab Dispos</source><year>2004</year><volume>32</volume><issue>1</issue><fpage>89</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1124/dmd.32.1.89</pub-id><pub-id pub-id-type="pmid">14709625</pub-id></element-citation><mixed-citation id="mc-CR156" publication-type="journal">Obach RS. Potent inhibition of human liver Aldehyde Oxidase By Raloxifene. Drug Metab Dispos. 2004;32(1):89&#8211;97.<pub-id pub-id-type="pmid">14709625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.32.1.89</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR157"><mixed-citation publication-type="other">Oikonomou E, Souvaliotis N, Lampsas S, Siasos G, Poulakou G, Theofilis P, u.&amp;nbsp;a. Endothelial dysfunction in acute and long standing COVID&#8722;19: A prospective cohort study. Vascular Pharmacology. 2022;144:106975.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vph.2022.106975</pub-id><pub-id pub-id-type="pmcid">PMC8893931</pub-id><pub-id pub-id-type="pmid">35248780</pub-id></mixed-citation></ref><ref id="CR158"><mixed-citation publication-type="other">Oliveira ASF, Ibarra AA, Bermudez I, Casalino L, Gaieb Z, Shoemark DK, u.&amp;nbsp;a. A potential interaction between the SARS-CoV-2 spike protein and nicotinic acetylcholine receptors. Biophysical Journal. 2021;120(6):983&#8211;93.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bpj.2021.01.037</pub-id><pub-id pub-id-type="pmcid">PMC7889469</pub-id><pub-id pub-id-type="pmid">33609494</pub-id></mixed-citation></ref><ref id="CR159"><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ortona</surname><given-names>E</given-names></name><name name-style="western"><surname>Malorni</surname><given-names>W</given-names></name></person-group><article-title>Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy</article-title><source>Eur Respir J</source><year>2022</year><volume>59</volume><issue>2</issue><fpage>2102245</fpage><pub-id pub-id-type="doi">10.1183/13993003.02245-2021</pub-id><pub-id pub-id-type="pmid">34531277</pub-id><pub-id pub-id-type="pmcid">PMC8462012</pub-id></element-citation><mixed-citation id="mc-CR159" publication-type="journal">Ortona E, Malorni W. Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy. Eur Respir J. 2022;59(2):2102245.<pub-id pub-id-type="pmid">34531277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.02245-2021</pub-id><pub-id pub-id-type="pmcid">PMC8462012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR160"><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osipov</surname><given-names>AV</given-names></name><name name-style="western"><surname>Averin</surname><given-names>AS</given-names></name><name name-style="western"><surname>Shaykhutdinova</surname><given-names>ER</given-names></name><name name-style="western"><surname>Dyachenko</surname><given-names>IA</given-names></name><name name-style="western"><surname>Tsetlin</surname><given-names>VI</given-names></name><name name-style="western"><surname>Utkin</surname><given-names>YN</given-names></name></person-group><article-title>Muscarinic and Nicotinic Acetylcholine Receptors in the Regulation of the Cardiovascular System</article-title><source>Russ J Bioorg Chem</source><year>2023</year><volume>49</volume><issue>1</issue><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1134/S1068162023010211</pub-id></element-citation><mixed-citation id="mc-CR160" publication-type="journal">Osipov AV, Averin AS, Shaykhutdinova ER, Dyachenko IA, Tsetlin VI, Utkin YN. Muscarinic and Nicotinic Acetylcholine Receptors in the Regulation of the Cardiovascular System. Russ J Bioorg Chem. 2023;49(1):1&#8211;18.</mixed-citation></citation-alternatives></ref><ref id="CR161"><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ouagazzal</surname><given-names>A</given-names></name><name name-style="western"><surname>Kenny</surname><given-names>PJ</given-names></name><name name-style="western"><surname>File</surname><given-names>SE</given-names></name></person-group><article-title>Stimulation of nicotinic receptors in the lateral septal nucleus increases anxiety</article-title><source>Eur J of Neuroscience</source><year>1999</year><volume>11</volume><issue>11</issue><fpage>3957</fpage><lpage>3962</lpage><pub-id pub-id-type="doi">10.1046/j.1460-9568.1999.00823.x</pub-id><pub-id pub-id-type="pmid">10583484</pub-id></element-citation><mixed-citation id="mc-CR161" publication-type="journal">Ouagazzal A, Kenny PJ, File SE. Stimulation of nicotinic receptors in the lateral septal nucleus increases anxiety. Eur J of Neuroscience. 1999;11(11):3957&#8211;62.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1460-9568.1999.00823.x</pub-id><pub-id pub-id-type="pmid">10583484</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR162"><mixed-citation publication-type="other">O&#8217;Brien KK, Brown DA, McDuff K, St. Clair-Sullivan N, Solomon P, Chan Carusone S, u.&amp;nbsp;a. Conceptualising the episodic nature of disability among adults living with Long COVID: a qualitative study. BMJ Glob Health. 2023;8(3):e011276.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjgh-2022-011276</pub-id><pub-id pub-id-type="pmcid">PMC9979585</pub-id><pub-id pub-id-type="pmid">36863719</pub-id></mixed-citation></ref><ref id="CR163"><mixed-citation publication-type="other">O&#8217;Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, u.&amp;nbsp;a. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. eClinicalMedicine. 2023;55:101762.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2022.101762</pub-id><pub-id pub-id-type="pmcid">PMC9714474</pub-id><pub-id pub-id-type="pmid">36474804</pub-id></mixed-citation></ref><ref id="CR164"><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Brien</surname><given-names>BCV</given-names></name><name name-style="western"><surname>Weber</surname><given-names>L</given-names></name><name name-style="western"><surname>Hueffer</surname><given-names>K</given-names></name><name name-style="western"><surname>Weltzin</surname><given-names>MM</given-names></name></person-group><article-title>SARS-CoV-2 spike ectodomain targets &#945;7 nicotinic acetylcholine receptors</article-title><source>J Biol Chem</source><year>2023</year><volume>299</volume><issue>5</issue><fpage>104707</fpage><pub-id pub-id-type="doi">10.1016/j.jbc.2023.104707</pub-id><pub-id pub-id-type="pmid">37061001</pub-id><pub-id pub-id-type="pmcid">PMC10101490</pub-id></element-citation><mixed-citation id="mc-CR164" publication-type="journal">O&#8217;Brien BCV, Weber L, Hueffer K, Weltzin MM. SARS-CoV-2 spike ectodomain targets &#945;7 nicotinic acetylcholine receptors. J Biol Chem Mai. 2023;299(5): 104707.<pub-id pub-id-type="pmid">37061001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbc.2023.104707</pub-id><pub-id pub-id-type="pmcid">PMC10101490</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR165"><mixed-citation publication-type="other">Pakala RS, Brown KN, Preuss CV. Cholinergic Medications. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Verf&#252;gbar unter: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK538163/">http://www.ncbi.nlm.nih.gov/books/NBK538163/</ext-link>. Zitiert 26. Mai 2024.</mixed-citation></ref><ref id="CR166"><mixed-citation publication-type="other">Papke RL, Lindstrom JM. Nicotinic acetylcholine receptors: Conventional and unconventional ligands and signaling. Neuropharmacology. 2020;168:108021.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2020.108021</pub-id><pub-id pub-id-type="pmcid">PMC7610230</pub-id><pub-id pub-id-type="pmid">32146229</pub-id></mixed-citation></ref><ref id="CR167"><mixed-citation publication-type="other">Patterson F, Benowitz N, Shields P, Kaufmann V, Jepson C, Wileyto P, u.&amp;nbsp;a. Individual differences in nicotine intake per cigarette. Cancer Epidemiol Biomarkers Prev. 2003;12(5):468&#8211;71.<pub-id pub-id-type="pmid">12750245</pub-id></mixed-citation></ref><ref id="CR168"><mixed-citation publication-type="other">Patt M, Schildan A, Habermann B, Fischer S, Hiller A, Deuther-Conrad W, u.&amp;nbsp;a. Fully automated radiosynthesis of both enantiomers of [18F]Flubatine under GMP conditions for human application. Applied Radiation and Isotopes. 2013;80:7&#8211;11.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apradiso.2013.05.009</pub-id><pub-id pub-id-type="pmid">23792828</pub-id></mixed-citation></ref><ref id="CR169"><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pawloski</surname><given-names>JR</given-names></name><name name-style="western"><surname>Hess</surname><given-names>DT</given-names></name><name name-style="western"><surname>Stamler</surname><given-names>JS</given-names></name></person-group><article-title>Impaired vasodilation by red blood cells in sickle cell disease</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><issue>7</issue><fpage>2531</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1073/pnas.0409876102</pub-id><pub-id pub-id-type="pmid">15699345</pub-id><pub-id pub-id-type="pmcid">PMC548996</pub-id></element-citation><mixed-citation id="mc-CR169" publication-type="journal">Pawloski JR, Hess DT, Stamler JS. Impaired vasodilation by red blood cells in sickle cell disease. Proc Natl Acad Sci USA. 2005;102(7):2531&#8211;6.<pub-id pub-id-type="pmid">15699345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0409876102</pub-id><pub-id pub-id-type="pmcid">PMC548996</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR170"><mixed-citation publication-type="other">Peluso MJ, Deveau TM, Munter SE, Ryder D, Buck A, Beck-Engeser G, u.&amp;nbsp;a. Chronic viral coinfections differentially affect the likelihood of developing long COVID. Journal of Clinical Investigation. 2023;133(3):e163669.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI163669</pub-id><pub-id pub-id-type="pmcid">PMC9888380</pub-id><pub-id pub-id-type="pmid">36454631</pub-id></mixed-citation></ref><ref id="CR171"><mixed-citation publication-type="other">Peng K, Li X, Yang D, Chan SCW, Zhou J, Wan EYF, u.&amp;nbsp;a. Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study. eClinicalMedicine. 2023;63:102154.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2023.102154</pub-id><pub-id pub-id-type="pmcid">PMC10458663</pub-id><pub-id pub-id-type="pmid">37637754</pub-id></mixed-citation></ref><ref id="CR172"><mixed-citation publication-type="other">P&#233;rez-Stable EJ. Nicotine Metabolism and Intake in Black and White Smokers. JAMA. 1998;280(2):152.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.280.2.152</pub-id><pub-id pub-id-type="pmid">9669788</pub-id></mixed-citation></ref><ref id="CR173"><citation-alternatives><element-citation id="ec-CR173" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfl&#252;ger</surname><given-names>E</given-names></name></person-group><article-title>Ueber die Ursache der Athembewegungen, sowie der Dyspno&#235; und Apno&#235;</article-title><source>Archiv F&#252;r Die Gesamte Physiologie des Menschen und der Tiere</source><year>1868</year><volume>1</volume><issue>1</issue><fpage>61</fpage><lpage>106</lpage></element-citation><mixed-citation id="mc-CR173" publication-type="journal">Pfl&#252;ger E. Ueber die Ursache der Athembewegungen, sowie der Dyspno&#235; und Apno&#235;. Archiv F&#252;r Die Gesamte Physiologie des Menschen und der Tiere. 1868;1(1):61&#8211;106.</mixed-citation></citation-alternatives></ref><ref id="CR174"><mixed-citation publication-type="other">Plazas PV, Katz E, Gomez-Casati ME, Bouzat C, Elgoyhen AB. Stoichiometry of the &#945;9&#945;10 Nicotinic Cholinergic Receptor. J Neurosci. 2005;25(47):10905&#8211;12.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.3805-05.2005</pub-id><pub-id pub-id-type="pmcid">PMC6725887</pub-id><pub-id pub-id-type="pmid">16306403</pub-id></mixed-citation></ref><ref id="CR175"><citation-alternatives><element-citation id="ec-CR175" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Picciotto</surname><given-names>MR</given-names></name><name name-style="western"><surname>Higley</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Mineur</surname><given-names>YS</given-names></name></person-group><article-title>Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior</article-title><source>Neuron</source><year>2012</year><volume>76</volume><issue>1</issue><fpage>116</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.08.036</pub-id><pub-id pub-id-type="pmid">23040810</pub-id><pub-id pub-id-type="pmcid">PMC3466476</pub-id></element-citation><mixed-citation id="mc-CR175" publication-type="journal">Picciotto MR, Higley MJ, Mineur YS. Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior. Neuron. 2012;76(1):116&#8211;29.<pub-id pub-id-type="pmid">23040810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2012.08.036</pub-id><pub-id pub-id-type="pmcid">PMC3466476</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR176"><citation-alternatives><element-citation id="ec-CR176" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Posselt</surname><given-names>R</given-names></name></person-group><article-title>Ueber das Nikotin, ein neuentdeckter Stoff im Taback</article-title><source>Archiv der Pharmazie</source><year>1829</year><volume>31</volume><issue>2</issue><fpage>247</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1002/ardp.18290310218</pub-id></element-citation><mixed-citation id="mc-CR176" publication-type="journal">Posselt R. Ueber das Nikotin, ein neuentdeckter Stoff im Taback. Archiv der Pharmazie. 1829;31(2):247&#8211;50.</mixed-citation></citation-alternatives></ref><ref id="CR177"><mixed-citation publication-type="other">Pretorius E, Venter C, Laubscher GJ, Kotze MJ, Oladejo SO, Watson LR, u.&amp;nbsp;a. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc Diabetol. 2022;21(1):148.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12933-022-01579-5</pub-id><pub-id pub-id-type="pmcid">PMC9356426</pub-id><pub-id pub-id-type="pmid">35933347</pub-id></mixed-citation></ref><ref id="CR178"><mixed-citation publication-type="other">Pricoco R, Meidel P, Hofberger T, Zietemann H, Mueller Y, Wiehler K, u.&amp;nbsp;a. One-year follow-up of young people with ME/CFS following infectious mononucleosis by Epstein-Barr virus. Front Pediatr. 2024;11:1266738.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fped.2023.1266738</pub-id><pub-id pub-id-type="pmcid">PMC10830704</pub-id><pub-id pub-id-type="pmid">38304441</pub-id></mixed-citation></ref><ref id="CR179"><mixed-citation publication-type="other">Proceedings of the 2nd International Symposium on Non-Neuronal Acetylcholine, August 31-September 2, 2006, Mainz, Germany. Life Sci. 2007;80(24&#8211;25):2181&#8211;396.<pub-id pub-id-type="pmid">17668475</pub-id></mixed-citation></ref><ref id="CR180"><citation-alternatives><element-citation id="ec-CR180" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prochaska</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name></person-group><article-title>The Past, Present, and Future of Nicotine Addiction Therapy</article-title><source>Annu Rev Med.</source><year>2016</year><volume>67</volume><issue>1</issue><fpage>467</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1146/annurev-med-111314-033712</pub-id><pub-id pub-id-type="pmid">26332005</pub-id><pub-id pub-id-type="pmcid">PMC5117107</pub-id></element-citation><mixed-citation id="mc-CR180" publication-type="journal">Prochaska JJ, Benowitz NL. The Past, Present, and Future of Nicotine Addiction Therapy. Annu Rev Med. 2016;67(1):467&#8211;86.<pub-id pub-id-type="pmid">26332005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-med-111314-033712</pub-id><pub-id pub-id-type="pmcid">PMC5117107</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR181"><mixed-citation publication-type="other">Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, u.&amp;nbsp;a. Transdermal Nicotine for Active Ulcerative Colitis. N Engl J Med. 1994;330(12):811&#8211;5.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM199403243301202</pub-id><pub-id pub-id-type="pmid">8114833</pub-id></mixed-citation></ref><ref id="CR182"><mixed-citation publication-type="other">Rangon CM. Vagus nerve stimulation for long COVID. In: Vagus Nerve Stimulation. Elsevier; 2025. S. 383&#8211;92. Verf&#252;gbar unter: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/B9780128169964000204">https://linkinghub.elsevier.com/retrieve/pii/B9780128169964000204</ext-link>. Zitiert 3. Dezember 2024.</mixed-citation></ref><ref id="CR183"><mixed-citation publication-type="other">Ramsay R, Tipton K. Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs. Molecules. 2017;22(7):1192.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules22071192</pub-id><pub-id pub-id-type="pmcid">PMC6152246</pub-id><pub-id pub-id-type="pmid">28714881</pub-id></mixed-citation></ref><ref id="CR184"><citation-alternatives><element-citation id="ec-CR184" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reiken</surname><given-names>S</given-names></name><name name-style="western"><surname>Sittenfeld</surname><given-names>L</given-names></name><name name-style="western"><surname>Dridi</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Marks</surname><given-names>AR</given-names></name></person-group><article-title>Alzheimer&#8217;s-like signaling in brains of COVID-19 patients</article-title><source>Alzheimer&#8217;s &amp; Dementia</source><year>2022</year><volume>18</volume><issue>5</issue><fpage>955</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1002/alz.12558</pub-id><pub-id pub-id-type="pmcid">PMC9011576</pub-id><pub-id pub-id-type="pmid">35112786</pub-id></element-citation><mixed-citation id="mc-CR184" publication-type="journal">Reiken S, Sittenfeld L, Dridi H, Liu Y, Liu X, Marks AR. Alzheimer&#8217;s-like signaling in brains of COVID-19 patients. Alzheimer&#8217;s &amp; Dementia. 2022;18(5):955&#8211;65.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12558</pub-id><pub-id pub-id-type="pmcid">PMC9011576</pub-id><pub-id pub-id-type="pmid">35112786</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR185"><mixed-citation publication-type="other">Rutkai I, Mayer MG, Hellmers LM, Ning B, Huang Z, Monjure CJ, u.&amp;nbsp;a. Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates. Nat Commun. 2022;13(1):1745.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-29440-z</pub-id><pub-id pub-id-type="pmcid">PMC8975902</pub-id><pub-id pub-id-type="pmid">35365631</pub-id></mixed-citation></ref><ref id="CR186"><mixed-citation publication-type="other">Sabri O, Becker GA, Meyer PM, Hesse S, Wilke S, Graef S, u.&amp;nbsp;a. First-in-human PET quantification study of cerebral &#945;4&#946;2* nicotinic acetylcholine receptors using the novel specific radioligand (&#8722;)-[18F]Flubatine. NeuroImage. 2015;118:199&#8211;208.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2015.05.065</pub-id><pub-id pub-id-type="pmid">26037057</pub-id></mixed-citation></ref><ref id="CR187"><mixed-citation publication-type="other">Sabri O, Meyer PM, Gr&#228;f S, Hesse S, Wilke S, Becker GA, u.&amp;nbsp;a. Cognitive correlates of &#945;4&#946;2 nicotinic acetylcholine receptors in mild Alzheimer&#8217;s dementia. Brain. 2018;141(6):1840&#8211;54.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awy099</pub-id><pub-id pub-id-type="pmcid">PMC5972585</pub-id><pub-id pub-id-type="pmid">29672680</pub-id></mixed-citation></ref><ref id="CR188"><citation-alternatives><element-citation id="ec-CR188" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakellaropoulos</surname><given-names>SG</given-names></name><name name-style="western"><surname>Ali</surname><given-names>M</given-names></name><name name-style="western"><surname>Papadis</surname><given-names>A</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>M</given-names></name><name name-style="western"><surname>Mitsis</surname><given-names>A</given-names></name><name name-style="western"><surname>Zivzivadze</surname><given-names>Z</given-names></name></person-group><article-title>Is Long COVID Syndrome a Transient Mitochondriopathy Newly Discovered: Implications of CPET</article-title><source>Cardiol Res</source><year>2022</year><volume>13</volume><issue>5</issue><fpage>264</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.14740/cr1419</pub-id><pub-id pub-id-type="pmid">36405232</pub-id><pub-id pub-id-type="pmcid">PMC9635775</pub-id></element-citation><mixed-citation id="mc-CR188" publication-type="journal">Sakellaropoulos SG, Ali M, Papadis A, Mohammed M, Mitsis A, Zivzivadze Z. Is Long COVID Syndrome a Transient Mitochondriopathy Newly Discovered: Implications of CPET. Cardiol Res. 2022;13(5):264&#8211;7.<pub-id pub-id-type="pmid">36405232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14740/cr1419</pub-id><pub-id pub-id-type="pmcid">PMC9635775</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR189"><mixed-citation publication-type="other">Saldanha C. Erythrocyte Acetylcholinesterase is a Signaling Receptors. NAPDD. 2018 ;3(4). Verf&#252;gbar unter: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://juniperpublishers.com/napdd/NAPDD.MS.ID.555617.php">https://juniperpublishers.com/napdd/NAPDD.MS.ID.555617.php</ext-link>. Zitiert 18. Februar 2024.</mixed-citation></ref><ref id="CR190"><mixed-citation publication-type="other">Saldanha C. Human Erythrocyte Acetylcholinesterase in Health and Disease. Molecules. 2017;22(9):1499.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules22091499</pub-id><pub-id pub-id-type="pmcid">PMC6151671</pub-id><pub-id pub-id-type="pmid">28885588</pub-id></mixed-citation></ref><ref id="CR191"><mixed-citation publication-type="other">Sandhu A, Hosseini SA, Saadabadi A. Nicotine Replacement Therapy. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Verf&#252;gbar unter: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK493148/">http://www.ncbi.nlm.nih.gov/books/NBK493148/</ext-link>. Zitiert 27. Februar 2024.<pub-id pub-id-type="pmid">29630200</pub-id></mixed-citation></ref><ref id="CR192"><citation-alternatives><element-citation id="ec-CR192" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanner</surname><given-names>T</given-names></name><name name-style="western"><surname>Grimsrud</surname><given-names>TK</given-names></name></person-group><article-title>Nicotine: Carcinogenicity and Effects on Response to Cancer Treatment - A Review</article-title><source>Front Oncol</source><year>2015</year><volume>5</volume><fpage>196</fpage><pub-id pub-id-type="doi">10.3389/fonc.2015.00196</pub-id><pub-id pub-id-type="pmid">26380225</pub-id><pub-id pub-id-type="pmcid">PMC4553893</pub-id></element-citation><mixed-citation id="mc-CR192" publication-type="journal">Sanner T, Grimsrud TK. Nicotine: Carcinogenicity and Effects on Response to Cancer Treatment - A Review. Front Oncol. 2015;5:196.<pub-id pub-id-type="pmid">26380225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2015.00196</pub-id><pub-id pub-id-type="pmcid">PMC4553893</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR193"><citation-alternatives><element-citation id="ec-CR193" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scarr</surname><given-names>E</given-names></name></person-group><article-title>Muscarinic Receptors: Their Roles in Disorders of the Central Nervous System and Potential as Therapeutic Targets</article-title><source>CNS Neuroscience &amp; Therapeutics</source><year>2012</year><volume>18</volume><issue>5</issue><fpage>369</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1111/j.1755-5949.2011.00249.x</pub-id><pub-id pub-id-type="pmid">22070219</pub-id><pub-id pub-id-type="pmcid">PMC6493542</pub-id></element-citation><mixed-citation id="mc-CR193" publication-type="journal">Scarr E. Muscarinic Receptors: Their Roles in Disorders of the Central Nervous System and Potential as Therapeutic Targets. CNS Neuroscience &amp; Therapeutics. 2012;18(5):369&#8211;79.<pub-id pub-id-type="pmid">22070219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1755-5949.2011.00249.x</pub-id><pub-id pub-id-type="pmcid">PMC6493542</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR194"><citation-alternatives><element-citation id="ec-CR194" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schedel</surname><given-names>A</given-names></name><name name-style="western"><surname>Thornton</surname><given-names>S</given-names></name><name name-style="western"><surname>Schloss</surname><given-names>P</given-names></name><name name-style="western"><surname>Kl&#252;ter</surname><given-names>H</given-names></name><name name-style="western"><surname>Bugert</surname><given-names>P</given-names></name></person-group><article-title>Human Platelets Express Functional &#945;7-Nicotinic Acetylcholine Receptors</article-title><source>ATVB</source><year>2011</year><volume>31</volume><issue>4</issue><fpage>928</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.110.218297</pub-id><pub-id pub-id-type="pmid">21051662</pub-id></element-citation><mixed-citation id="mc-CR194" publication-type="journal">Schedel A, Thornton S, Schloss P, Kl&#252;ter H, Bugert P. Human Platelets Express Functional &#945;7-Nicotinic Acetylcholine Receptors. ATVB. 2011;31(4):928&#8211;34.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/ATVBAHA.110.218297</pub-id><pub-id pub-id-type="pmid">21051662</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR195"><mixed-citation publication-type="other">Schettino EW, Chai SK, Kasaian MT, Schroeder HW, Casali P. VHDJH gene sequences and antigen reactivity of monoclonal antibodies produced by human B-1 cells: evidence for somatic selection. J Immunol. 1997;158(5):2477&#8211;89.<pub-id pub-id-type="pmcid">PMC4631314</pub-id><pub-id pub-id-type="pmid">9037000</pub-id></mixed-citation></ref><ref id="CR196"><citation-alternatives><element-citation id="ec-CR196" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>NG</given-names></name><name name-style="western"><surname>Olmstead</surname><given-names>RE</given-names></name><name name-style="western"><surname>Franzon</surname><given-names>MA</given-names></name><name name-style="western"><surname>Lunell</surname><given-names>E</given-names></name></person-group><article-title>The Nicotine Inhaler: Clinical Pharmacokinetics and Comparison with Other Nicotine Treatments</article-title><source>Clin Pharmacokinet</source><year>2001</year><volume>40</volume><issue>9</issue><fpage>661</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.2165/00003088-200140090-00003</pub-id><pub-id pub-id-type="pmid">11605715</pub-id></element-citation><mixed-citation id="mc-CR196" publication-type="journal">Schneider NG, Olmstead RE, Franzon MA, Lunell E. The Nicotine Inhaler: Clinical Pharmacokinetics and Comparison with Other Nicotine Treatments. Clin Pharmacokinet. 2001;40(9):661&#8211;84.<pub-id pub-id-type="pmid">11605715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200140090-00003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR197"><mixed-citation publication-type="other">Seijsing J, Yu S, Frejd FY, H&#246;iden-Guthenberg I, Gr&#228;slund T. In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor. Sci Rep. 2018;8(1):5141.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-23481-5</pub-id><pub-id pub-id-type="pmcid">PMC5865129</pub-id><pub-id pub-id-type="pmid">29572538</pub-id></mixed-citation></ref><ref id="CR198"><citation-alternatives><element-citation id="ec-CR198" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sellers</surname><given-names>E</given-names></name></person-group><article-title>Inhibition of cytochrome P450 2A6 increases nicotine&#8217;s oral bioavailability and decreases smoking</article-title><source>Clinical Pharmacology &amp; Therapeutics</source><year>2000</year><volume>68</volume><issue>1</issue><fpage>35</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1067/mcp.2000.107651</pub-id><pub-id pub-id-type="pmid">10945314</pub-id></element-citation><mixed-citation id="mc-CR198" publication-type="journal">Sellers E. Inhibition of cytochrome P450 2A6 increases nicotine&#8217;s oral bioavailability and decreases smoking. Clinical Pharmacology &amp; Therapeutics. 2000;68(1):35&#8211;43.<pub-id pub-id-type="pmid">10945314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2000.107651</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR199"><mixed-citation publication-type="other">Sellers E, Ramamoorthy Y, Zeman M, Djordjevic M, Tyndale R. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. Nicotine &amp; Tobacco Research. 2003;5(6):891&#8211;9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14622200310001615231</pub-id><pub-id pub-id-type="pmid">14668073</pub-id></mixed-citation></ref><ref id="CR200"><mixed-citation publication-type="other">Shahbaznejad L, Davoudi A, Eslami G, Markowitz JS, Navaeifar MR, Hosseinzadeh F, u.&amp;nbsp;a. Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial. Clinical Therapeutics. 2021;43(6):1007&#8211;19.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinthera.2021.04.007</pub-id><pub-id pub-id-type="pmcid">PMC8101859</pub-id><pub-id pub-id-type="pmid">34052007</pub-id></mixed-citation></ref><ref id="CR201"><mixed-citation publication-type="other">Shi P, Zhang L, Zhang M, Yang W, Wang K, Zhang J, u.&amp;nbsp;a. Platelet-Specific p38&#945; Deficiency Improved Cardiac Function After Myocardial Infarction in Mice. ATVB. Dezember 2017;37(12). Verf&#252;gbar unter: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/10.1161/ATVBAHA.117.309856">https://www.ahajournals.org/doi/10.1161/ATVBAHA.117.309856</ext-link>
. Zitiert 15. April 2024.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/ATVBAHA.117.309856</pub-id><pub-id pub-id-type="pmid">28982666</pub-id></mixed-citation></ref><ref id="CR202"><mixed-citation publication-type="other">Shiyam Sundar LK, Lassen ML, Gutschmayer S, Ferrara D, Calabr&#242; A, Yu J, u.&amp;nbsp;a. Fully Automated, Fast Motion Correction of Dynamic Whole-Body and Total-Body PET/CT Imaging Studies. J Nucl Med. 2023;64(7):1145&#8211;53.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.122.265362</pub-id><pub-id pub-id-type="pmcid">PMC11937726</pub-id><pub-id pub-id-type="pmid">37290795</pub-id></mixed-citation></ref><ref id="CR203"><citation-alternatives><element-citation id="ec-CR203" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sihver</surname><given-names>W</given-names></name><name name-style="western"><surname>Gillberg</surname><given-names>PG</given-names></name><name name-style="western"><surname>Svensson</surname><given-names>AL</given-names></name><name name-style="western"><surname>Nordberg</surname><given-names>A</given-names></name></person-group><article-title>Autoradiographic comparison of [3H](-)nicotine, [3H]cytisine and [3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer&#8217;s disease</article-title><source>Neuroscience</source><year>1999</year><volume>94</volume><issue>3</issue><fpage>685</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1016/S0306-4522(99)00295-X</pub-id><pub-id pub-id-type="pmid">10579560</pub-id></element-citation><mixed-citation id="mc-CR203" publication-type="journal">Sihver W, Gillberg PG, Svensson AL, Nordberg A. Autoradiographic comparison of [3H](-)nicotine, [3H]cytisine and [3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer&#8217;s disease. Neuroscience. 1999;94(3):685&#8211;96.<pub-id pub-id-type="pmid">10579560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0306-4522(99)00295-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR204"><citation-alternatives><element-citation id="ec-CR204" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skok</surname><given-names>M</given-names></name><name name-style="western"><surname>Grailhe</surname><given-names>R</given-names></name><name name-style="western"><surname>Changeux</surname><given-names>JP</given-names></name></person-group><article-title>Nicotinic receptors regulate B lymphocyte activation and immune response</article-title><source>European J Pharmacol</source><year>2005</year><volume>517</volume><issue>3</issue><fpage>246</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2005.05.011</pub-id><pub-id pub-id-type="pmid">15963492</pub-id></element-citation><mixed-citation id="mc-CR204" publication-type="journal">Skok M, Grailhe R, Changeux JP. Nicotinic receptors regulate B lymphocyte activation and immune response. European Journal of Pharmacology. 2005;517(3):246&#8211;51.<pub-id pub-id-type="pmid">15963492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2005.05.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR205"><citation-alternatives><element-citation id="ec-CR205" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skok</surname><given-names>MV</given-names></name><name name-style="western"><surname>Grailhe</surname><given-names>R</given-names></name><name name-style="western"><surname>Agenes</surname><given-names>F</given-names></name><name name-style="western"><surname>Changeux</surname><given-names>JP</given-names></name></person-group><article-title>The role of nicotinic receptors in B-lymphocyte development and activation</article-title><source>Life Sciences</source><year>2007</year><volume>80</volume><issue>24&#8211;25</issue><fpage>2334</fpage><lpage>2336</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2007.02.005</pub-id><pub-id pub-id-type="pmid">17363009</pub-id></element-citation><mixed-citation id="mc-CR205" publication-type="journal">Skok MV, Grailhe R, Agenes F, Changeux JP. The role of nicotinic receptors in B-lymphocyte development and activation. Life Sciences. 2007;80(24&#8211;25):2334&#8211;6.<pub-id pub-id-type="pmid">17363009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2007.02.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR206"><mixed-citation publication-type="other">Skok M. Mitochondrial nicotinic acetylcholine receptors: Mechanisms of functioning and biological significance. The International Journal of Biochemistry &amp; Cell Biology. 2022;143:106138.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biocel.2021.106138</pub-id><pub-id pub-id-type="pmid">34929396</pub-id></mixed-citation></ref><ref id="CR207"><mixed-citation publication-type="other">Skok MV, Kalashnik EN, Koval LN, Tsetlin VI, Utkin YN, Changeux JP, u.&amp;nbsp;a. Functional Nicotinic Acetylcholine Receptors Are Expressed in B Lymphocyte-Derived Cell Lines. Mol Pharmacol. 2003;64(4):885&#8211;9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/mol.64.4.885</pub-id><pub-id pub-id-type="pmid">14500745</pub-id></mixed-citation></ref><ref id="CR208"><citation-alternatives><element-citation id="ec-CR208" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>C</given-names></name></person-group><article-title>Particulate and vapor phase constituents of cigarette mainstream smoke and risk of myocardial infarction</article-title><source>Atherosclerosis</source><year>2001</year><volume>158</volume><issue>2</issue><fpage>257</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1016/S0021-9150(01)00570-6</pub-id><pub-id pub-id-type="pmid">11583703</pub-id></element-citation><mixed-citation id="mc-CR208" publication-type="journal">Smith C. Particulate and vapor phase constituents of cigarette mainstream smoke and risk of myocardial infarction. Atherosclerosis. 2001;158(2):257&#8211;67.<pub-id pub-id-type="pmid">11583703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0021-9150(01)00570-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR209"><mixed-citation publication-type="other">Son Y, Kim S, Chung HT, Pae HO. Reactive Oxygen Species in the Activation of MAP Kinases. In: Methods in Enzymology. Elsevier; 2013. S. 27&#8211;48. Verf&#252;gbar unter: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/B9780124058811000021">https://linkinghub.elsevier.com/retrieve/pii/B9780124058811000021</ext-link>. Zitiert 15. April 2024.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-12-405881-1.00002-1</pub-id><pub-id pub-id-type="pmid">23849857</pub-id></mixed-citation></ref><ref id="CR210"><mixed-citation publication-type="other">Spurny R, Debaveye S, Farinha A, Veys K, Vos AM, Gossas T, u.&amp;nbsp;a. Molecular blueprint of allosteric binding sites in a homologue of the agonist-binding domain of the &#945;7 nicotinic acetylcholine receptor. Proc Natl Acad Sci USA. 2015;112(19):E2543&#8211;52.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1418289112</pub-id><pub-id pub-id-type="pmcid">PMC4434711</pub-id><pub-id pub-id-type="pmid">25918415</pub-id></mixed-citation></ref><ref id="CR211"><mixed-citation publication-type="other">Stefanou MI, Palaiodimou L, Bakola E, Smyrnis N, Papadopoulou M, Paraskevas GP, u.&amp;nbsp;a. Neurological manifestations of long-COVID syndrome: a narrative review. Therapeutic Advances in Chronic Disease. 2022;13:204062232210768.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/20406223221076890</pub-id><pub-id pub-id-type="pmcid">PMC8859684</pub-id><pub-id pub-id-type="pmid">35198136</pub-id></mixed-citation></ref><ref id="CR212"><mixed-citation publication-type="other">Swank Z, Borberg E, Chen Y, Senussi Y, Chalise S, Manickas-Hill Z, u. a. Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study. Clinical Microbiology and Infection. 2024;30(12):1599&#8211;605.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmi.2024.09.001</pub-id><pub-id pub-id-type="pmcid">PMC11578795</pub-id><pub-id pub-id-type="pmid">39389851</pub-id></mixed-citation></ref><ref id="CR213"><mixed-citation publication-type="other">Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, u.&amp;nbsp;a. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae.&#160;Clin&#160;Infect&#160;Dis. 2023;76(3):e487&#8211;90.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciac722</pub-id><pub-id pub-id-type="pmcid">PMC10169416</pub-id><pub-id pub-id-type="pmid">36052466</pub-id></mixed-citation></ref><ref id="CR214"><mixed-citation publication-type="other">Sundar LKS, Yu J, Muzik O, Kulterer OC, Fueger B, Kifjak D, u.&amp;nbsp;a. Fully Automated, Semantic Segmentation of Whole-Body <sup>18</sup> F-FDG PET/CT Images Based on Data-Centric Artificial Intelligence. J Nucl Med. 2022;63(12):1941&#8211;8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.122.264063</pub-id><pub-id pub-id-type="pmcid">PMC9730926</pub-id><pub-id pub-id-type="pmid">35772962</pub-id></mixed-citation></ref><ref id="CR215"><citation-alternatives><element-citation id="ec-CR215" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taly</surname><given-names>A</given-names></name><name name-style="western"><surname>Corringer</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Guedin</surname><given-names>D</given-names></name><name name-style="western"><surname>Lestage</surname><given-names>P</given-names></name><name name-style="western"><surname>Changeux</surname><given-names>JP</given-names></name></person-group><article-title>Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system</article-title><source>Nat Rev Drug Discov</source><year>2009</year><volume>8</volume><issue>9</issue><fpage>733</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1038/nrd2927</pub-id><pub-id pub-id-type="pmid">19721446</pub-id></element-citation><mixed-citation id="mc-CR215" publication-type="journal">Taly A, Corringer PJ, Guedin D, Lestage P, Changeux JP. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov. 2009;8(9):733&#8211;50.<pub-id pub-id-type="pmid">19721446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd2927</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR216"><citation-alternatives><element-citation id="ec-CR216" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name></person-group><article-title>Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia</article-title><source>J Thromb Haemost</source><year>2020</year><volume>18</volume><issue>4</issue><fpage>844</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1111/jth.14768</pub-id><pub-id pub-id-type="pmid">32073213</pub-id><pub-id pub-id-type="pmcid">PMC7166509</pub-id></element-citation><mixed-citation id="mc-CR216" publication-type="journal">Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844&#8211;7.<pub-id pub-id-type="pmid">32073213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jth.14768</pub-id><pub-id pub-id-type="pmcid">PMC7166509</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR217"><mixed-citation publication-type="other">Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. Journal of Clinical Investigation. 2007;117(2):289&#8211;96.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI30555</pub-id><pub-id pub-id-type="pmcid">PMC1783813</pub-id><pub-id pub-id-type="pmid">17273548</pub-id></mixed-citation></ref><ref id="CR218"><citation-alternatives><element-citation id="ec-CR218" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tucci</surname><given-names>S</given-names></name><name name-style="western"><surname>Genn</surname><given-names>RF</given-names></name><name name-style="western"><surname>Marco</surname><given-names>E</given-names></name><name name-style="western"><surname>File</surname><given-names>SE</given-names></name></person-group><article-title>Do different mechanisms underlie two anxiogenic effects of systemic nicotine?</article-title><source>Behavioural Pharmacology</source><year>2003</year><volume>14</volume><issue>4</issue><fpage>323</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1097/01.fbp.0000081782.35927.c6</pub-id><pub-id pub-id-type="pmid">12838038</pub-id></element-citation><mixed-citation id="mc-CR218" publication-type="journal">Tucci S, Genn RF, Marco E, File SE. Do different mechanisms underlie two anxiogenic effects of systemic nicotine? Behavioural Pharmacology. 2003;14(4):323&#8211;9.<pub-id pub-id-type="pmid">12838038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.fbp.0000081782.35927.c6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR219"><citation-alternatives><element-citation id="ec-CR219" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>S</given-names></name><name name-style="western"><surname>Khan</surname><given-names>MA</given-names></name><name name-style="western"><surname>Putrino</surname><given-names>D</given-names></name><name name-style="western"><surname>Woodcock</surname><given-names>A</given-names></name><name name-style="western"><surname>Kell</surname><given-names>DB</given-names></name><name name-style="western"><surname>Pretorius</surname><given-names>E</given-names></name></person-group><article-title>Long COVID: pathophysiological factors and abnormalities of coagulation</article-title><source>Trends in Endocrinology &amp; Metabolism</source><year>2023</year><volume>34</volume><issue>6</issue><fpage>321</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2023.03.002</pub-id><pub-id pub-id-type="pmid">37080828</pub-id><pub-id pub-id-type="pmcid">PMC10113134</pub-id></element-citation><mixed-citation id="mc-CR219" publication-type="journal">Turner S, Khan MA, Putrino D, Woodcock A, Kell DB, Pretorius E. Long COVID: pathophysiological factors and abnormalities of coagulation. Trends Endocrinol Metabol. 2023;34(6):321&#8211;44.<pub-id pub-id-type="pmid">37080828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tem.2023.03.002</pub-id><pub-id pub-id-type="pmcid">PMC10113134</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR220"><citation-alternatives><element-citation id="ec-CR220" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vitte</surname><given-names>J</given-names></name><name name-style="western"><surname>Vibhushan</surname><given-names>S</given-names></name><name name-style="western"><surname>Bratti</surname><given-names>M</given-names></name><name name-style="western"><surname>Montero-Hernandez</surname><given-names>JE</given-names></name><name name-style="western"><surname>Blank</surname><given-names>U</given-names></name></person-group><article-title>Allergy, Anaphylaxis, and Nonallergic Hypersensitivity: IgE, Mast Cells, and Beyond</article-title><source>Med Princ Pract</source><year>2022</year><volume>31</volume><issue>6</issue><fpage>501</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1159/000527481</pub-id><pub-id pub-id-type="pmid">36219943</pub-id><pub-id pub-id-type="pmcid">PMC9841766</pub-id></element-citation><mixed-citation id="mc-CR220" publication-type="journal">Vitte J, Vibhushan S, Bratti M, Montero-Hernandez JE, Blank U. Allergy, Anaphylaxis, and Nonallergic Hypersensitivity: IgE, Mast Cells, and Beyond. Med Princ Pract. 2022;31(6):501&#8211;15.<pub-id pub-id-type="pmid">36219943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000527481</pub-id><pub-id pub-id-type="pmcid">PMC9841766</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR221"><mixed-citation publication-type="other">Vollenberg R, Tepasse PR, Ochs K, Floer M, Strauss M, Rennebaum F, u.&amp;nbsp;a. Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis. Viruses. 2021;13(11):2324.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v13112324</pub-id><pub-id pub-id-type="pmcid">PMC8619155</pub-id><pub-id pub-id-type="pmid">34835130</pub-id></mixed-citation></ref><ref id="CR222"><mixed-citation publication-type="other">Wadgave U, Nagesh L. Nicotine Replacement Therapy: An Overview. Int J Health Sci (Qassim). 2016;10(3):425&#8211;35.<pub-id pub-id-type="pmcid">PMC5003586</pub-id><pub-id pub-id-type="pmid">27610066</pub-id></mixed-citation></ref><ref id="CR223"><citation-alternatives><element-citation id="ec-CR223" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walls</surname><given-names>AC</given-names></name><name name-style="western"><surname>Park</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Tortorici</surname><given-names>MA</given-names></name><name name-style="western"><surname>Wall</surname><given-names>A</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>AT</given-names></name><name name-style="western"><surname>Veesler</surname><given-names>D</given-names></name></person-group><article-title>Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein</article-title><source>Cell</source><year>2020</year><volume>181</volume><issue>2</issue><fpage>281</fpage><lpage>292.e6</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id><pub-id pub-id-type="pmid">32155444</pub-id><pub-id pub-id-type="pmcid">PMC7102599</pub-id></element-citation><mixed-citation id="mc-CR223" publication-type="journal">Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281-292.e6.<pub-id pub-id-type="pmid">32155444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.02.058</pub-id><pub-id pub-id-type="pmcid">PMC7102599</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR224"><mixed-citation publication-type="other">Wang L, Shang S, Kang X, Teng S, Zhu F, Liu B, u.&amp;nbsp;a. Modulation of dopamine release in the striatum by physiologically relevant levels of nicotine. Nature communications. 2014;5(1):3925.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms4925</pub-id><pub-id pub-id-type="pmid">24968237</pub-id></mixed-citation></ref><ref id="CR225"><mixed-citation publication-type="other">Wang Z, Lin X, Shi W, Cao C. Nicotinic Acetylcholine Receptor Alpha6 Contributes to Antiviral Immunity via IMD Pathway in Drosophila melanogaster. Viruses. 2024;16(4):562.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v16040562</pub-id><pub-id pub-id-type="pmcid">PMC11054842</pub-id><pub-id pub-id-type="pmid">38675904</pub-id></mixed-citation></ref><ref id="CR226"><citation-alternatives><element-citation id="ec-CR226" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinstock</surname><given-names>LB</given-names></name><name name-style="western"><surname>Brook</surname><given-names>JB</given-names></name><name name-style="western"><surname>Walters</surname><given-names>AS</given-names></name><name name-style="western"><surname>Goris</surname><given-names>A</given-names></name><name name-style="western"><surname>Afrin</surname><given-names>LB</given-names></name><name name-style="western"><surname>Molderings</surname><given-names>GJ</given-names></name></person-group><article-title>Mast cell activation symptoms are prevalent in Long-COVID</article-title><source>Int J Infect Dis</source><year>2021</year><volume>112</volume><fpage>217</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2021.09.043</pub-id><pub-id pub-id-type="pmid">34563706</pub-id><pub-id pub-id-type="pmcid">PMC8459548</pub-id></element-citation><mixed-citation id="mc-CR226" publication-type="journal">Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. Mast cell activation symptoms are prevalent in Long-COVID. Int J Infect Dis. 2021;112:217&#8211;26.<pub-id pub-id-type="pmid">34563706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijid.2021.09.043</pub-id><pub-id pub-id-type="pmcid">PMC8459548</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR227"><citation-alternatives><element-citation id="ec-CR227" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wessler</surname><given-names>I</given-names></name><name name-style="western"><surname>Kirkpatrick</surname><given-names>CJ</given-names></name></person-group><article-title>Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans</article-title><source>British J Pharmacology</source><year>2008</year><volume>154</volume><issue>8</issue><fpage>1558</fpage><lpage>1571</lpage><pub-id pub-id-type="doi">10.1038/bjp.2008.185</pub-id><pub-id pub-id-type="pmcid">PMC2518461</pub-id><pub-id pub-id-type="pmid">18500366</pub-id></element-citation><mixed-citation id="mc-CR227" publication-type="journal">Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. British J Pharmacology. 2008;154(8):1558&#8211;71.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjp.2008.185</pub-id><pub-id pub-id-type="pmcid">PMC2518461</pub-id><pub-id pub-id-type="pmid">18500366</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR228"><mixed-citation publication-type="other">West R, Hajek P, Foulds J, Nilsson F, May S, Meadows A. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology. 2000;149(3):198&#8211;202.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002130000382</pub-id><pub-id pub-id-type="pmid">10823399</pub-id></mixed-citation></ref><ref id="CR229"><citation-alternatives><element-citation id="ec-CR229" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wildbaum</surname><given-names>G</given-names></name><name name-style="western"><surname>Nahir</surname><given-names>MA</given-names></name><name name-style="western"><surname>Karin</surname><given-names>N</given-names></name></person-group><article-title>Beneficial Autoimmunity to Proinflammatory Mediators Restrains the Consequences of Self-Destructive Immunity</article-title><source>Immunity</source><year>2003</year><volume>19</volume><issue>5</issue><fpage>679</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(03)00291-7</pub-id><pub-id pub-id-type="pmid">14614855</pub-id></element-citation><mixed-citation id="mc-CR229" publication-type="journal">Wildbaum G, Nahir MA, Karin N. Beneficial Autoimmunity to Proinflammatory Mediators Restrains the Consequences of Self-Destructive Immunity. Immunity. 2003;19(5):679&#8211;88.<pub-id pub-id-type="pmid">14614855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1074-7613(03)00291-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR230"><mixed-citation publication-type="other">Wilson C, Lee MD, McCarron JG. Acetylcholine released by endothelial cells facilitates flow&#8208;mediated dilatation. J Physiol. 2016;594(24):7267&#8211;307.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1113/JP272927</pub-id><pub-id pub-id-type="pmcid">PMC5157078</pub-id><pub-id pub-id-type="pmid">27730645</pub-id></mixed-citation></ref><ref id="CR231"><citation-alternatives><element-citation id="ec-CR231" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>M</given-names></name><name name-style="western"><surname>Jing</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Novakovic</surname><given-names>VA</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name></person-group><article-title>Damage to endothelial barriers and its contribution to long COVID</article-title><source>Angiogenesis</source><year>2024</year><volume>27</volume><issue>1</issue><fpage>5</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1007/s10456-023-09878-5</pub-id><pub-id pub-id-type="pmid">37103631</pub-id><pub-id pub-id-type="pmcid">PMC10134732</pub-id></element-citation><mixed-citation id="mc-CR231" publication-type="journal">Wu X, Xiang M, Jing H, Wang C, Novakovic VA, Shi J. Damage to endothelial barriers and its contribution to long COVID. Angiogenesis. 2024;27(1):5&#8211;22.<pub-id pub-id-type="pmid">37103631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10456-023-09878-5</pub-id><pub-id pub-id-type="pmcid">PMC10134732</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR232"><mixed-citation publication-type="other">Xu H, Shi X, Li X, Zou J, Zhou C, Liu W, u.&amp;nbsp;a. Neurotransmitter and neuropeptide regulation of mast cell function: a systematic review. J Neuroinflammation. 2020;17(1):356.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-020-02029-3</pub-id><pub-id pub-id-type="pmcid">PMC7691095</pub-id><pub-id pub-id-type="pmid">33239034</pub-id></mixed-citation></ref><ref id="CR233"><mixed-citation publication-type="other">Xu S, Ilyas I, Little PJ, Li H, Kamato D, Zheng X, u.&amp;nbsp;a. Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Ma Q, Herausgeber. Pharmacol Rev. 2021;73(3):924&#8211;67.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/pharmrev.120.000096</pub-id><pub-id pub-id-type="pmid">34088867</pub-id></mixed-citation></ref><ref id="CR234"><citation-alternatives><element-citation id="ec-CR234" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yildiz</surname><given-names>D</given-names></name></person-group><article-title>Nicotine, its metabolism and an overview of its biological effects</article-title><source>Toxicon</source><year>2004</year><volume>43</volume><issue>6</issue><fpage>619</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2004.01.017</pub-id><pub-id pub-id-type="pmid">15109883</pub-id></element-citation><mixed-citation id="mc-CR234" publication-type="journal">Yildiz D. Nicotine, its metabolism and an overview of its biological effects. Toxicon. 2004;43(6):619&#8211;32.<pub-id pub-id-type="pmid">15109883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.toxicon.2004.01.017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR235"><citation-alternatives><element-citation id="ec-CR235" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Kilicarslan</surname><given-names>T</given-names></name><name name-style="western"><surname>Tyndale</surname><given-names>RF</given-names></name><name name-style="western"><surname>Sellers</surname><given-names>EM</given-names></name></person-group><article-title>Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro</article-title><source>Drug Metab Dispos</source><year>2001</year><volume>29</volume><issue>6</issue><fpage>897</fpage><lpage>902</lpage><pub-id pub-id-type="pmid">11353760</pub-id></element-citation><mixed-citation id="mc-CR235" publication-type="journal">Zhang W, Kilicarslan T, Tyndale RF, Sellers EM. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos. 2001;29(6):897&#8211;902.<pub-id pub-id-type="pmid">11353760</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR236"><mixed-citation publication-type="other">Zhao M, Yang Y, Bi X, Yu X, Jia H, Fang H, u.&amp;nbsp;a. Acetylcholine Attenuated TNF-&#945;-Induced Apoptosis in H9c2 Cells: Role of Calpain and the p38-MAPK Pathway. Cell Physiol Biochem. 2015;36(5):1877&#8211;89.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000430157</pub-id><pub-id pub-id-type="pmid">26183016</pub-id></mixed-citation></ref><ref id="CR237"><mixed-citation publication-type="other">Zhao ZS, Granucci F, Yeh L, Schaffer PA, Cantor H. Molecular Mimicry by Herpes Simplex Virus-Type 1: Autoimmune Disease After Viral Infection. Science. 1998;279(5355):1344&#8211;7.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.279.5355.1344</pub-id><pub-id pub-id-type="pmid">9478893</pub-id></mixed-citation></ref><ref id="CR238"><mixed-citation publication-type="other">Zheng ZS, Simonian N, Wang J, Rosario ER. Transcutaneous vagus nerve stimulation improves Long COVID symptoms in a female cohort: a pilot study. Front Neurol. 2024;15:1393371.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2024.1393371</pub-id><pub-id pub-id-type="pmcid">PMC11097097</pub-id><pub-id pub-id-type="pmid">38756213</pub-id></mixed-citation></ref><ref id="CR239"><citation-alternatives><element-citation id="ec-CR239" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>DY</given-names></name></person-group><article-title>Neuronal nitric oxide synthase: Structure, subcellular localization, regulation, and clinical implications</article-title><source>Nitric Oxide</source><year>2009</year><volume>20</volume><issue>4</issue><fpage>223</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1016/j.niox.2009.03.001</pub-id><pub-id pub-id-type="pmid">19298861</pub-id></element-citation><mixed-citation id="mc-CR239" publication-type="journal">Zhou L, Zhu DY. Neuronal nitric oxide synthase: Structure, subcellular localization, regulation, and clinical implications. Nitric Oxide. 2009;20(4):223&#8211;30.<pub-id pub-id-type="pmid">19298861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.niox.2009.03.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR240"><citation-alternatives><element-citation id="ec-CR240" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>ZH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hu</surname><given-names>YF</given-names></name><name name-style="western"><surname>Wahl</surname><given-names>LM</given-names></name><name name-style="western"><surname>Cisar</surname><given-names>JO</given-names></name><name name-style="western"><surname>Notkins</surname><given-names>AL</given-names></name></person-group><article-title>The Broad Antibacterial Activity of the Natural Antibody Repertoire Is Due to Polyreactive Antibodies</article-title><source>Cell Host &amp; Microbe</source><year>2007</year><volume>1</volume><issue>1</issue><fpage>51</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2007.01.002</pub-id><pub-id pub-id-type="pmid">18005681</pub-id><pub-id pub-id-type="pmcid">PMC2212603</pub-id></element-citation><mixed-citation id="mc-CR240" publication-type="journal">Zhou ZH, Zhang Y, Hu YF, Wahl LM, Cisar JO, Notkins AL. The Broad Antibacterial Activity of the Natural Antibody Repertoire Is Due to Polyreactive Antibodies. Cell Host &amp; Microbe. 2007;1(1):51&#8211;61.<pub-id pub-id-type="pmid">18005681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2007.01.002</pub-id><pub-id pub-id-type="pmcid">PMC2212603</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR241"><mixed-citation publication-type="other">Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, u.&amp;nbsp;a. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12(570):eabd3876.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.abd3876</pub-id><pub-id pub-id-type="pmcid">PMC7724273</pub-id><pub-id pub-id-type="pmid">33139519</pub-id></mixed-citation></ref><ref id="CR242"><mixed-citation publication-type="other">2008 PHS Guideline Update Panel, Liaisons, and Staff. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir Care. 2008;53(9):1217&#8211;22.<pub-id pub-id-type="pmid">18807274</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>